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ABSTRACT
Connexins are integral membrane proteins that oligomerize to form gap junction
channels. Ions and small molecules diffuse intercellularly through these channels, allowing
individual cellular events to synchronize into the functional response of an entire organ.
Gap junction channels composed of Connexin43 (Cx43) mediate electrical coupling and
impulse propagation in the normal working myocardium. In the failing heart, Cx43
remodeling (decreased expression, altered phosphorylation state, loss at intercalated
discs, and increased presence at lateral membranes) contributes to rhythm disturbances
and contractile dysfunction. While there is considerable information regarding key
interactions of Cx43 in the regulation of gap junction channels, unfortunately, the precise
mechanisms that lead to remodeling have not been defined, nor have the critical
accessory proteins involved been fully characterized.
Several parameters, such as lipophilic compounds, voltage, pH, and phosphorylation
influence the function of Cx43. Importantly, Cx43 phosphorylation is a key regulator of gap
junction assembly, stability, degradation, channel gating, and selectivity properties.
Changes in the level and pattern of Cx43 phosphorylation are commonly observed in both
ischemic and nonischemic forms of human heart failure. Therefore, understanding the
mechanistic basis of Cx43 phosphorylation will lead to possible points of therapeutic
intervention to restore proper gap junction intercellular communication (GJIC) that has
ii

been altered due to heart failure. Much progress has been made on how serine
phosphorylation regulates Cx43 (23 serine phosphorylation sites; 8 serine kinases);
however, the understanding of tyrosine phosphorylation of Cx43 has been limited to
residues Y247 and Y265, both known to be phosphorylated by kinases Src and Tyk2.
Because of this lack of knowledge, the objective of my research is to use a multidisciplinary approach to identify if additional tyrosine phosphorylation site(s) and kinase(s)
play a role in altering Cx43 function in cardiac diseases. Our studies identified Cx43
residue Y313 as a novel site targeted for phosphorylation by Src. Src phosphorylation of
Cx43 residue Y313 contributes to intracellular localization of Cx43 and inhibiting the Cx43
interaction with the F-actin binding protein Drebrin. We generated a Cx43 Y313 phosphospecific antibody and demonstrated that Cx43 Y313 phosphorylation is increased in
diseased human left ventricle. We identified that Protein tyrosine kinase 2 beta (Pyk2)
phosphorylated purified Cx43 carboxyl-terminal (CT) domain by an in vitro tyrosine
phosphorylation kinase screen. Pyk2 interacted with Cx43 at the plasma membrane and
intracellularly in HeLa cells, and a heart failure rat model showed an increase in Pyk2
activity and interaction with Cx43 in vivo. Activation of Pyk2 was inhibited by the small
molecule PF4618433, leading to increased Cx43 GJIC, and preserved GJIC to the normal
level when paired with a Src inhibitor. Our data suggested that phosphorylation of Cx43
by Pyk2 is a “second process” that must be inhibited, in addition to Src, to further (if not
completely) reverse Cx43 remodeling and improve cardiac function. This information is
pivotal if the role of GJIC in normal and diseased states is to be fully understood and
utilized for therapeutic benefit in cardiac pathologies.
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CHAPTER ONE

Introduction
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1. Gap Junction Overview
Gap junctions are integral membrane proteins that allow a direct cytoplasmic exchange
of ions and small molecules (<1000 Da) between the cytoplasm of adjacent cells (1-5).
They provide a pathway for propagating and/or amplifying intercellular signal transduction
cascades triggered by cytokines, growth factors, mechanical stretch, and other molecules
that are essential for cell growth and differentiation (6-22). Dysfunctional gap junction
intercellular communication (GJIC) is implicated in numerous human pathologies and
genetic diseases, such as heart diseases, oculodentodigital dysplasia, hearing loss, and
X-linked Charcot-Marie-Tooth disease (23-29).

1.1. Connexin Structure and the Cytoplasmic Domains
Gap junctions are formed by the apposition of connexons from adjacent cells. Each
connexon is a hexamer of connexin proteins (Figure 1.1A). Each connexin contains a
cytoplasmic amino-terminus

(NT), four transmembrane (TM1-4) domains, two

extracellular loops (EL1 and EL2), a cytoplasmic loop (CL), and a carboxyl-terminus (CT)
(Figure 1.1B). There are 21 human connexin isoforms and only 20 in mice (30-32). Six
same or different connexin isoforms form a homomeric or heteromeric connexon,
respectively, that can further dock with another connexon apposed from adjacent cells to
form homotypic channel (formed by same homomeric or heteromeric connexons) or
heterotypic channel (formed by different homomeric or heteromeric connexons) (Figure
1.1C and D) (1). Connexins are most commonly named based on their molecular weight
(e.g. Cx43 is a connexin protein of 43 kDa) (33). Additionally, connexins are divided into
subgroups (α, β or γ) according to the extent of their genetic sequence and proteic
similarities (e.g. Cx43 is the first connexin of the α-group and Cx32 is the first connexin of
the β-group).
2

Figure 1.1. Structure of gap junctions and connexin. (A) Intercellular gap junction
channels cluster into a gap junction plaque. A gap junction channel is composed of two
hemichannels from the neighboring cells. (B) Structure of a single connexin, including four
transmembrane (TM1-4) domains, two extracellular loops (EL1 and EL2), a cytoplasmic
loop (CL), a cytoplasmic amino terminal domain (NT), and a cytoplasmic carboxyl terminal
domain (CT). (C) A connexon consists of six Cx subunits. Homomeric connexon is formed
by six same Cx isoforms, while heteromeric connexon is formed by different Cx isoforms.
(D)
Gap
junction
channels
have
four
types:
homomeric/homotypic,
homomeric/heterotypic, heteromeric/homotypic, and heteromeric/heterotypic). This figure
is reprinted and modified with permission (Verheule et al., 2013) (34).

3

Connexins are found in most tissues and organs under normal conditions except in
differentiated skeletal muscle, red blood cells, and mature sperm cells (35). Three
connexins (Cx43, Cx40, and Cx45) have been observed in human cardiac tissues, and
Cx43 is the most abundant connexin expressed in the heart and is the focus of my
dissertation (36-39).
The cytoplasmic NT, CL, and CT domains are all important for gap junction channel
formation, gating, and regulation (40). The largest homology is between the extracellular
and transmembrane domains of all connexin family members; however the cytoplasmic
domains show significant divergence (41, 42). The cytoplasmic domains contain many
sites for protein-protein interactions as well as post-translational modifications (43).
Detailed structure and function of each cytoplasmic domain are discussed below.
The NT domain of connexins is a highly conserved domain among all isoforms in terms
of amino acid number (44, 45). For example, the NT of all connexins has 22 (β-connexins)
or 23 (α-connexins) amino acids. Two exceptions are Cx36 and Cx47, which are 24 and
25 NT residues in length, respectively (45). Despite the similarity in size, the NT domains
of different family members have been found to have distinct secondary structures (45).
Solution NMR has been used to solve the structure of the NT domains of Cx32 and Cx26,
identifying the Cx32NT is disordered while the Cx26NT shows an α-helical structure (46,
47). The NT domain is important for plaque formation and normal channel function
(reviewed in (45)). Mutations in the NT domain of many family members (Cx26, Cx30,
Cx30.2/Cx31.3, Cx31, Cx32, Cx43, Cx46, and Cx50) have been connected to various
diseases. For example, multiple mutations within the Cx26NT sequence cause hearing
impairment. Mutations in Cx31NT have been attributed to erythrokeratodermia variabilis,
and Cx32NT mutations cause X-linked dominant Charcot-Marie-Tooth neuropathy.
Furthermore, several mutations linked to oculodentodigital dysplasia (ODDD) have been
identified in the Cx43NT sequence. Additionally, mutations in Cx46NT and Cx50NT have
4

been showed to associate with cataracts (reviewed in (45)). However, the consequences
of those mutations are various: among the mutations that have been studied at the
molecular level, some lead to impaired trafficking and plaque assembly, a subset of others
cause channels to be non-functional, and the rest induce cell death when aberrantly
expressed

(48-58).

Post-translational

modifications,

including

phosphorylation,

acetylation, and hydroxylation, have been identified in the NT domain by mass
spectroscopy (59, 60).
In contrast to the NT domain, the CL domain of connexins shows greater divergence
in the number and composition of amino acids. Family members can be categorized into
three groups according to the length of the CL domain (and total sequence homology):
small/α (30-35 residues; e.g. Cx43, Cx40), medium/β; (50-55 residues; e.g. Cx26, Cx32),
and large/γ (80-105 residues; e.g. Cx45, Cx47) (32). The CL domain plays a role in
channel formation and gating (61). However, the dynamic and disordered nature of the CL
domain renders crystallographic studies useless to resolve the CL domain (62, 63).
Although the crystal structure of the CL domain is not available, solution NMR and circular
dichroism (CD) have provided helpful structural information showing that the CL domain
is primarily disordered with a tendency to form α-helical structure (64). NMR reveals the
Cx43CL contains two small regions that adopt α-helical structure when induced by
acidification or upon interaction with Calmodulin (CaM) (64, 65). CD spectroscopy studies
also confirm that the CL domain of Cx43, Cx32, and Cx36 tend to form α-helices when the
peptides are treated with the secondary structure stabilizer trifluoroethanol (66).
Furthermore, truncation studies have indicated the significance of the CL domain also in
connexin trafficking and gap junction assembly (67, 68). For example, gap junction
assembled by Cx43 synthetic mutants lacking the CL residues (e.g. Δ112–116, Δ122–
127, Δ130–134, and Δ139–143) are found to be non-functional or dysfunctional,
suggesting a crucial role for the CL in gap junction function (67, 68). Mutations of the
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Cx32CL also impair connexin trafficking as well as GJIC, which indicates the important
role of the CL to channel function is a common feature of connexins (69). The CL domain
also contains post-translational modifications such as phosphorylation and carboxylation
(59, 60, 70); however no functional role has been associated with them.
The CT domain of connexins is the most divergent domain among all isoforms in terms
of length and primary structure and is suggested as a determinant for the differences in
channel properties and regulation among the different connexins (1, 71). For example,
Cx26 has a CT domain of only 10 residues, while Cx62 has 310 residues (1). The CT
domain is crucial for connexin trafficking, channel gating, and regulation of gap junctions
(1, 62, 63). The structure of CT domain is dynamic and not suitable for crystallographic
studies (62, 63). Solution NMR and CD studies have been used to show that CT domains
of several connexins were mainly disordered (72-74). Even though most of them are
disordered, some structural studies have demonstrated both the Cx43CT and Cx45CT
contained α-helical domains (74, 75). The helical regions of the Cx43CT are involved in
the dimerization of Cx43CT domains and are critical for the CT-CL interaction during pH
gating and the helical region (A331-N361) of Cx45CT is also linked to high affinity (Kd
~100 nM) homodimerization (64, 74, 75). Furthermore, a published study in our laboratory
has suggested CT dimerization is necessary for proper Cx45 function, including
membrane localization, turnover, phosphorylation status, interaction with protein partners,
hemichannel activity, and GJIC (76). Cx43CT will be discussed in more detail in next
section.
1.2. Connexins in the Heart
1.2.1 Cardiac Electrical System
The cardiac electrical system, composed of a group of specialized cardiac muscle cells
in the heart wall with diverse cytoarchitecture and electrophysiological properties, is
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responsible for generating and transmitting signals that trigger the heart to beat. The
precise working system in a healthy heart controls the heart rate and heart rhythm,
allowing the heart to contract in a smooth and orderly fashion. The main components
include the sinoatrial (SA) node, the internodal pathways, the atrioventricular (AV) node,
the bundle of His, the bundle branches, and the Purkinje fiber (Figure 1.2). The SA node
first sends out the electrical impulse to cause the atrial muscles to contract. The electrical
signal then travels to the AV node, down to the bundle of His, further down to the bundle
branches, and finally into the Purkinje fibers, causing both left and right ventricles to
contract. The SA node then sends out another signal and starts the cycle over again.
Because the heart rate is dependent on the rhythm of electrical signals that SA node sends
out, the SA node is also called the anatomical pacemaker.

1.2.2 Cardiac Connexins
Gap junctions formed by Cx43, the most abundant cardiac connexin, mediate the
electrical coupling and ventricular propagation of electrical impulse originating from the
SA node and are involved in the maintenance of a regular beating rhythm in the heart (37,
39, 77-79). Significant alteration in cellular expression, localization or phosphorylation of
Cx43 occurring after myocardial infarction and in the failing heart can cause the closure,
dysregulation or mis-location of gap junctions and disrupt the impulse propagation,
resulting in lethal arrhythmias (80, 81).
Even though human cardiac Cx45 is the first connexin expressed during
embryogenesis, after birth Cx45 expression becomes limited to the myocytes of the
specialized conductance and pace making system (82). Channels formed by Cx45 exhibit
distinct functional properties from those by Cx43 (e.g. unitary conductance, pH-dependent
closure sensitivity, voltage-dependent closure sensitivity, and selective permeability to
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Figure 1.2. Cardiac electrical system. Representation of the anatomy of the heart
anterior view of a frontal cut-away view. Components of the cardiac conduction system,
path of the action potential propagation (black arrows) and delayed action potential at the
AV junction (green) are labeled. This figure is reprinted and modified with permission
(Monteiro et al., 2017) (83).
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ions and small molecules) (84). These differences as well as the distinct expression
patterns of Cx43 and Cx45 in the normal heart are critical for cardiac function. Cx45 gap
junctions in the AV node have relatively high voltage sensitivity and slow conduction, and
those unique properties are thought to prevent current backflow from the myocardium to
the conduction system, enabling sequential contraction of the atria and ventricles (80, 84).
Remodeling of connexins (alterations in connexin distribution and/or expression level)
has been found in a number of heart diseases, such as ischemic heart disease, atrial
fibrillation, and heart failure (80). Numerous studies have revealed loss of Cx43
expression at the intercalated disc during cardiac remodeling, e.g. after cardiac ischemia
or during end stage heart failure (85). In addition to Cx43, alterations in Cx45 and Cx40
expression level as well as Cx45 localization have also been reported (80, 81, 86-90).
Cx40 is primarily expressed in the atria but not expressed in the ventricles (91). However,
an overall increase of Cx40 expression is found in ischemic heart and is localized in a
band of working myocytes adjacent to the conduction system in the ventricles (92). It is
presumed to be a compensatory mechanism for the loss of Cx43 coupling in the ventricle
but could also cause increased incidence of atrial fibrillation (92, 93). Cx45 has low
expression in the adult ventricular myocardium but is found to be upregulated in various
heart disease states (94, 95). Specifically, in end stage heart failure, Yamada et al. (2003)
have demonstrated upregulation of Cx45 leading to its localization at the ID in ventricular
myocytes, which was also synchronized with the typical lateralization and downregulation
of Cx43 (94).
While there is substantial knowledge about crucial interactions of Cx43 in the regulation
of gap junction channels, unfortunately the precise mechanisms that cause the remodeling
have not been clarified, nor have the key partner proteins involved been fully
characterized. Those data are essential if the role of GJIC in normal and diseased hearts
is to be fully understood.
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2. Gap Junction Regulation
Gap junctions are regulated through transcriptional, posttranscriptional, translational,
post-translational, trafficking, assembly, and turnover mechanisms (96). In addition, gap
junction opening and closing are also regulated through the gating mechanism including
voltage dependent, Ca2+ dependent, and pH-dependent gating (97). We will focus on
those important regulators for cardiac connexins: Cx43, Cx40, and Cx45.

2.1 Transcriptional Regulation of Connexins
Several important transcriptional factors especially the Sp1/Sp3 and AP-1 complex
mediate the transcriptional control of the Cx43 gene (98). The zinc-finger transcription
factor specificity protein 1 (Sp1) can potentially bind to four GC rich regions of Cx43
promoters (98). The AP-1 complex is a heterodimer composed of the c-Jun, c-Fos,
activating transcription factor (ATF), and Jun dimerization protein (JDP) protein families
and binds to the consensus sequence 5’-TGA (G/C) TCA-3’ (99). AP-1 can bind to two
sites in the proximal promoter for Cx43 in rat and only one site in human and mouse (100).
Transforming growth factor β (TGF-β), mitogen activated kinase kinase 4 (MKK4), and
Erk1/3 signaling can activate AP-1 mediated transcription of Cx43 (101-103). Other
signaling molecules such as Ras, Wnt1, and cAMP have also been found to affect the
transcription of Cx43 (104).
Cardiac specific transcription factors are also critical regulators of connexin expression.
Nkx2.5 is a transcription factor that is crucial for cardiac development and can bind to the
promoters of Cx40, Cx43, and Cx45 (105-107). Studies have shown that Nkx2.5 could upregulate both Cx43 and Cx40 in most conditions and down-regulate Cx43 expression
under certain conditions (106, 108, 109). Shox2, another essential homeobox type
transcription factor for cardiac development, functions upstream of the Nkx2.5 and
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represses the genes activated by Nkx2.5 (Cx43 and Cx40); however, Shox2 can also
activate Cx45 gene expression to promote the differentiation of pace-making system (110112). The transcription factor Irx3 can suppress the expression of Cx43 but activate the
expression of Cx40 (113). When over-expressed, the transcription factor Hop reduces the
expression of Cx40 in the atria in animals with hypertrophy (114). The Tbx family of
transcription factors have played multiple roles: Tbx2 and Tbx3 can down-regulate Cx43
and Cx40 expression but have no effect on Cx45 (115, 116); Tbx18 repressed the
expression of Cx43 but did not down-regulate Cx40 and Cx45 expression (117). Moreover,
Tbx5 is found to activate Cx40 expression in a dose-dependent manner (118).
Connexin gene expression can also be dictated epigenetically (119). Histone
acetylation is found to upregulate the expression of Cx43 and Cx45 (120). DNA
methylation also control the expression of connexins as reviewed in (119). MicroRNAs
(miRNAs) are another important player in mediating posttranscriptional control of connexin
expression (121). For example, miR-1 can bind to the 3’-UTR of Cx43 mRNA and is
overexpressed in patients with coronary artery diseases (122). MiR-17-92 and miR-130a
could down-regulate Cx43 and cause arrhythmias (123, 124). MiR-208a is found to
enhance Cx40 expression in the heart (125).

2.2 Connexin Life Cycle
Most connexin (e.g. Cx26, Cx32, Cx37, Cx43 and Cx45) proteins have a short half-live
of 1-5 hours. However, it can be variable depending on the cell type and tissues hours
(126-139). For example, Cx45.6 and Cx56 located in the eye lens have half-lives of about
90 hr when the dissected organ remains intact, but their half-lives are shortened to that of
other family members when the primary cells are isolated and cultured in vitro (140). The
connexin life cycle contains a number of steps, including 1) connexin biosynthesis; 2)
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connexin trafficking and gap junction assembly, and 3) gap junction internalization and
degradation (141). The control of connexin expression by various transcription factors has
been discussed above. Downstream factors making significant contribution to the
regulation of the connexin life cycle include interactions with protein partners and posttranslational modifications such as phosphorylation (142, 143). An overview of the
connexin life cycle and the important regulators is provided below. In addition, we will
focus on Cx43 life cycle as it is the most well characterized.

2.2.1 Connexin Biosynthesis
Biosynthesis of connexin proteins starts in the nucleus when the connexin genes are
transcribed. The degree of the gene transcription is a combination effect of different
available transcription factors. Once transcribed, relevant mRNAs are transferred from the
nucleus to the endoplasmic reticulum (ER) for translation at the ribosomes (132). The
specific structure of the mRNA of connexin contains an abnormally long 5’-UTR, so a capindependent translation is preferred, in which specific sequences localize in the 5’-UTR
enhanced ribosomal entry and the initiation of translation (144-146). Meanwhile the
connexin polypeptides are co-translationally integrated into the ER membrane where the
folding of the transmembrane topology (i.e. 4 transmembrane domains with cytoplasmic
NT and CT domains) is achieved (147). Certain ER resident chaperone proteins (e.g.
Erp29) play important roles in stabilizing the connexin monomer (148, 149). Despite
protein synthesis at the rough ER, no signal peptide sequence is present in connexin and
none of the amino acids are glycosylated (150).
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2.2.2 Trafficking and Assembly of Gap Junctions
After successful translation in the ER, connexins are oligomerized into hemichannels
and are transported by forward trafficking to the plasma membrane through the secretory
pathway

(143).

Hemichannels

are

hexameric

connexin

assemblies

and

the

oligomerization step occurs in the trans-Golgi network (151). Following oligomerization,
another critical step involves the trafficking of the vesicles (100-150 nm in size) containing
hemichannels along the microtubules and actin filament to the plasma membrane (152).
The trafficking process can be regulated by connexin phosphorylation as reviewed in
(142). The next step is the head-to-head docking of two hemichannels from adjacent cells
to form the gap junction channel (153). Such process involves complex interactions
between the extracellular loop regions of apposed connexin (154). The gap junction
channels then organize and form the gap junction plaque that has a wide size range
containing hundreds to thousands of gap junction channels (155). Zonula occludens-1
(ZO-1), a scaffolding protein containing an F-actin binding domain, is involved in the
inclusion step of newly assembled gap junction into a plaque (156, 157). Both E- and Ncadherins are important for gap junction assembly although their exact roles are still still
up for debate (158-162). In addition, the association of cadherin-associated cytoskeletal
anchor proteins (catenins) with Cx43 is found to be critical to gap junction formation (163).
Cx43 trafficking is also regulated by two serine kinases, PKA and Akt. Phosphorylation at
at S364 and S365 by PKA facilitates Cx43 trafficking and hence gap junction assembly
(164, 165). Phosphorylation at S373 by Akt also promotes forward trafficking of Cx43
through interaction with 14-3-3 proteins (166).
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2.2.3 Internalization and Gap Junction Turnover
The final stage of the connexin life cycle is internalization and subsequent turnover (or
recycling) of gap junctions, which happens in many physiological processes such as cell
division, growth factor activation, differentiation, apoptosis and wound healing as reviewed
in (132, 141).
Degradation of gap junctions can take place by different routes. The primary
mechanism suggests the initial internalization of intact gap junction plaques by one of the
adjoined cells, which are also described as annular gap junction (167). The internalization
process can happen by clathrin- or caveolin-dependent endocytosis (168, 169). Some
other mechanisms have been proposed by which the gap junctions are disassembled into
connexons and then internalized through endocytosis (170). Some recent studies have
shown the central “older” connexons of Cx43 gap junction plaques can be partially
internalized with new synthesized connexons integrated into the peripheral region of the
gap junction plaques (131, 171).
Cx43 can be degraded by proteasomal and lysosomal pathways. After the treatment
of proteasomal or lysosomal degradation inhibitors, the Cx43 expression levels are
increased in both conditions (129). Phosphorylation of Cx43 can be related to which
pathway was adopted (129). Phosphorylated Cx43 level is increased when lysosomal
degradation is inhibited and the non-phosphorylated Cx43 was accumulated when
proteasomal degradation is prevented (129).
Ubiquitination of connexin contributes substantially to gap junction turnover as
ubiquitination is essential for proteasomal pathway (172). Ubiquitin-binding protein
Tsg101 (tumor susceptibility gene 101) binds to connexins and leads to connexin
degradation through endosomal/lysosomal pathway (173, 174). The ubiquitin ligase
Nedd4a can either recruit the endocytic adapter protein Eps15 for Cx43-ubiquitin fusion
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protein internalization or engage the adapter protein 2 (AP2) and clathrin for Cx43
internalization and transport to the lysosome (175-177). Additionally, there is growing
evidence suggesting the involvement of autophagic degradation of connexins, but this
needs to be explored further in detail (178).

2.3 Gap Junction Channel Gating
Although the expression and turnover of gap junction is a primary control mechanism
for gap junction functions, another important mechanism is called channel gating, which
controls when and how much channels are opened and closed (61). The three major types
of channel gating are voltage, pH, and Ca2+ gating and will be discussed individually
below. However, it’s necessary to point out that channel gating is very complex and can
vary substantially between different connexins.

2.3.1 Voltage Gating
Voltage gating can modulate channel opening by converting the electrical potential
change neighboring the gap junction channel into large conformational changes, which
causes the channel to shut-down (179). A variety of charged amino acid residues in gap
junction proteins work as the “voltage sensor” (180-182). The gap junctions voltage gating
can be trans-junctional voltage (Vj) dependent or transmembrane voltage (Vm, less
common) dependent (183).
All gap junction family members can be gated by the Vj and the Vj dependent gating
are categorized into two types: fast-gating and slow-gating (61). For fast Vj gating,
transitions between open and residual states happen within ~1-4 ms and for slow Vj
gating, transitions between fully open and closed states occur in ~2-25 ms (61). All three
intracellular domains participate in the Vj gating. The CT domain of Cx43 and Cx32 is
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involved in fast-gating as the truncation forms caused a disruption of fast conductance
(184). Mutations in the NT domain also affect the fast-gating (185).
The Vm dependent gating is much less common among connexin family members
which involves only Cx43, Cx45 and Cx57 (186-188). The Vm dependent gating appears
to be related to cell type or species as Cx43 channels showed limited Vm dependence in
HeLa cells but heavy Vm dependence in oocyte (188, 189). The Vm dependent gating
may function as preventing the spread of excess charge from damaged cells to healthy
surrounding cells.

2.3.2 pH-dependent Gating
Intracellular acidification, which happens during ischemia, causes gap junction closure
and is another important gating system, i.e. pH-gating (190-193). This could be a
protective mechanism for the cells to restrain the “bystander” effect (194). pH-gating is
related to the CT domain as truncation of the CT domain prevents Cx43 channels closure
to pH change while coexpression of a soluble Cx43CT domain rescues pHi sensitivity
(195). Moreover, like the “ball-and-chain” model proposed for the closure of Na+ and K+
channels, a model of “particle-receptor” (Cx43 CT-CL interaction) is proposed to describe
intracellular acidification mediated channel closure. Duffy et al. (2002) first demonstrated
that pH-dependent structural order and the interaction between Cx43 CT and CL domains,
showing intracellular acidification induced binding of Cx43CT to L2 domain of Cx43
(aa119-144) (64). Among Cx43CT domain, peptides with different sequences (aa271-287,
aa336-350, and aa346-360) all binds to Cx43 L2 domain (aa119-144), determined by
mirror resonance spectroscopy (64). Of note, the first two regions cover the SH3 binding
domain (aa274-284) and an α-helical domain (aa340-348), respectively. CT-truncated
Cx40 is also showed a decreased pH sensitivity and rescued by coexpression of a
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separate Cx40CT fragment. Interestingly, Cx43CT could increase the pH sensitivity of CTtruncated Cx40 and vice versa (196). Additionally, a study by Bouvier at el. (2009) further
supported the “particle-receptor” model for pH-gating of Cx40 and Cx43 gap junction
channels, showing a direct interaction between the Cx40CL and Cx40CT or Cx43CT by
NMR (195). However, truncation of CT domains of Cx45 failed to render the channels pH
insensitive, suggesting alternative mechanisms may be involved (196). Some other
studies have shown the increased α-helical content in the Cx32, Cx43 and Cx45 CT
domain after acidification, which resulted in altered affinity for the CL or other protein
partners (176, 197).

2.3.3 Ca2+-dependent Gating
The last important gating mechanism is Ca2+ dependent (198). Ca2+ dependent gating
is a crucial effect of cellular Ca2+ signaling, and plays a critical role in cardiac tissues where
Ca2+ signaling is essential for each contraction cycle and proper cardiomyocyte function
(199, 200). There have been two proposed Ca2+ dependent gating mechanisms, i.e. the
direct way via Ca2+ ions binding to connexin hemichannels and indirect way through the
involvement of CaM (201, 202). The direct mechanism mediates connexin hemichannel
closure by Ca2+ ions binding to the charged residues, which cause a disruption of a salt
bridge between the hemichannel subunits in the extracellular region of the pore and the
subsequent conformational change (201). In the indirect mechanism, Ca2+ ions bind to
CaM and modify the affinity of CaM to the cytoplasmic domains of connexins (including
Cx32, Cx36, Cx43, Cx44, Cx45, and Cx50), which induce secondary structure change of
the cytoplasmic domains after CaM binding and mediate the gap junction channel closure
when the intracellular Ca2+ is increased (202-209). CaM has been found to interact with
both the CL and CT domains of Cx43 and increase the helical content in the CL domain
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(65, 75). The CaM binding domain of Cx32 is located on the NT and a significant increase
of helical content is found for the CT domain of Cx32 (210-212). Binding of CaM to the CL
domain of Cx45 is enhanced by Ca2+ ions and resulted in channel closure (213). The CT
domain of Cx45 is also found to interact with CaM although the implied function remains
to be explored (75).

3. Cx43 Phosphorylation
3.1 Introduction to Cx43 Phosphorylation
Multiple migratory bands have been observed during SDS-PAGE for connexins
including Cx32, Cx40, Cx43, Cx45, Cx46, and Cx50, with those bands showing slower
electrophoretic mobility (214-218). This is resulting from the disruption of the SDS to
protein binding ratio from the negatively charged phosphate and structural changes
caused by phosphorylation sites adjacent to proline residues (219, 220).
Phosphorylation of Cx43 is very well-studied and characterized. Phosphorylation
controls Cx43 gap junction assembly, size, turnover, as well as the regulation of electrical
and metabolic coupling. Serine and tyrosine residues are the major phosphorylation sites
in Cx43. PhosphoSitePlus is a web-based systems biology resource which provides
comprehensive information and tools for the study of protein phosphorylation. Table 1
summarizes all the identified phosphorylated serine and tyrosine residues by high
throughput papers (HTP) (30 residues) and low throughput papers (LTP) (21 residues)
from PhosphoSitePlus. HTP indicates the number of records in which this modification site
is assigned using only proteomic discovery mass spectrometry; while LTP indicates the
number of records in which this modification site is determined using methods other than
discovery mass spectrometry. The negative charge of the phosphate could affect the
permeability of ions to the pore, alter the structure of the transmembrane α-helices to
18

Phosphorylation site
S5-p
Y137-p
S244-p
Y247-p
S251-p
S255-p
S262-p
Y265-p
Y267-p
S272-p
S273-p
S279-p
S282-p
Y286-p
S296-p
S297-p
Y301-p
S306-p
Y313-p
S314-p
S325-p
S328-p
S330-p
S344-p
S364-p
S365-p
S368-p
S369-p
S372-p
S373-p

LTP
0
0
0
11
0
18
26
20
1
0
0
37
36
1
1
2
0
1
3
0
7
7
7
0
5
13
36
15
4
15

HTP
3
22
8
254
5
19
8
13
11
1
1
6
7
12
13
11
8
21
314
11
12
11
12
2
5
13
5
7
6
6

Table 1. The identified phosphorylated Cx43 serine and tyrosine residues from
PhosphoSitePlus. HTP (High Throughput Papers): The number of records in which this
modification site was assigned using only proteomic discovery mass spectrometry; LTP
(Low Throughput Papers HTP): The number of records in which this modification site was
determined using methods other than discovery mass spectrometry.
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influence pore size, or modify the binding affinities of protein partners involved in
regulating Cx43. Notably, if phosphorylation alters the kinetics of channel assembly or
degradation, cell-to-cell communication will be altered. The major Cx43 phosphorylation
residues, responsible kinases, and phosphorylation effects are summarized in Table 2
(143, 221-225).

3.2 Methods for Studying Connexin Phosphorylation
Traditionally, [32P]orthophosphate metabolic radiolabeling of intact cells has been used
to investigate the phosphorylation of connexins. In general, the radiolabeled connexins
from cell lysates are immunoprecipitated and the resolution of the common
phosphoisoforms of connexins is analyzed by SDS-PAGE. A limitation is the requirement
of highly specific antibodies for immunoprecipitation use in order to identify the
phosphoproteins. After successful immunoprecipitation of connexin from [32P] labeled
cells, the target can be separated by SDS-PAGE and detected by autoradiography (226).
However, this method does not allow to determine the number nor the identity of the
different phosphorylated residues (pSer vs. pThr vs. pTyr). Two-dimensional
electrophoresis provides a direct and reliable way to identify the content of the three major
phosphoamino acids. By applying the tryptic digestion to the immunoprecipitated [32P]
labeled protein prior to two-dimensional electrophoresis, the number of phosphorylated
sites and the pattern of connexin phosphorylation at certain condition (control or treatment)
are determined. (226). Although these methods are useful to identify specific
phosphorylation sites in connexin proteins at that time, their limitation includes that they
require large amounts of starting materials and take a long time (3-6 days) and they could
not identify residue specific phosphorylation. Edman degradation is an effective method
for quantitating p-Ser and p-Thr following β-elimination and derivatisation. However, other
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modifications on serine or threonine residues such as glycosylation, will also undergo βelimination and derivatisation to form the same end product. Hence this method may
overestimate the level of p-Ser and p-Thr. In this case, a method with higher accuracy is
needed, especially when glycosylation is involved in the post-translational modifications
(227, 228).
Recent advances in mass spectrometry have become the gold standard method for
the investigation of site-specific phosphorylation of connexins (229). Mass spectrometry
is a high sensitivity method, which provides qualitative and quantitative analysis on
attomolar to nanomolar amounts of samples. It also overcomes the handling and safety
issues associated with the radioactive materials and reduce radioactive waste (230). In
addition, mass spectrometry samples can be analyzed very fast at much lower cost.
However, the application of mass spectrometry to study site-specific phosphorylation is
complicated by the low signal of phospho-peptides and the abundance of nonphosphorylated proteins (231). To solve this problem, an enrichment step is usually
adopted. The easiest way of enrichment is the immunoprecipitation of phospho-peptide
using general pTyr, pSer, or pThr antibodies (232). Another reliable enrichment method is
called immobilized metal affinity chromatography (IMAC), in which the columns containing
chelated Fe3+ bind to phospho-peptides and separate them from non-phospho-peptides
(233). The phosphate group in the phospho-peptide can also be derivatized into stable
thiol group and captured by thiol-affinity resin (231). Finally, phosphorylated residue can
also be converted into aminoethylcysteine that can be recognized by trypsin (231). This
method also improves analysis of the peptides as it places the phosphorylated residue at
the C-terminus, generating a unique y1 ion (231). The development and application of
matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) have also improved
the detection limit of phospho-peptides and analyze the phosphorylation quantitatively
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(234). The high sensitivity and good reliability of mass spectrometry have successfully
helped identify many specific phospho-residues of connexins (235-237).
More recently, the development of high-quality phosphorylation specific antibodies has
also helped discern the effects of site-specific phosphorylation of connexins. The
development of phospho-specific connexin antibodies could be dated back to the mid
2000’s (238, 239). Phospho-specific Cx43 antibodies have helped partially reveal the
identity of the several electrophoretic bands, such as phosphorylation of S325/328/330
residues contributing to the P2 migratory form (238, 240). However, tyrosine
phosphorylation of Cx43 (pY265 and pY247), is observed in the P0, P1, and P2 bands of
Cx43, which may be attributed to the complexity of the altered mobility by phosphorylation
(239). Unfortunately, other than Cx43, there is still a lack of commercially available
phospho-specific antibodies for other family members.

3.3 Cx43 Serine Phosphorylation
The abundance of serine phosphorylation sites implicates the important functional
effect of serine phosphorylation on Cx43 regulation (241). Serine phosphorylation of Cx43
is triggered by various stimuli, which affect the channel trafficking, channel opening and
closure, internalization and intercellular coupling (157, 224, 242). A number of different
kinases have been involved in the serine phosphorylation of Cx43, and many residues are
targets for multiple protein kinases. (221). Currently known serine phosphorylation sites
and their corresponding kinases and effects are summarized in Table 2. In general,
phosphorylation by kinases such as protein kinase A (PKA), protein kinase B (PKB/Akt),
and Casein kinase 1 (CK1) is associated with forward trafficking, gap junction assembly,
and channel opening (142, 165, 240, 243). However, phosphorylation by kinases including
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protein kinase C (PKC), Cyclin-dependent kinases 1 and 5 (CDK1 and CDK5), and
mitogen-activated protein kinase (MAPK) promotes gap junction channel closure and
prime Cx43 for internalization (142, 244).
PKA. PKA is also known as cAMP (cyclic adenosine monophosphate)-dependent
protein kinase. Elevated intracellular cAMP is shown to enhance membrane trafficking of
Cx43 and up-regulate GJIC through the activation of PKA and subsequent
phosphorylation of Cx43 at S364 (164, 245). Residues including S365, S368, S369 and
S373 of Cx43 are phosphorylated in primary granulosa cells when the intracellular cAMP
level is increased (246). Interestingly, even though Cx43 is a poor substrate of PKA
compared to PKC, the phosphorylation at S364 by PKA is a requirement for the
subsequent phosphorylation of Cx43 by PKC at other sites (165). Additionally, Ezrin binds
to Cx43 and recruits PKA to promote phosphorylation on S369 and S373, which facilitates
gap junction assembly (247, 248). Of note, phosphorylation of S365 is reported as a
“gatekeeper”, by preventing PKC phosphorylation of S368 (249).
AKT (PKB). Phosphorylation of Cx43 at S369 and S373 promotes the Cx43 trafficking
to the membrane and stabilizes gap junctions (250-252). Especially, under wounding or
hypoxia condition, phosphorylation of Cx43 at S373 in skin or heart tissues increases gap
junction size and GJIC (253). Additionally, when S373 is phosphorylated, Cx43 is
predominantly found at the cell membrane and phosphorylation of S373 promotes
dissociation of ZO-1 and association with 14-3-3 protein, therefore leads to an increase in
gap junction size and communication level (166, 254, 255). ZO-1 localizes to the periphery
of Cx43 gap junction plaques at the membrane and controls the rate of Cx43 channel
accretion (156).
PKC. PKC is a family member of serine/threonine kinases which are activated by
diacylglycerol (DAG) and/or Ca2+. Increased phosphorylation of Cx43 by PKC is found in
many sites including S365, S368, S369, S372 and S373 in a variety of cells (256-260).
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The PKC dependent phosphorylation of Cx43 at S368 is reported to significantly downregulate the GJIC and reduce the half-life of Cx43 (258, 259, 261). The increased
phosphorylation of S368 in Cx43 appeared to reduce gap junction conductance during
ischemia condition (262). Solan et al. (2007) showed that the S365D mutant (mimicking
phosphorylation at S365) Cx43CT formed a different stable conformation than
unphosphorylated wild type Cx43CT. PKC-dependent phosphorylation of S368 is
significantly

reduced

by

mimicking

phosphorylation

at

S365,

indicating

that

phosphorylation of Cx43 at S365 serves a “gatekeeper” function by causing a change in
conformation that allows maintenance of GJIC (249).
Ca2+/CaM-dependent protein kinase II (CaMKII). CaMKII is a serine/threonine
protein kinase expressed in many tissue types, and is activated by an increase of cytosolic
Ca2+. A total of 15 Cx43 residues have been identified to be phosphorylated by CaMKII in
vitro by mass spectrometry analysis (Table 2). However, the role of CaMKII in the
regulation of Cx43 and site-specific function are still not completely discovered (263).
CaMKII is found to co-localize with Cx43 at the border region of infarcted hearts (264).
During ischemia progression, S306 is dephosphorylated, which resulted in reduced
electrical coupling (265).
CK1. CK1 family of serine/threonine protein kinases are found in eukaryotic cells and
contribute to multiple biological processes. Phosphorylation of Cx43 at S325, S328 and
S330 by CK1δ promotes gap junction assembly, which increases the overall level of GJIC
(240). CK1 dephosphorylation has been related to many pathological processes. For
example, upon ischemia, Cx43 is rapidly dephosphorylated at CK1 sites, followed by gap
junction disassembly (238, 262). Cx43CK1 S3A mice (S325, S328 and S330 are mutated
to inhibit serine phosphorylation) develop a proarrhythmic phenotype with impaired gap
junction function and formation, while Cx43CK1 S3E mice (S325, S328 and S330 are
mutated to mimic serine phosphorylation) are resistant to pathological gap junction
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Table 2. Kinases that phosphorylate Cx43 serine and tyrosine residues and their
effects on GJIC.
Serine Phosphorylation of Cx43
Kinase

Phosphorylated Residue(s)

Effect on GJs

PKA

S364/365/369/373

Increased GJIC
GJ assembly

AKT
(PKB)

S369/S373

Increased GJIC
Increased GJ plaque size

CK1

S325/328/330

Increased GJ assembly

CaMKII

S244/255/257/296/306/314/325/
328/330/364/365/369/372/373

Increased GJIC (S306)

PKC

S365/368/369/372/373

CDK1

S255/262

Decreased GJIC
Decreased GJ assembly
GJ internalization

CDK5

S279/282

Decreased GJIC

MAPK

S255/262/279/282

Decreased GJIC
GJ internalization

Tyrosine Phosphorylation of Cx43
Kinase

Phosphorylated Residue(s)

Effect on GJIC

Src

Y247/265

Decreased GJIC
GJ plaque disassembly

Tyk2

Y247/265/267/313

Decreased GJIC
Increased the intracellular Cx43
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remodeling and to the induction of ventricular arrhythmias (266). However, study by Solan
et al. (2019) found Cx43CK1 S3A mice were resistant to ischemia reperfusion injury (267).
Also, CK1 is found to be involved in wound repaired. Phosphorylation at S325, S328 and
S330 occurs within 5-30 min upon wounding (254, 255). A recent study by Lastwika et al.
(2019) showed that the genetically engineered Cx43CK1 S3A mice 1) experienced a
significant delay in wound closure; 2) an increase in epidermal thickness both in the healed
wound region as well as healthy skin; 3) a significant decrease in Ki67 (a marker for cell
proliferation) staining in the skin epidermis.
CDK1 and CDK5. Both CDK1 and CDK5 belong to the CDK family and function as
serine/threonine kinases. CDK1 plays a vital role in cell cycle regulation, while CDK5 is
mainly detected in the brain and found as an essential kinase in sensory pathways. In
brain, phosphorylation of Cx43 at S279 and S282 by CDK5 inhibits the membrane
trafficking and promotes the proteasome-dependent degradation of Cx43 in neurons
(268). During mitosis, GJIC is reduced due to phosphorylation on S255 and S262 residues
by CDK1 (269, 270). In addition, phosphorylation of S255 and S262 is associated with
the gap junction internalization and the loss of intercellular gap junction structures (271).
MAPK. MAPKs belong to a large family of serine/threonine protein kinases that
regulate a wide variety of cellular functions. Many MAPK family members (ERKs (ERK1,
ERK2, and ERK5), p38, and JNK) have been found to phosphorylate Cx43 including sites
of S255, S262, S279 and S282 (244, 272-274). For example, Cx43 is strongly
phosphorylated by ERK2 and relatively weaker phosphorylated by p38 or JNK at S279
and S282 (275). Phosphorylation of Cx43 at S279/282 helps mediate the interaction with
Nedd4, the first ubiquitin protein ligase identified to interact with Cx43 and involved in gap
junction internalization and degradation (175, 176, 276). The S255 phosphorylation by
ERK5 is found in EGF-treated HEK 293 cells, and therefore resulted in inhibition of GJIC
(277). Additionally, VEGF-mediated MAPK phosphorylation of S255, S262 and S279/282
26

can cause rapid gap junction internalization and inhibition of GJIC. Cx43 S368
phosphorylation is found to occur at the same time with observed phosphorylation of S255,
S262 and S279/282 when cells are treated with VEGF (274). This result indicates that gap
junction channel closure requires S262 phosphorylation by MAPK and likely occurs
simultaneously to PKC phosphorylation of S368 (142).

3.4 Cx43CT Tyrosine Phosphorylation
Although extensive research has been carried out on Cx43 serine phosphorylation
(addressed in 3.3), the effects of tyrosine phosphorylation have only been examined
recently. To date, there are a small number of tyrosine kinases (Src, EGFR, Tyk2) that
have been identified and investigated that regulate Cx43 (237, 278-280). In this part, we
will discuss the importance of Cx43 tyrosine phosphorylation as well as the tyrosine
kinases, Src and Protein tyrosine kinase 2 beta (Pyk2).

3.4.1 Src Kinase
In 1911, Rous injected chicken fibrosarcoma extract into healthy chicks and they
developed sarcomas (281). The agent responsible for the tumor was called Rous sarcoma
virus (RSV). In 1977, the Src gene was first identified from genome of avian sarcoma
viruses (ASV) by Brugge and Erikson (282). In 1980, Sefton et al. demonstrated that
protein Src is a tyrosine kinase (283). In parallel, c-Src has been identified and
characterized as the first proto-oncogene from normal avian DNA (284). Unlike v-Src from
viral genome, c-Src is present in the genome of eukaryotes. Although both v-Src and cSrc share sequence similarities, v-Src has increased transforming ability compared to csrc, due to lack of the C-terminal regulatory domain (285). The Src family include 3
subfamilies: SrcA subfamily (Src, Yes, Fyn, and Fgr), SrcB subfamily (Lck, Hck, Blk, and
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Lyn), and Frk in its own subfamily (286). Src is a non-receptor tyrosine kinase that is very
well studied and known to phosphorylate Cx43.

3.4.1.1 Src Kinase Structure and Function
As illustrated in Figure 1.3, from the N- to C-terminus, the Src kinase contains a
myristoylated SH4 domain, a unique region, an SH3 domain, an SH2 domain, and a
protein-tyrosine kinase (SH1) domain (287, 288). The N-terminal myristoyl group
facilitates the localization of Src to the cell membrane is required for cellular transformation
by v-Src, while nonmyristoylated Src could not bind to membranes (289-292). A regulatory
segment which contains an autoinhibitory phosphorylation site is positioned at the Cterminal tail (293). When the C-terminal tail is phosphorylated, the human Src SH2 and
SH3 domains are associated into a dormant form through intramolecular interactions (294,
295). A total of 536 amino acids are encoded by the human SRC gene (288). Each
component domain has its distinct structure and functions. A brief description regarding
the three major domains SH1-3 is given below.
The SH1 domain is the catalytic domain. It has a bi-lobal structure consisting of a large
peptide substrate-binding C-terminal lobe and a small ATP-binding N-terminal lobe (296).
The N-terminal lobe contains a glycine-rich sequence GXGXXGXV and has an
architecture composed of five β-strands and a single α-helix. The C-terminal lobe is mostly
α-helical and contains the activation site that catalyzes the transfer of the phosphate group
from ATP to tyrosine (296). The ATP binding and phosphate group transfer is considered
to happen in the cleft between the two lobes (296).
The Src SH2 domain lies between the SH1 and SH3 domains and interacts with
phosphorylated tyrosine in a sequence specific manner. For example, it binds to the pYEEI
motif preferentially (296, 297). SH2 domain contains about 100 amino acid residues and
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Inactive

Active

Figure 1.3. Schematic domain structure and secondary structures of Src. C-t, Cterminus; N-t, N-terminus. This figure is reprinted with permission (Roskoski et al., 2015)
(288).
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has a central β-sheet, with a single helix packed against each side (α1 and α2) (288). Two
recognition pockets are formed in the SH2 domain, one pocket coordinates to the
phosphotyrosine and the other pocket interacts with one or more hydrophobic amino acid
residues C-terminal to the phospho-tyrosine (288). The first pocket is conserved among
SH2 domains and includes an arginine residue (Arg178 in human Src) that forms
electrostatic interactions with the phosphorylated tyrosine (298). The second pocket is
more divergent and is responsible for binding to a variety of sequences that do not fit in
the pYEEI motif (299). The affinity between an SH2 domain and its binding
phosphotyrosine substrate is in the nanomolar range (300).
The Src SH3 domain contains about 60 amino acid residues and has a β-barrel
structure, which is composed of five antiparallel β-strands and two prominent loops, i.e.
the RT and n-Src loops (288, 298). Those loops are lying at either end of a surface
consisting of aromatic and hydrophobic residues that contain the recognition site for
proline-rich sequences with the “PXXP” motif (288, 296, 301). These proline-rich regions
present a polyproline type II helical conformation to form complex with the SH3 domain,
mediating the intramolecular interactions with SH3 domain (302).

3.4.1.2 Regulation of Cx43 by Src
Early studies described that phosphorylation of Cx43 by Src is a key initiator of gap
junction internalization and channel closure (303, 304). Later on, Src was shown to directly
phosphorylate Cx43 at residues Y247 and Y265 (305, 306). Swenson et al. (1990) (305)
used a functional expression system to investigate the effect of v-Src over-expression on
the regulation of GJIC. They detected that Cx43 was phosphorylated at residue Y265 by
v-Src while GJIC was inhibited. Lau et al. (2001) (306) used in vivo experimental system
to further examine the regulation of Cx43 by v-Src. By stably expressing v-Src and Cx43
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WT, or Y247F, Y265F, or Y247/265F mutants in a Cx43 knockout mouse cell line, they
found that phosphorylation on both Y247 and Y265 of Cx43 led to the disruption of GJIC.
Moreover, they summarized the model of the interaction between v-Src and Cx43. SH3
domain of v-Src directly binds to the proline-rich region (PXXP; P274–P284) of Cx43, leading
to phosphorylation on residue Y265 by the kinase domain of v-Src. Phosphorylation at
Y265 provides a binding site for the SH2 domain of v-Src, which not only stabilizes the
binding of Cx43 to v-Src, but also leads to subsequent phosphorylation on the Y247
residue.
Several studies have proposed mechanisms for Src-mediated channel closure,
including 1) the particle-receptor (or ball-and-chain) model (195, 307), 2) dissociation of
protein partners, and 3) activation of other kinases mediated by Src. Morley et al. (1996)
confirmed the hypothesis that pH gating of Cx43 resulted from intramolecular interactions
between the Cx43CT domain and the region of pore-forming structure (195). In 1999,
Zhou et al. found that truncations of the Cx43CT domain remained channel conductance
upon expression of v-Src, but this was reversed by coexpression of the CX43CT peptide.
Their findings suggest a particle-receptor model, which is similar to the mechanism
proposed for pH gating of Cx43 (307).
An additional explanation of decreased GJIC by Src is that phosphorylation of Cx43 by
Src leads to dissociation of protein partners, resulting in Cx43 gap junction plaque
disassembly and degradation. β-tubulin, Drebrin, and ZO-1 are Cx43 protein partners
affected by Src phosphorylation (85, 308-310). Microtubules extend directly to and are
associated with Cx43 gap junction plaques between adjacent cells (311). In normal
condition, β-tubulin helps to stabilize Cx43 plaque at the intercalated disc. In ischemic
heart disease mice models, dissociation of β-tubulin from Cx43 contribute to loss of cellcell coupling and Cx43 remodeling (internalization or lateralization) (312). One study by
Brikci-Nigassa at el. (2012) demonstrated the region of Cx43CT234-259 directly interacted
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with β-tubulin by NMR. They also showed that phosphorylation of Y247 inhibited Cx43
binding to β-tubulin (308). Drebrin (developmentally regulated brain protein) binds to and
organizes filamentous actin (F-actin) in dendritic spines (313-315). The N terminal domain
of Drebrin (Drebrin1-300, which contains the F-actin binding domain) directly interacts with
the Cx43CT, mediating the interaction between Cx43 and F-actin. Src phosphorylation of
Cx43 residue Y265 decreases the binding affinity for the gap junction stabilizing protein
Drebrin (309, 316). Dissociation of Drebrin from Cx43 results in impaired GJIC and
internalization of gap junction plaques (316). Localization of Cx43 at gap junction plaques
is also associated with interaction of Cx43 with the PDZ-containing scaffolding protein,
ZO-1. Although phosphorylation of the Cx43CT by Src does not directly affect ZO-1
binding, our lab demonstrated that the SH3 domain of Src can competitively bind to ZO-1
and therefore compromise the interaction between Cx43 and ZO-1 (85).
Finally, activated Src kinase mediates activation of AKT, PKC, and MAPK, indirectly
leading to phosphorylation of Cx43 at residues S373 (by AKT), S368 (by PKC), and S255,
S279, and S282 (by MAPK). Phosphorylation of S368 by PKC and S255, S279, and S282
by MAPK contributes to decreased GJIC (discussed in 3.3). Dunn et al. (2014)
demonstrated that phosphorylation at S373 by AKT eliminates the Cx43 interaction with
ZO-1 and increases gap junction size and communication by using a phospho-specific
antibody pS373 Cx43 (254). Also, phosphorylation of S373 is required for the Aktmediated interaction of Cx43 with 14-3-3, leading to Cx43 gap junction internalization and
degradation (166). Together these studies provide important insights into the role Src
plays in the regulation of Cx43.
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3.4.2 Tyk2
In addition to Src, another tyrosine kinase identified and characterized to
phosphorylate the Cx43CT is non-receptor tyrosine-protein kinase 2 (Tyk2) (237). Work
from our laboratory identified that phosphorylation of Cx43CT residues Y247 and Y265
by Tyk2 decreased gap junction stability at the plasma membrane and inhibited GJIC, and
Tyk2 increased the intracellular protein level of Cx43 through STAT3 activation (237).
Tyk2 can functionally substitute for Src since both can directly phosphorylate the same
Cx43CT residues, although the level of phosphorylation at each site and the overall
amount of Cx43 protein are different. While another difference is that phosphorylation of
these sites by Src would compete with Cx43 to directly bind to ZO-1 through the SH3
domain (discussed in 3.4.1.2), while Tyk2 could not lead to the dissociation of ZO-1 from
Cx43CT due to the lack of the SH3 domain (317). Additionally, Phosphorylation of
S279/282 by MAPK and S368 by PKC is found to decrease in the presence of Tyk2 siRNA,
indicating like Src, Tyk2 also indirectly affects serine phosphorylation (237).

3.4.3 Pyk2
Pyk2 is a Ca2+-dependent nonreceptor tyrosine kinase of the FAK family, known to
transduce signals from Ca2+, integrins, and G protein-coupled receptor to the downstream
MAPK and PI3K/PDK1/Akt signaling pathways (318, 319). Pyk2 is predominantly
distributed in the cytoplasm and regulates a wide range of physiological effects, including
cell proliferation, differentiation, apoptosis, and cytoskeletal regulation.

3.4.3.1 Pyk2 Structure and Function
From the N-terminal to the C-terminal, Pyk2 has three major domains: a N-terminal
band 4.1 and ERM (ezrin, radixin, moesin) homology domain (FERM) domain, a catalytic
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kinase domain, and a C-terminal focal adhesion targeting (FAT) domain (Figure 1.4) (320).
Additionally, an isoform of the Pyk2 gene (PTK2b) is specified by mRNAs that encode
only part of the C-terminal domain of Pyk2. (321). The endogenously expressed noncatalytic C-terminal fragment is expressed from mRNAs with alternative transcription start
sites (322) and is named as CRNK for calcium-dependent tyrosine kinase-related
nonkinase or PRNK for Pyk2-related nonkinase (323). CRNK includes protein binding
sites (proline-rich sites PR3), phosphorylation sites (Y849 and S866) and the FAT domain
(Figure 1.4) (324). Pyk2 contains binding sites for several proteins partners which are
labeled in Figure 1.4 (325). Among these interacting proteins, Paxillin plays an important
role as a scaffolding protein due to the interaction with both Pyk2 and Src. Function of
Paxillin will be addressed and discussed in detail in Chapter 4. Besides Pyk2, the FAK
family has another family member, FAK. Pyk2 evolved from FAK due to gene duplication
(326). In human, Pyk2 and FAK share 65% sequence similarity and both have the same
three major domains (327, 328). Same with FAK, Pyk2 can function as a protein scaffold
with kinase-dependent and kinase-independent functions (324). However, unlike FAK,
Pyk2 can be activated by calcium ions (Ca2+), even though the detailed molecular
mechanism for activation of Pyk2 by Ca2+ remains debatable (329). It is presumed that
Ca2+ does not bind directly to Pyk2 but binds through CaM, which has been reported to
bind to the FERM and the kinase domain of Pyk2 (330, 331). It could also possibly function
through Ca2+-activated Pyk2-modifying kinases including PKC, CaMKII and PKA, or
phosphatases such as calcineurin and PP1 or Ca2+-activated proteins such as PSD-95
(320, 329). Pyk2 activation occurs from an interaction with CaM causing homodimerization
and auto-phosphorylation at Y402 which facilitates Src binding (332). Subsequent Src
phosphorylation at multiple sites on Pyk2 enhances kinase activity and enables binding of
several other adaptor proteins (318). However, the trans-autophosphorylation of Pyk2 has
shown to be a Src-independent Process (333). A recent study by Zhao et al. (2016)
34

Figure 1.4. Schematic domain structure of Pyk2 and CRNK. The domains of Pyk2 and
CRNK are shown above. Interacting protein partners for Pyk2 are shown in blue boxes
with arrows pointing at the interacting domain or linker region. FERM domain: band 4.1
and ERM (ezrin, radixin, moesin) homology domain; FAT domain: focal adhesion targeting
domain; PR domain: Proline-rich domain. This figure is reprinted and modified with
permission (Naser et al., 2018) (324).
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revealed a novel function of Src in priming Pyk2 phosphorylation (334). An initial
interaction may be responsible for bringing Src and an unphosphorylated Pyk2 together,
such as through the SH3-domain of Src binds to the proline-rich region of Pyk2. Active
Src then directly phosphorylates Y402 residue of Pyk2, which forms a binding site for the
SH2-domain of Src. SH2-domain associates with and stabilizes the Src-Pyk2 interaction,
which contributes to further phosphorylation of Pyk2 by Src at Y579 and/or Y580 in the
activation loop. This results in Pyk2 additional activation which allows full phosphorylation
of Pyk2 by itself via transphosphorylation (334).

3.4.3.2 Pyk2 and Diseases
Heart diseases. In the heart, Pyk2 expression is much higher in neonatal rat
ventricular myocytes (NRVMs), compared to adult ventricular myocytes (335, 336). Pyk2
expression in cardiomyocytes is responsive to stress and will undergo substantial changes
under intracellular and extracellular stimuli (336). Tyrosine phosphorylation of Pyk2 occurs
under stressful stimuli such as Ca2+ overload, H2O2, and AngII-treatment (337). Both
expression and activity of Pyk2 are significantly increased in mouse models with cardiac
diseases including cardiomyopathy and heart failure (338). Many findings have shown the
critical role of Pyk2 in the pathogenesis of cardiomyocyte contractile dysfunction (323,
336, 339, 340). Expression and activity of Pyk2 in the left ventricle of failing human hearts
are markedly increased and related to lethal arrhythmias (339). Furthermore, during the
left ventricle pathological remodeling process, inhibition of Pyk2 activation can improve
heart function. For example, autonomously expressed PRNK (also called CRNK) is found
to block the auto-phosphorylation of Pyk2 at Y402, inhibiting the activation of Pyk2 (341).
Moreover, the overexpression of CRNK has been found to improve cardiomyocyte
survival, increase left ventricle contractile function and fractional shortening, as well as to
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change the gene expression profile (decreased β-, and increased α-myosin heavy chain)
in left ventricle hypertrophy (LVH) models of myocardial infarction and dilated
cardiomyopathy (323, 340). The molecular mechanisms responsible for the adverse
effects of Pyk2 dysregulation that accompany LVH and heart failure are not completely
clear. Through identification of Cx43 as substrates of Pyk2, studies in Chapter 3 will
determine the impact of Pyk2 phosphorylation on gap junction regulation and cardiac
electrical coupling.
Cancer. Pyk2 plays an essential role in tumor progression by regulating cancer cell
proliferation, migration, local invasion, distant metastasis, and drug-resistance (342, 343).
Overexpression of Pyk2 has been found in many types of tumors, such as breast cancer,
liver cancer, and lung cancer, and is associated with poor prognosis and decreased
survival (344). However, in a few tumors such as androgen-dependent prostate cancer
cells and neuroblastoma, Pyk2 shows a suppressive effect (345, 346). The oncogene role
of Pyk2 in several types of cancer is discussed below. Nearly 80% of breast cancer
patients have elevated Pyk2 expression (344). Pyk2 can promote breast cancer cell
proliferation and breast tumor growth through the phosphoinositide 3-kinase (PI3K)/Akt
and MAPK signaling pathways (347, 348). One study by Rucci (2004) has shown Pyk2 is
associated with breast cancer cell adhesion and motility and promotes breast cancer
invasion in part by increasing matrix metalloproteinase secretion and extracellular matrix
degradation (349). Pyk2 also promotes the epithelial-mesenchymal transition of breast
cancer cells and leads to cancer cell metastasis (350). Pyk2 is over-expressed in almost
60% of hepatocellular carcinoma patients (351). Pyk2 promotes tumor angiogenesis by
regulating the phosphoinositide 3-kinase (PI3K)/Akt pathway (352). Pyk2 is also correlated
with hepatocellular carcinoma metastasis and progression by upregulating hepatocellular
carcinoma cell motility through 1) increased phosphorylation at Y402 (353); 2) activating
Rho small GTPases Rac1 and RhoAI; 3) downregulating E-cadherin and cytokeratin and
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upregulating hydrogen peroxide inducible clone-5 (Hic-5) and signal transducers and
activators of transcription 5b (STAT5b) (354). In non-small-cell lung cancer patients, Pyk2
is correlated with the expression of cancer stem cell markers (ALDH1a1, ABCG2, and
Bmi-1), as well as lymph-node metastasis (355, 356). Therefore, Pyk2 upregulation serves
as a potential prognostic biomarker for NSCLC patients, and high Pyk2 expression and
activation (Pyk2 pY881) are related to poor overall survival. Pyk2 is also involved in the
signaling pathways downstream of Src that mediates lung adenocarcinoma cell survival
(357).

3.4.4 Cx43 Phosphorylation and Diseases
Injury and wound repair. Cx43 plays an important role in wound healing as inhibition
of Cx43 promotes skin cell proliferation and migration. During wound repair, Cx43
regulation through a variety of kinases, including Akt, CK1, MAPK, PKC, and Src (227,
240, 244, 254, 255, 260, 306, 358, 359). For example, Dunn et al. (2014) showed
phosphorylation of S373 by Akt significantly increased within 5-30 min upon wounding.
Additionally, phosphorylation on S373 increases the size of gap junction plaques as well
as GJIC, potentially leading to activation and migration of keratinocytes in the skin (254).
However, Cx43 dephosphorylation (CK1 phosphorylation sites S325, S328 and S330) or
phosphorylation (at MAPK phosphorylation sites S279 and S282, and Src phosphorylation
site Y265) or results in gap junction disassembly at 5-30 min (CK1), 15-60 min (MAPK),
and 30 min-24 h (Src), respectively (240, 244, 254, 255, 306, 358, 360). Phosphorylation
at the PKC sites S368 has been found to regulate Cx43 through changing channel
selectivity (227). Richards et al. reported that phosphorylation on S368 by PKC is highly
regulated in basal keratinocytes and essentially lost from suprabasal layers adjacent to
the wound. The changes were observed only at 24 h after wounding and were not
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observed at 6 or 72 h after wounding, indicating that PKC mediated phosphorylation of
Cx43 on S368 can temporally and spatially regulate wound healing (359). A recent study
provides direct in vivo evidence that phosphorylation of Cx43 by different kinases changes
the physiological response during wound healing by performing wounding procedures and
measurements on three knock-in mouse models expressing Cx43 mutants (CK1, MAPK
or PKC sites were mutated to eliminate serine phosphorylation, respectively) (360). They
found that eliminating serine phosphorylation sites of PKC or CK1 leads to a significant
decrease in the wound healing rate in vivo. In contrast, preventing Cx43 phosphorylation
by MAPK through site mutation significantly increased the rate of wound healing in vivo.
Because of the essential role that Cx43 plays during wound healing, it has been studied
as a therapeutic target for a many years. In 2003, Qiu et al. first demonstrated in vivo that
wound healing rate was increased by application of a Cx43 antisense gel directly to the
healing wounds (361). A Recent study found that both scrape wound closure and cell
proliferation were enhanced in human dermal fibroblasts when Cx43 siRNA was used to
knockdown total Cx43 level (362). Additionally, peptides which targets Cx43 have been
developed and used in the treatment of wound healing, including alpha connexin carboxyl
terminus 1 (αCT1), Gap19, Gap26, Gap27 (363-366). Although a number of these
peptides have been developed and studied, only αCT1 peptide, has been proved for
Phase I and Phase II clinical trials. αCT1 peptide (contains last nine amino acids of the
Cx43CT) competitively disrupts the interaction between the PDZ domain of the Cx43CT
and the second PDZ domain of ZO-1, inhibiting Cx43 recycling and transport facilitated by
ZO-1 (156, 367).

Cancer. Cx43 expression is inversely correlated with lymph node metastasis by
suppressing tumorigenesis in primary tumors such as gastric cancer, pancreatic cancer,
and non-small-cell lung cancer (368-371). However, Cx43 is found increased and
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localized at the cell membrane in metastatic lesions of several cancer types, like breast
cancer and melanoma (372-375). A study by Gould et al. (2005), examined whether Cx43
phosphorylation correlated with breast cancer stage, using a phospho-specific antiserum
(SA226P) that selectively reacts with Cx43 pS279/S282 (376). In their study, they
examined a total of 98 breast samples which include normal, fibrocystic disease, benign,
and malignant tumors. All samples were stained with SA226P antiserum and compared
to total Cx43 IHC staining. Cx43 pS279/S282 was increased in the epithelial part of in situ
carcinomas and in the overwhelming majority of invasive carcinomas. A study with human
pancreatic tumor cell lines BxPC3 and Capan-1 demonstrated that phosphorylation on
S279/282 of Cx43 results in gap junction disassembly and inhibiting phosphorylation on
these residues restores gap junction assembly (377).

Inflammation.

Pro-inflammatory

stimulus

(lipopolysaccharide,

LPS)

and

proinflammatory mediator (TNF-α) are involved in the regulation of Cx43 by activation of
kinases which phosphorylate Cx43. For example, Lidington at el. showed LPS led to Cx43
tyrosine phosphorylation and inhibition of GJIC in cultured rat microvascular endothelial
cells. In addition, it is reported that TNF-α activated c-Src in non-cystic fibrosis airway
cells. Therefore, a rapid decrease in GJIC is observed due to activation of c-Src. Moreover,
decrease of GJIC can be prevented by pharmacological antagonists of c-Src or
overexpression of a dominant negative construct of c-Src or a Cx43 mutant lacking
tyrosine phosphorylation sites for c-Src in non-cystic fibrosis cells (378).
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4. Connexins and Cardiac Diseases
4.1 Ischemia-Reperfusion Injury
Patients with acute myocardial infarction usually present with a blockage in the
coronary artery (379). The occlusion deprives the oxygen and nutrient supply to the nearby
cardiomyocyte, inhibits the normal contractile function, and therefore causes cell death as
well as many biochemical and metabolic changes (380). The hypoxia environment
prevents oxidative phosphorylation and results in ATP depletion (381). Cells are forced to
utilize the anaerobic glycolysis, leading to intracellular lactate accumulation and acidic pH
(382). Cx43 localization and phosphorylation are significantly varied during ischemia
caused injury, which is tightly correlated with the cellular ATP content (383). Studies from
isolated cardiomyocytes subjected to prolonged ischemia indicated that Cx43 distribution
was changed with reduced Cx43 localization at the intercalated disc and increased Cx43
at the lateral membrane (384, 385). At the same time, Cx43 phosphorylation levels are
also changed by a significant decrease at residues S325, S328, S330, and S365 and a
substantial increase at residues S368 and S373 (238, 249, 254, 386). Those changes
damage the normal gap junction function of cardiomyocytes and also cause sustained
opening of hemichannel during ischemia/reperfusion, which finally results in ion transport
being overloaded and consequently causes cell swelling and cell damage (387). It is
presumed that the opening of Cx43 hemichannels during ischemia-reperfusion is likely a
critical mechanism for ischemia-reperfusion injury in the heart (388). After reperfusion, the
recovery of cardiac function is correlated with an increase in the Cx43 phosphorylation
(389).
Pharmacological modulation of Cx43 function and expression may provide cardioprotection in ischemic cardiovascular disease (390). Connexin mimetic peptides such as
Gap26 (VCYDKSFPISHVR) that contains the sequence identical to the first EL of Cx43,
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and mimetic peptide such as Gap19 (KQIEIKKFK) that contains the sequence located on
the L2 domain of CL (reviewed in (366)), can inhibit Cx43 hemichannels and are found to
increase cardiomyocyte survival in a simulated ischemic condition (391, 392). Animal
studies also revealed that blocking Cx43 hemichannels decreased the size of infarction
by using Gap19 and Gap26 (391-393). Interestingly, the effect of Gap26 on infarction area
reduction seems to be greater than that of Gap19, which might be related to the fact that
Gap26 is less selective towards to hemichannel inhibition and channels composed of
connexin other than Cx43 can also be inhibited (390). Many pharmacological treatments
are reported to reduce infarction size after ischemia-reperfusion with their effects
associated with Cx43 phosphorylation (143). For example, the effect of inhibition of p38
MAPK is correlated with an increase in S368 phosphorylation of Cx43 (394). The effect of
sphingosine-1 phosphate on increased cell survival and reduced infarction size in
ischemia-reperfusion is accompanied with an increase of phosphorylated S368 in Cx43
(395, 396). Such an effect is lost when the S368 of Cx43 is mutated to Ala (396).
Ischemic preconditioning is a process whereby transient short episodes of ischemia
protects the heart against subsequent prolonged myocardial ischemia/reperfusion injury
and reduces the size of the myocardial infarction in model systems (397). One explanation
is that ischemic preconditioning could prevent the ischemia-induced dephosphorylation of
Cx43 in vitro and in vivo. The preserved phosphorylation of Cx43 is associated with
activation of PKC, and the effect of ischemic preconditioning on the reduction of infarction
sizes is lost in mice knockout of PKC (398).

4.2 Hypertension and Hypertrophy
LVH is characterized by an abnormal mass increase in the left ventricle and can
progress into stroke, heart failure, and cardiovascular mortality in patients (399).

42

Hypertension is the most common cause of LVH (400). In patients, Cx43 expression is
initially increased in mild phase of hypertrophy but gradually decreased and redistributed
when hypertrophy progresses into severe hypertrophy (401). Animal studies from different
study groups showed that expression of Cx43 was up-regulated in spontaneously
hypertensive rats (402-404), while other groups have found that Cx43 expression was
decreased (405, 406). The difference could be partially explained by the degree and stage
of LVH associated with hypertension. Similar connexin expression change during
hypertrophy progression is found in pigs with left ventricular volume-overload (407). In
humans, sarcolemmal distribution of Cx43 in the hearts is found altered in mild LVH
caused by pressure or volume overload (408). In mice, the transverse aortic constriction
either caused Cx43 redistribution with unchanged total Cx43 expression in some studies
(409) or a reduction of the total and phosphorylated Cx43 expression (resulting from an
enhanced Cx43 ubiquitination) (410-412).
In vitro stretching of cultured cardiomyocytes can mimic the mechanical stress
response and could induce cardiomyocyte hypertrophy but is preferential for studying the
initial cardiac change (413-416). A dramatic increase in Cx43 expression have been found
in many stretch studies at 1 to 6 hours (417). Cardiac hypertrophy can be remodeled in
transgenic mice models (416). Transgenic mice over-expressing active calcineurin, a
calcium-dependent phosphatase in cardiomyocytes, develop severe hypertrophy, which
is accompanied by decreased expression of Cx43 and dephosphorylation of Cx43 (418).
However, it is unclear whether calcineurin directly affects Cx43 expression or whether
NFAT activation is involved (419). Significantly reduced levels of Cx43 protein and RNA
are found in the enlarged heart chamber in transgenic mice overexpressing wild type
Nkx2.5 (108). Hypertrophy can also be biochemically induced. For example, the long-term
exposure of isoproterenol to rats induced cardiac hypertrophy and Cx43 is reduced in
expression and redistributed in cardiomyocytes (420).
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Changes in Cx43 expression, phosphorylation, and redistribution found in hypertension
and hypertrophy can be restored or attenuated by treatments that ameliorate hypertension
and hypertrophy, suggesting a reversible process involved (390). Those pharmacological
modulations include but are not limited to angiotensin II type 1receptor blockers such as
losartan, aldosterone antagonists, and renin inhibitors (405, 411, 421). Melatonin could
also restore myocardial Cx43 redistribution, upregulates Cx43 mRNA and protein
expression, and preserve the phosphorylated Cx43 in rat models with spontaneous
hypertension (422). Similar results were achieved in spontaneously hypertensive rats fed
with red palm oils (423).

4.3 Heart Failure
Heart failure is characterized by the abnormal function of the heart, unable to pump
enough blood to meet the body’s needs (424). It can be caused by many cardiac diseases,
including previous myocardial infarction, hypertension, and atrial fibrillation (425). Other
factors such as infections, toxins, and valvular heart diseases that affect the normal
structure or function of the heart can also contribute to heart failure (426). Heart failure
can be categorized based on pathophysiological conditions, including ischemic
cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy (427). Tissue
sample staining from failing hearts of patients suffering from ischemic cardiomyopathy and
dilated cardiomyopathy revealed that the expression of Cx43 was reduced and Cx43 was
redistributed to the lateral side of the cardiomyocyte (91, 428-430). Some studies
presumed that the reduction in ventricular gap junctional Cx43 in patients of congestive
heart failure might be partially mediated by changes in Cx43/ZO-1 interaction as the ratio
of Cx43 interacting with ZO-1 was found increased (431). Regardless of the cause of heart
failure, both Cx43 total expression and gap junctional Cx43 are reduced in heart failure
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animal models of many species, including rabbits, mice, rats, and dogs (123, 432-434).
Most studies also have reported significant dephosphorylation of Cx43 in failing hearts of
animal models (432, 434). Interventions targeting Cx43 expression and phosphorylation
have been applied. The dephosphorylation of Cx43 in rabbits with pacing caused heart
failure is correlated with the activation of p21-activated kinase 1 and related protein
phosphatase 2A (435, 436). The inhibition of protein phosphatase 2A in the isolated
cardiomyocyte from the failing rabbit heart restored Cx43 phosphorylation (436). By overexpressing Cx43 in failing hearts of rabbits using adenovirus transfection, the cardiac
function, such as intercellular coupling, could be improved (437). The reduction of Cx43
expression in adriamycin-induced failing heart in rats is associated with the induction of
mitophagy and activation of matrix metalloproteinase (438) and the reduction of connexin
expression is found to be attenuated by inhibition of the related proteasome (439).
However, there is a lack of studies about the function of mitochondrial Cx43 in heart
failure. One study in dilated cardiomyopathy induced by furazolidone found decreased
Cx43 expression in both myocardium and isolated mitochondria (440). Dephosphorylation
at S368 of mitochondrial Cx43 is also found, but the importance behind those changes on
mitochondrial function is unclear (440).

4.4 Arrhythmias
The heart is rhythmically beating which requires synchronized contraction achieved by
organized transmission of action potentials that trigger the heart to beat smoothly and
orderly (441). Gap junctions and other ion channels are responsible for the propagation of
the action potentials. Formed by various connexin isoforms, gap junctions have distinct
expression and distribution patterns as well as different conduction characteristics in
cardiac tissues, playing important roles for normal cardiac function (442).
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Arrhythmia, also known as irregular heartbeat, can be divided into: slow heartbeat or
bradycardia, fast heartbeat or tachycardia, irregular heartbeat or fibrillation, and early
heartbeat, or premature contraction (443). Arrhythmia can also be categorized into several
types according to where in the heart the arrhythmia originates: atrial fibrillation, atrial
flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and
long QT syndrome (444).
Perturbations to the gap junction and connexins contribute to arrhythmias, including
ventricular fibrillation, atrial fibrillation, etc. (445). Ventricular fibrillation is considered as
the most dangerous type (446). In many cases, the development ventricular fibrillation is
secondary to other cardiac pathologies, such as acute ischemia, which is characterized
by two peaks of ventricular fibrillation incidence (447). The first peak happens in 5 min
after ischemia and the second takes place after 20-30 min. The gap junction uncoupling
is related to the second peak (448, 449). Upon acute ischemia, the acidified intracellular
pH and ATP depletion interfere with various membrane pumps and ion exchangers,
leading to intracellular accumulation of Na+ and Ca2+ and membrane depolarization, which
finally results in a reduction of gap junction conductance (or gap junction uncoupling) (143,
450, 451). Consequently, action potential conduction is delayed or even stopped (143).
Antiarrhythmic peptides such as AAP10 or rotigaptide could antagonize the ischemia
related uncoupling by maintaining Cx43 phosphorylation and preserving the gap junctional
Cx43 distribution (452-454). The potential transverse conduction due to Cx43
redistribution at the lateral side of the cardiomyocyte and the reduced expression of gap
junctional Cx43 might also affect the gap junction conduction and local propagation
patterns, contributing to the arrhythmia incident (455, 456).
Atrial fibrillation is the most common type of cardiac arrhythmia (457). Atrial gap
junctions contain two connexin isoforms: Cx43 and Cx40 with similar abundances (458).
While inconsistent changes in the expression and distribution of Cx43 and Cx40 have
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been found both in patients and animals with atrial fibrillation (459), a consistent decrease
in the Cx40/Cx43 ratio has been reported (460-462). One study in a rabbit model found
the development of atrial fibrillation was promoted when activated JNK caused Cx43
reduction (463). Genetic mutations in Cx40 and Cx43 genes, causing a defect in gap
junction function, formation, or degradation, have also been discovered and linked to AF
in patients (464-467).

5. Objective
In diseased human heart, altered ventricular Cx43 gap junction expression, cellular
localization, and phosphorylation state (i.e. remodeling) are key contributors to rhythm
disturbances and contractile dysfunction. While there is considerable information
regarding key interactions of Cx43 in the regulation of gap junction channels, unfortunately
the precise mechanisms that lead to remodeling have not been fully defined. This
information is pivotal if the role of GJIC in normal and diseased states is to be fully
understood.
The objective of this dissertation is to use a multi-disciplinary approach to investigate
the role of tyrosine phosphorylation in altering Cx43 function in cardiac diseases. Chapter
Two includes studies focused on identifying Cx43 residue Y313 as a novel site targeted
for phosphorylation by Src and investigating the biological significance of phosphorylation
of Y313 by Src. In Chapter Three, for the first time, we identified that Protein tyrosine
kinase 2 beta (Pyk2) targeted Cx43, and characterized the impact of this phosphorylation
on Cx43 function. Chapter Four contains additional on-going studies on 1) a scaffolding
protein, Paxillin, and its function in the regulation of Cx43 phosphorylation by Pyk2 and
Src, and 2) a mechanism that promotes Cx45 expression and ventricle localization in heart
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failure. Finally, Chapter Five is a summary all of my projects and proposed future
directions.
Mechanisms underlying the initiation and persistence of heart failure and lethal cardiac
rhythms are of significant clinical interest. Changes in connexin distribution, density,
and/or channel properties are characteristic of cardiac disease. Therefore, knowing what
causes these alterations is essential to define the pathological cellular substrate and
devise effective therapies.
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CHAPTER TWO

Identifying the Biological
Significance of Cx43 Y313
Phosphorylation by Src
The data presented in this Chapter is published Zheng et al. (2019),
Journal of Molecular and Cellular Cardiology (468)
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6. Introduction
Gap junctions are integral membrane proteins that enable the direct cytoplasmic
exchange of ions and low molecular mass metabolites between adjacent cells (469). They
provide a pathway for propagating and amplifying signal transduction cascades triggered
by cytokines, growth factors, and other cell signaling molecules involved in cellular
development, growth, and differentiation. In the heart, gap junctions mediate propagation
of cardiac action potentials and the maintenance of a regular beating rhythm (80).
Dysfunctional intercellular communication via gap junctions has been implicated in
causing many human diseases (470). Gap junctions are formed by the apposition of
connexons from adjacent cells, where each connexon is a hexamer of connexin proteins.
Though the 21-connexin isoforms share significant sequence homology, the major
divergence in primary structures occurs in the cytoplasmic loop and carboxyl-terminal (CT)
domain.
The regulation of gap junction assembly, stability, degradation, as well as channel
gating and selectivity properties, all involve CT phosphorylation. Over 20 amino acids in
the connexin43 CT (43 kDa isoform; Cx43CT) domain have been identified as
phosphorylated and significant progress has been achieved in characterizing the involved
kinases (221-224). The negative charge of the phosphate could affect the permeability of
ions to the pore (471), introduce conformational changes distinct from charge alone to
alter the CT structure and/or transmembrane α-helices to influence pore size (472), or
directly modify the binding affinities of protein partners involved in regulating Cx43 (254,
308, 473). Notably, if phosphorylation alters the kinetics of channel assembly or
degradation, cell-to-cell communication will be altered. For example, studies have
demonstrated that MAPK phosphorylation of Cx43 residues S279 and S282 increases the
binding affinity for the E3 ubiquitin ligase Nedd4, which leads to Cx43 degradation (175,
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177, 473) and Src phosphorylation of Cx43 residue Y265 decreases the binding affinity
for the gap junction stabilizing protein Drebrin (309, 316). Other studies have shown that
Src phosphorylation of Cx43 residue Y247 inhibits the binding of β-tubulin (308) and Akt
phosphorylation of Cx43 residue S373 inhibits the interaction with ZO-1 (254). In addition,
phosphorylation of S373 enables the binding of 14-3-3 leading to gap junction
ubiquitination, internalization, and degradation during acute cardiac ischemia (166).
Clearly, our understanding of connexin regulation will not be complete until all kinases,
protein-binding partners, and CT sites phosphorylated have been identified, and the
impact of such modifications recognized.
We therefore searched the web-based systems biology resource PhosphoSitePlus in
an attempt to identify phosphorylation sites that have not been correlated with Cx43
function (474). Of interest was Y313, which had the greatest number of reported
phosphorylation modifications (312 hits) of any Cx43 serine or tyrosine residue (Y247 was
next with 253 hits) as observed from proteomic discovery mode mass spectroscopy (474).
Based upon the study of Lin et al. (306), which still observed tyrosine phosphorylation by
Src when using a Cx43 Y247/Y265F mutant, we addressed in this study the possibility
that Src phosphorylates Cx43 residue Y313. We established an in cyto experimental
system by stably expressing Cx43 wild type (WT) and mutants (Y247F, Y265F, Y313F,
Y247/265F, Y247/313F, Y265/313F, or Y247/265/313F) in Cx43-deficient HeLa cells.
Expression of v-Src causes phosphorylation of Cx43 residue Y313, which contributes to
loss of gap junction intercellular communication (GJIC), intracellular localization of Cx43,
and the inhibition of the Cx43 interaction with Drebrin. Additionally, an increase in
phosphorylation of Cx43 Y313 was observed in diseased human heart.
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7. Materials and Methods
7.1 Antibodies
Cx43 pY247 and pY265 antibodies were generous gifts from Dr. Paul Lampe (Fred
Hutchinson Cancer Research Center). The Cx43 pY313 antibody was produced in rabbit
from a peptide designed and chemically synthesized (LifeTein). Additional antibodies used
in this study include α-Src (#2123S), α-phospho-Src (Y416) (#6943S), α-rabbit-Alexa488
(#4413), α-mouse-Alexa647 (#4410), Normal Rabbit IgG (#2729), and α-pTyr-1000 MultiMab (#8954) purchased from Cell Signaling; α-mouse-HRP (H+L; #12-439) and α-Drebrin
(#AB10140) purchased from EMD Millipore; α-Cx43 (#C6219) purchased from SigmaAldrich; Texas Red Dextran (3 kDa; #D1863) and Lucifer yellow CH (#L453) purchased
from Life Technologies; α-rabbit-HRP (H+L; #20320) purchased from Alpha Diagnostics;
α-Cx43 (ab87645 and ab15189) and α-goat-Alexa555 (ab150130), α-rabbit-Alexa647
(ab150079) purchased from Abcam; and DAPI (#157574) purchased from MP
Biomedicals.

7.2 Molecular biology
Cx43 WT was PCR amplified from a pGEM-HE (Clontech) plasmid containing the
human Cx43 (hCx43) sequence using primers suitable for Gibson assembly into the
pD2529 vector (Atum). Purified PCR product and vector were assembled using NEBuilder
HIFI DNA Assembly Master Mix (NEB) per manufacturer protocol. All mutant constructs
of hCx43 (Y247F, Y265F, Y313F, Y247/265F, Y247/313F, Y265/313F, Y247/265F,
Y247/265/313F, and Y313E) were generated using the QuikChange Lightning SiteDirected Mutagenesis Kit (Agilent) and confirmed by DNA sequencing (ACGT, Inc.).
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7.3 Cell Culture
HeLa and LA-25 cells were generous gifts from Dr. Steve Caplan (University of
Nebraska Medical Center) and Dr. Paul Lampe (Fred Hutchinson Cancer Center),
respectively. LA-25 is a modified NRK cell line that endogenously expresses Cx43 and
contains a temperature sensitive v-Src (239). All cells were cultured in Dulbecco’s
modified Eagle medium (Corning) supplemented with 10% fetal bovine serum (Atlanta
biologicals), 2 mM L-glutamine (HyClone), 1% pen-strep (Corning), and 0.2% Normocin
(Invivogen) at 37°C in a humidified 5% CO2 atmosphere.

7.4 Stable clone generation
Approximately 60-70% confluent HeLa cells were transfected with pD2529 SalI
linearized hCx43 WT and Y→F mutants using Lipofectamine 2000 in OptiMem.
Transfections were carried out under antibiotic free conditions, and cells were cultured 72
hr prior to addition of puromycin (2 µg/mL; Tocris) selection media. All Cx43 WT and Y→F
mutant cell lines were clonally selected using Whatman paper cloning disks. Western blots
and immunofluorescence were used to screen clones.

7.5 Immunofluorescence
Cells grown on coverslips were fixed with 4% Paraformaldehyde for 20 min at room
temperature (RT). Coverslips were washed 2x 5 min in 1x Tris-buffered saline (TBS) and
then blocked for 60 min at RT with blocking buffer (1x TBS, 5% Goat Serum, 0.2% Triton
X-100). Cells were immunostained with appropriate primary antibodies diluted in blocking
buffer overnight at 4°C. Coverslips were washed 3x 10 min with 1x TBS, incubated with
secondary antibody for 1 hr at RT, stained with DAPI (100 ng/mL) (MP Biomedicals) for
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10 min, and then washed 3x 10 min with 1x TBS. Coverslips were mounted on a drop of
SlowFade anti-fade (Life Tech), sealed with clear nail polish, and imaged.

7.6 Confocal imaging
All cell immunofluorescence images were acquired on a Zeiss LSM 800 Confocal
system using appropriate numerical aperture objectives and appropriate filter sets.

7.7 Western blot
Cultured cells were rinsed 2x with cold 1x TBS and then lysed in lysis buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 0.2% SDS, Complete protease inhibitor and PhosSTOP)
on ice for 30 min. Protein concentration was quantified by BCA assay (Pierce). A total of
30 μg protein lysate was resolved by SDS-PAGE and transferred to PVDF (EMD Millipore)
membrane. Blots were blocked in 5% BSA in TBST (1x TBS with 0.1% Tween-20 plus 5
mM Na3VO4) for 1 hr at RT and incubated with indicated primary antibody in blocking
buffer overnight at 4°C. Blots were washed 3x 10 min with TBST, and then incubated for
1 hr at RT with secondary antibody. Blots were then washed again 3x 10 min with TBST
and detected using the Signal West Femto kit (Thermo) per manufacturer protocol and
exposed to autoradiography film. Quantifications were done using NIH ImageJ software
using a minimum of three independent replicates.

7.8 Co-immunoprecipitation
HeLa cells stably expressing Cx43 were seeded in 10 cm plates, transfected with or
without v-Src (Addgene, #14578), and then grown to confluency. Cells were rinsed 2x with
1x TBS + 1 mM EDTA and then scraped up in either 0.5 or 1.0 mL of IP lysis buffer (25
mM Tris, 150 mM NaCl, 0.25% sodium deoxycholate, 0.05% SDS, 1% Triton X-100 plus
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protease, 10% glycerol, and phosphatase inhibitors). Cells were mechanically lysed
(syringe pumping) and then incubated for 30 min at 4°C with rotation. Lysates were
precleared with normal rabbit IgG (2 µg) bound protein G agarose for 1 hr at 4°C and then
clarified by centrifugation. Clarified lysates were quantified by BCA (Pierce) and
normalized. Input samples were reserved and 2 mg of lysate was immunoprecipitated with
2 μg of either mouse α-Cx43 IF1 (from Dr. Lampe) or rabbit α-Drebrin overnight at 4°C.
Immune-protein complexes were captured by 2 hr incubation with protein G agarose
(Pierce) at 4°C, washed 5x with IP wash buffer (IP lysis buffer excluding sodium
deoxycholate). Immunoprecipitated proteins were eluted using 35-50 μL of 3x SDS
sample buffer. Equal volumes of each sample were analyzed by Western blot.

7.9 In vitro kinase assay
Rat Cx43CT236-382 was expressed and purified as described previously (475). Purified
Cx43CT WT and Y→F mutants were incubated with or without (Control) active Src (Life
Technologies) for 16 hr at 30°C (235). Products from kinase assay were ran on SDSPAGE gel, stained with Coomassie blue, and Western blotted with an α-pTyr antibody.
Abbreviations:

Y247/265=Y267/286/301/313F,

Y286=Y247/265/267/301/313F,

Y267=Y247/265/286/301/313F,

Y301=Y247/265/267/286/313F,

and

Y313=Y247/265/267/286/301F.

7.10 Mass spectrometry
Purified Cx43CT236-382 was incubated in vitro with active Src as described above. The
reaction was stopped on ice, and 1 nmol of protein was ran on a SDS-PAGE gel and
Western blotted using a α-p-Tyr antibody. 10 nmol of protein was run on a SDS-PAGE gel
and stained with Coomassie blue. The Cx43CT band was cut out and sent to the Beth
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Israel Deaconess Medical Center Mass Spectrometry Facility for post-translational
mapping.

7.11 NMR
NMR data were acquired at the University of Nebraska Medical Center NMR Facility
using a 600 MHz Bruker Avance-III HD NMR Spectrometer outfitted with a cryo-probe.
NMR spectra were phased and processed using Bruker TopSpin software and NMRPipe
(476), and analyzed using NMRView (477). Binding isotherms were obtained from
gradient-enhanced

N-heteronuclear single quantum coherence (HSQC) experiments,

15

acquired with 1024 complex points in the direct dimension and 128 complex points in the
indirect dimension. Sweep widths were 8,000 Hz in the 1H dimension and 1,720 Hz in the
N dimension. 15N-labeled Cx43CT236-382 domain (Y313D or Y265/313D mutant) in 1x PBS

15

(pH 7.5) was maintained constant at 50 μM while adding increasing amount of Drebrin1300

(purification previously described in (316)). Dissociation constants (KD) were calculated

by nonlinear fitting of the decrease in signal intensity of at least three residues (KD ±
standard deviation of the mean) using GraphPad Prism 5.0 (GraphPad Software).

7.12 Dye-transfer assay
Cells were scrape-loaded as described previously (210). Briefly, HeLa cells seeded on
coverslips were transfected with or without v-Src for 24 hr prior to scrape loading at 37˚C.
100% confluent cells were removed from the incubator, washed 1x with 1x PBS, and then
overlaid with pre-warmed (at 37˚C) 1x PBS containing 0.25% Lucifer yellow (anionic) and
Texas Red Dextran (3 kDa, 1.5 mg/ml). Cells were scrape-loaded with a fine edged microscalpel by two longitudinal scratches and then incubated at RT for 5 min. Cells were rinsed
quickly 2x with warm 1x PBS and incubated in cell culture medium at 37˚C for 5 min. After
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incubation, cells were washed 2x with warm 1x PBS containing 1 mM CaCl2 to stop dye
spread and fixed with 4% Paraformaldehyde for 20 min. Auto-fluorescence was quenched
by treatment with 0.1 M glycine for 15 min. Coverslips were mounted onto glass slides in
a drop of SlowFade anti-fade (Invitrogen). The cells were imaged using confocal
microscope with appropriate filters.

7.13 Immunohistochemistry for human tissue array
Tissue arrays of human, left ventricular myocardial hypertrophy tissues were
purchased from BioCat and Pantomics Inc. Slides were deparaffinized in xylene and
rehydrated in graded ethanol. Slides were then incubated in 0.3% hydrogen peroxide
(H2O2) for 30 min in the dark to block endogenous peroxidase activity. After washing with
TBS-T (1x TBS, 0.025% Triton), slides were microwaved 25 min for heat-induced epitope
retrieval in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0). Slides
were washed again with TBS-T, blocked with 2.5% horse serum for 1 hr at RT and
incubated at 4°C overnight with the following primary antibodies: α-Cx43 (1:100, ab15189
Abcam) and α-Cx43 pY313 (1:200). The next day, sections were washed in TBS-T and
incubated in HRP-conjugated horse anti-rabbit/mouse secondary antibody (Vector
Laboratories #MP-7500) for 1 hr at RT. Slides were washed in TBS-T and developed
using DAB peroxidase substrate kit according to manufacturer instructions (Vector
Laboratories #SK4100) and counterstained with haematoxylin. Additional sections were
stained with HE for pathologic and histologic assessment. 24 human left heart tissue
specimens were reviewed by a cardiovascular pathologist (Dr. Radio) and graded
according to staining intensity and percentage positive staining (1=negative;
2=weak; 3=moderate; 4=strong staining). Immunohistochemistry staining scores were
analyzed and compared by one-way ANOVA and an independent t-test. All digital bright
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field IHC slide scanning were processed by VENTANA iScan HT (Roche) at UNMC tissue
Sciences facility. The images were analyzed using Image Viewer.

7.14 Immunofluorescence for human tissue array
Slides were deparaffinized in xylene and rehydrated in graded ethanol. After washing
with TBS-T (1x TBS, 0.025% Triton), slides were permeabilized in 50% methanol followed
by heat induced epitope retrieval by microwaving for 25 min in sodium citrate buffer (10
mM sodium citrate, 0.05% Tween 20, pH 6.0). Slides were washed again with TBS-T and
blocked (1x TBS with 2.5% horse serum and 0.2% Triton) for 1 hr at RT and incubated at
4°C overnight with the following primary antibodies: α-Cx43 (1:50, ab87645 Abcam) and
α-Cx43 pY313 (1:100). The next day, sections were washed 3x 10 min with 1x TBS-T,
incubated with secondary antibody (ab150130 and ab150079, Abcam) for 1 hr at RT,
stained with DAPI (100 ng/mL) (MP Biomedicals) for 10 min, and then washed 3x 10 min
with 1x TBS-T. Coverslips were mounted on a drop of SlowFade anti-fade (Life Tech),
sealed with clear nail polish, and imaged.

7.15 Statistical Analysis
All data were analyzed by using GraphPad Prism 5.0 and presented as the mean +
s.e.m. Statistical analysis performed in GraphPad Prism 5.0 were either one-way ANOVA
with a Neuman-Keuls post-hoc analysis or Student’s T-Test where appropriate. P-values
<0.05 were considered statistically significant.
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8. Results
8.1 Src phosphorylates Cx43 residue Y313
Motivation behind this study was based upon combining two pieces of data: 1) 312
proteomic discovery-mode mass spectroscopy studies showed phosphorylation of Cx43
residue Y313 (PhosphoSitePlus, (474)) and 2) tyrosine phosphorylation remained after
Src phosphorylation of Cx43 Y247/265F (306). To address the potential phosphorylation
of Cx43 residue Y313, purified Cx43CT236-382 (Figure 2.1A) was incubated in vitro with
active Src (Life Technologies) as described in (235, 478) and phosphorylation was
confirmed using an anti-pTyr antibody (Figure 2.1B; WT + Src lane). After trypsin
digestion, Tandem MS/MS identified phosphorylation at Y247, Y265, Y267, and Y313
(Table 3). To confirm that tyrosine phosphorylation can occur at residues other than Y247
and Y265, the in vitro kinase assay was performed using different Cx43CT236-382 (Y→F)
constructs. Phosphorylation was detected by SDS-PAGE and with an anti-pTyr antibody.
In the Cx43 WT, Y247/Y265 (all other Y→F), and Y313 (all other Y→F) lanes + Src, a
slower mobility band was observed after Coomassie staining (Figure 2.1B, top). The
altered mobility is likely due to the negative charges on the phosphate group interfering
with protein-SDS interactions, thereby disrupting the charge-to-mass ratio and altering the
electrophoretic mobility of the protein (472). Of note, phosphorylated Cx43 results in
multiple electrophoretic isoforms: a fast migrating isoform, which includes the nonphosphorylated isoform (P0), and multiple slower migrating isoforms (P1 and P2) (479481). The Cx43 WT, Y247/Y265, and Y313 lanes were also the only lanes where a
Western blot band was observed with the anti-pTyr antibody (Figure 2.1B, bottom). The
data indicate that while Src phosphorylation occurs on Y247 and Y265 as previously
observed (239, 306), Src can also phosphorylate Y313 and Y267 (only detected by MS)
in vitro. We moved forward with investigating Y313 because significantly more in vitro
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Figure 2.1. Identification of Cx43 Y313 as a novel Src phosphorylation site. A)
Sequence of the Cx43CT domain. Highlighted (grey) are the phosphorylated tyrosine
residues identified from mass spectrometry from the in vitro kinase assay. B) The same in
vitro kinase assay in (A) was performed using Cx43CT236-382 wild type (WT) or different
tyrosine substituted CT constructs (all replaced to a phenylalanine except the labeled
tyrosine) as substrate and phosphorylation was detected by Western blot using a general
anti-pTyr antibody (top: SDS-PAGE; bottom: Western blot). This figure is previously
published in ref. 468 (Zheng et al., 2019).
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Table 3. Phospho-tyrosine containing peptides identified from mass spectrometry of the Cx43CT in vitro
phosphorylated by Src. *Peptides with Mascot Delta Ion Score >7 were used to obtain the average Mascot Delta Ion
Score. This table is previously published in ref. 468 (Zheng et al., 2019).

phosphorylation and mass-spectroscopy “hits” were observed at this site than Y267 (312
vs. 10).

8.2 Cx43 pY313 antibody validation
To determine if phosphorylation of Y313 occurs in context of full length Cx43 and in
cells, as well as to complement the well-characterized phospho-specific pY247 and pY265
antibodies used in numerous studies to characterize the regulation of Cx43 by Src (237,
239), we generated a phospho-specific pY313 antibody. LifeTein produced the antibody
and tested specificity using pY313 phospho- (P-peptide; used to create the antibody) and
non-phospho- (Np-peptide) peptides (Figure 2.2A). We extended the validation process
using the LA-25 cell line (239, 307). The presence of active v-Src (35°C) increased the
level of phosphorylation at Cx43 residue Y313 (Figure 2.2B, top). The band is specific to
phosphorylation of Y313 as the presence of a general tyrosine phosphatase after
immunoprecipitation of Cx43 (Figure 2.2B, bottom) or pre-incubation of the antibody with
the pY313 peptide (Np-peptide had no effect on the binding of the antibody; Figure 2.3A)
caused complete loss of the Western blot signal. For comparison, we also present
Western blot data using a total Cx43 antibody (Figure 2.2B, bottom). Specificity of the
antibody was further confirmed by immunofluorescence in the LA-25 cells. All Cx43 pY313
co-localized with Cx43 (Fig 2D, top panel). Interestingly, while total Cx43 was distributed
between both the plasma membrane and cytoplasm, most Cx43 pY313 signal was at the
plasma membrane. Only pre-incubation of the antibody with the P-peptide, not the Nppeptide, caused complete loss of immunofluorescence signal (Figure 2.3B, middle and
bottom panels).
Western blots were also performed using stably Cx43 expressing HeLa cells and
parental HeLa cells (Cx43 deficient) transiently transfected with v-Src to define the
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Figure 2.2. Validation of the Cx43 Y313 phospho-specific antibody by IP. A) LifeTein
performed a dot-blot assay to demonstrate that the pY313 antibody does not recognize
non-phosphorylated Y313 peptides (non-phospho- (Np-peptide) and phospho- (P-peptide)
peptides). B) Western blot of total cell lysate (input) from LA-25 cells at 40ºC or 35ºC
(active v-Src) incubated with the Y313 phospho-specific antibody (left) or a total Cx43
antibody (right). The lysate was used to immunoprecipitate Cx43, which was subsequently
incubated with and without a general tyrosine phosphatase and Western blotted using the
same antibodies. This figure is previously published in ref. 468 (Zheng et al., 2019).
63

Figure 2.3. Validation of the Cx43 Y313 phospho-specific antibody by peptide
blocking. A) LA-25 cells at 40ºC or 35ºC (active v-Src) were incubated with the Y313
phospho-specific antibody in the presence of Np-peptide and P-peptide peptides. Data
were analyzed by Western blot (antibody used is indicated, left of each panel). B)
Immunofluorescence showing co-localization (yellow) of total Cx43 (red) with the Cx43
Y313 phospho-specific antibody (green) at the plasma membrane in LA-25 cells.
Preincubation with the P-peptide caused loss of the Y313 phospho-specific antibody
signal (green). This figure is previously published in ref. 468 (Zheng et al., 2019).
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specificity in a different cell line that is commonly used in the gap junction field. For the
stably Cx43 expressing HeLa cells, no signal was observed with the Cx43 pY313 antibody
in the control lane (no v-Src) (Figure 2.4A, left). Conversely, a number of bands were
observed in the presence of v-Src. The total Cx43 antibody (Figure 2.4A, right) and the
Cx43 pY313 antibody had equivalent bands corresponding to the P0, P1, and P2 isoforms
as well as a 50 kDa (P3) variant. The Cx43 pY313 antibody also labeled one slower
migrating bands at ~60 kDa (P4). The ~60 kDa band was also seen when the pY247 and
pY265 antibodies (and not when using a total Cx43 antibody) were initially characterized
for specificity and may represent a hyper-phosphorylated isoform (239). For the parental
HeLa cells, no signal observed with the Cx43 pY313 or total Cx43 antibodies in the
presence and absence of Src (Figure 2.4A, left and right). The data illustrates that the
antibody is specific to Cx43. Finally, we tested the feasibility of using the Cx43 pY313
antibody for Western blot using lysate from human tissue (Figure 2.4B). The bands from
a hypertensive human left ventricle are comparable to the bands observed from the Cx43
expressing HeLa cells + v-Src (P0-P4 isoforms); however, two additional bands at ~20
kDa and ~75 kDa (P5) were observed. We speculate that the ~20 kDa isoform is the same
variant as seen in (482, 483) and that the ~75 kDa (P5) isoform is a phosphorylated Cx43
dimer.
Unfortunately, the Western blots in the [20] study were cropped around ~70 kDa thus
not enabling a comparison with the ~75 kDa (i.e., between our pY313 and their pY247 and
pY265 antibodies). Altogether, the data indicates we generated a new tool to characterize
Cx43 regulation, a phospho-specific pY313 antibody.
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Figure 2.4. Specificity of the Cx43 Y313 phospho-specific antibody. E) Western blot
of total cell lysate from stably Cx43 expressing HeLa cells and parental HeLa cells
transiently transfected with v-Src using the Y313 phospho-specific antibody (left) or a total
Cx43 antibody (right). F) Western blot of total cell lysate from hypertensive human left
ventricle tissue (Novus Biologicals, NB820-59315) using the Y313 phospho-specific
antibody. This figure is previously published in ref. 468 (Zheng et al., 2019)
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8.3 pY313 contributes to gap junction disassembly
Cx43 residues Y247 and Y265 are well-established phosphorylation sites that
contribute to Src mediated down regulation of GJIC (along with MAPK and PKC sites;
(239, 306, 484)). To help determine the contribution of Cx43 Y313 phosphorylation in the
regulation imposed by Src, we established an in cyto experimental system by stably
expressing Cx43 WT and phosphorylation eliminating mutants (Y247F, Y265F, Y313F,
Y247/265F, Y247/313F, Y265/313F, or Y247/265/313F) in Cx43-deficient HeLa cells. We
initially evaluated the cellular localization of Cx43 WT and Y→F mutants alone and when
expressed with v-Src (Figure 2.5). In the absence of v-Src, there was no statistical
difference in the number of gap junction plaques formed per cell between Cx43 WT and
the Y→F mutants (Figure 2.6). In the presence of v-Src, Cx43 WT had the greatest
decrease in the number of gap junction plaques formed per cell (90%) (Figure 2.5). The
single and double Cx43 mutants containing Y265F (Y265F, Y247/265F, Y265/313F) had
~50% decrease in the number of gap junction plaques formed per cell and for all other
Cx43 mutants (Y247F, Y313F, Y247/313F) the decrease was ~75%. Interestingly, the
most phosphorylation resistant Cx43 mutant Y247/265/313F was the least affected
(0.2%). The data suggest that Cx43 residues Y247, Y265, and Y313 all contribute to gap
junction disassembly, with phosphorylation of residue Y265 playing a more critical role in
the process (i.e. largest decreases observed when this site is not mutated from Y→F).
To confirm the direct role of Y313 phosphorylation in gap junction disassembly, we
observed the cellular localization of HeLa cells transiently transfected with WT Cx43 or
Y313 mutants eliminating (F) or mimicking (E) phosphorylation (Figure 2.7). Y313E
causes a decrease in the number and size of the gap junction plaques. Diffuse localization
throughout the membrane is consistent with a low incidence of cellular coupling and nonfunctional channels.
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Figure 2.5. Phosphorylation of Cx43 residue Y313 by Src contributes to gap junction
disassembly. Localization of Cx43 in HeLa cells stably expressing Cx43 WT or
phosphorylation eliminating mutants (labeled above), and transiently transfected with vSrc. A) Immunofluorescence using an anti-Cx43 antibody (green). The nucleus has been
labeled with DAPI (blue). White arrows point to a gap junction plaque. B) Quantification of
the number of gap junction (GJ) plaques per cell shows the effect of inhibiting v-Src
phosphorylation of different Cx43 tyrosine residues. Results presented as the mean +
s.e.m. (n=3). Statistics used to analyze the data was one-way ANOVA with a NewmanKeuls post-hoc analysis (n=3, **P<0.01; and ***P<0.001). This figure is previously
published in ref. 468 (Zheng et al., 2019).
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Figure 2.6. Statistical analysis comparing the number of GJ plaques formed per cell
of Cx43 WT and Y→F mutants in the absence of v-Src. This figure is previously
published in ref. 468 (Zheng et al., 2019).
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Figure 2.7. Mimicking phosphorylation of Cx43 residue Y313 decreases the number
and size of the gap junction plaques. Immunofluorescence (anti-Cx43 antibody; green)
of HeLa cells transiently transfected with WT Cx43 or Y313 mutants eliminating (F) or
mimicking (E) phosphorylation. White arrows point to a gap junction plaque. The nucleus
has been labeled with DAPI (blue). This figure is previously published in ref. 468 (Zheng
et al., 2019).
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8.4 pY313 contributes to a decrease in GJIC
To determine whether phosphorylation of Y313 affects cell-to-cell communication,
junctional transfer of the tracer Lucifer Yellow (anionic) was measured in a scrape-loading
assay using the stably expressing Cx43 WT and phosphorylation eliminating mutant HeLa
cells (Figure 2.8). Texas Red Dextran (3 kDa; junction impermeable) marked the loaded
cells (data not shown). Similar to previously published studies, Cx43 WT expressing cells
(no v-Src) were extensively coupled with respect to Lucifer Yellow demonstrating greater
than a fifth order dye transfer (i.e., cell layers past scrape) (Figure 2.8A) (485). The Cx43
phosphorylation eliminating mutants (no v-Src) were similar to WT with respect to being
permeable to Lucifer Yellow (Figure 2.9). In the presence of v-Src, only the Cx43
Y247/265/313F mutant had intercellular communication similar to itself (v-Src vs. no vSrc). While all the other Cx43 mutants had reduced dye transfer, the decrease observed
for the double Cx43 mutants containing Y265F (Y247/265F and Y265/313F) was less than
50%. The reduced junctional dye transfer for the single and double mutants is consistent
with the altered size and number of junctional channels (Figure 2.5).

8.5 Determining the sequential order of Cx43 residues phosphorylated by Src
A suggested mechanism for Src phosphorylation of Cx43 includes the following: Src
SH3 domain initially interacts with Cx43 residues A276-S282, Src kinase domain
phosphorylates Y265, Src SH2 domain binds pY265, and then the Src kinase domain
phosphorylates Y247 (85, 306, 486). Here, we determined the role of Y313 in this
sequential order of Cx43 tyrosine phosphorylation by Src. HeLa cells stably expressing
Cx43 WT or phosphorylation eliminating mutants transiently transfected with v-Src were
analyzed by Western blot using total Src, active Src (p-Src), total Cx43, and the phosphospecific antibodies pY247, pY265, and pY313 (Figure 2.10 and Figure 2.11, different
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Figure 2.8. Phosphorylation of Cx43 residue Y313 contributes to reduced gap
junction intercellular communication (GJIC). The level of GJIC in HeLa cells stably
expressing Cx43 WT or phosphorylation eliminating mutants (labeled above) transiently
transfected with v-Src was determined using the scrape loading transfer assay. A)
Representative immunofluorescence images of HeLa cells stably expressing Cx43 WT or
phosphorylation eliminating mutants (labeled above) transiently transfected with v-Src
(Lucifer yellow, green; DAPI, Blue). B) Quantification of the distance of Lucifer Yellow
transfer shows the effect of inhibiting v-Src phosphorylation of different Cx43 tyrosine
residues. Results presented as the mean + s.e.m. (n=3). Statistics used to analyze the
data was one-way ANOVA with a Newman-Keuls post-hoc analysis (n=3, *P<0.05,
***P<0.001). This figure is previously published in ref. 468 (Zheng et al., 2019).
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Figure 2.9. Statistical analysis comparing the distance of Luciferase Yellow (LY)
transfer of Cx43 WT and Y→F mutants in the absence of v-Src. This figure is
previously published in ref. 468 (Zheng et al., 2019).
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Figure 2.10. Phosphorylation of Cx43 residue Y313 contributes to reduced gap junction intercellular communication
(GJIC). Western blot analysis using HeLa cells stably expressing Cx43 WT or phosphorylation eliminating mutants (labeled above)
transiently transfected with v-Src. Antibodies used are labeled on the left of each panel. Cx43 P0, P1, and P2 bands as well as
molecular weight markers are indicated. This figure is previously published in ref. 468 (Zheng et al., 2019).

Figure 2.11. Comparison of the different phospho-specific antibodies for Cx43 WT
and each Y→F mutant. Western blot analysis using HeLa cells stably expressing Cx43
WT or phosphorylation eliminating mutants (labeled on side) transiently transfected with
v-Src. Antibodies used are labeled above each panel. Cx43 P0, P1, and P2 bands as well
as molecular weight markers are indicated. This figure is previously published in ref. 468
(Zheng et al., 2019).
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orientation to compare the banding patterns of the same construct with the different
phospho-specific antibodies). In the absence of v-Src, no phosphorylation was observed
on Y247, Y265, and Y313 for Cx43 WT and the phosphorylation eliminating mutants. In
the presence of v-Src, Cx43 WT had the greatest increase in phosphorylation of Y247,
Y265, and Y313 while the Cx43 mutant Y247/265/Y313F was resistant to phosphorylation.
A comparison of the phosphorylation level between all the single and double mutants
clearly indicates that while phosphorylation can occur on any tyrosine residue,
phosphorylation of Y247 and Y313 is significantly enhanced by Y265 phosphorylation. In
addition, numerous studies have shown that differentially phosphorylated Cx43 results in
multiple electrophoretic isoforms: a fast migrating isoform, which includes the nonphosphorylated isoform (P0), and multiple slower migrating isoforms (P1 and P2) (479481). Interestingly, Cx43 mutants with the Y265F mutation retained the P2 isoform as well
as any mutant with the Y247F mutation retained the P1 isoform, the former is consistent
with open gap junction channels (240).

8.6 Phosphorylation of Y313 inhibits Cx43 binding with Drebrin
Our lab has previously published the Cx43CT

N-HSQC assignment (472) and

15

identified that three Cx43CT domains (Area 1, K264-T275; Area 2, S282-T290; and Area
3, R299-G321) were affected by the interaction with Drebrin (Area 1 contains Y265 and
Area 3 contains Y313) and that phosphorylation of Y265 partially inhibits this interaction
(316). With the knowledge that Src also phosphorylates Y313, we addressed if both sites
need to be phosphorylated for the complete dissociation of Cx43 from Drebrin. NMR
titration experiments were performed using purified soluble 15N-labeled Cx43CT phosphomimetics (residues 236-382; Y313D and Y265/Y313D) and different concentrations of
unlabeled Drebrin (residues 1-300). Of note, the use of Asp substitution to study biological
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effects of phosphorylation is a widely used tool in the gap junction field (249, 266, 472).
The 15N-HSQC spectrum of each control (no Drebrin, black) has been overlaid with Drebrin
(red) at a 1:14 molar ratio (Figure 2.12). For the Cx43CT Y313D mutant, significantly fewer
residues were affected by the addition of Drebrin when compared to the Cx43CT WT (316).
The Y313D mutation completely abolished the interaction over Area 3, while Areas 1 and
2 combined showed a weaker interaction with Drebrin (2-fold less, (316)). More
importantly, when both sites were mutated to mimic Src phosphorylation, the Cx43CT
interaction with Drebrin was completely inhibited (Figure 2.12B). Altogether, these results
implicate three areas in the Cx43CT domain as critical for the interaction with the Nterminal portion of Drebrin, as well as a strong potential for a regulation of this interaction
by Src. To confirm that Cx43CT phosphorylation by Src does inhibit the binding of Drebrin,
a reciprocal immunoprecipitation assay was performed using HeLa cells stably expressing
Cx43 WT transfected with v-Src (Figure 2.13). The presence of v-Src led to
phosphorylation on Cx43 residues Y265 and Y313 as well as inhibited the Cx43 interaction
with Drebrin; a result consistent with the NMR data (Figure 2.12).

8.7 Phosphorylation of Cx43 residue Y313 is increased in diseased human heart
tissue
To determine if Cx43 Y313 phosphorylation occurs in pathological conditions where
Src is activated (e.g. (85, 487, 488)), we stained left ventricular tissue from 24 patients for
total Cx43 and Cx43 pY313. Two patients served as normal controls with no underlying
cardiac pathology, 11 patients had left ventricular hypertrophy (LVH) without dilatation and
11 patients had LVH with dilatation (LVH was assessed by gross pathologic analysis, left
ventricular wall thickness, and overall heart weight while ventricular dilatation was noted
in the pathological analysis provided by tissue supplier). Histologically, there was an
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Figure 2.12. Mimicking phosphorylation of Cx43 residues Y265 and Y313 inhibits the interaction with Drebrin
in vitro. NMR titrations were performed using soluble 15N-Cx43CT236-382 phospho-mimetics and Drebrin1-300. 15NHSQC spectrum of (A) Cx43CT236-382 Y313D or (B) Cx43CT236-382 Y265/313D alone (black) has been over laid with
the spectrum obtained in the presence of Drebrin1-300 at a 1:14 molar ratio (red). Cx43CT residues affected by Drebrin
have been labeled. KD for the Cx43CT236-382 Y313D/Drebrin1-300 interaction was ~600 μM (Cx43CT WT/Drebrin1-300
was ~300 μM (314)). This figure is previously published in ref. 468 (Zheng et al., 2019).

Figure 2.13. Phosphorylation of Cx43 residues Y265 and Y313 inhibits the
interaction with Drebrin in cyto. HeLa cells stably expressing Cx43 WT were transiently
transfected with v-Src. Cx43 and Drebrin were reciprocally co-immunoprecipitated and
analyzed by Western blot with Cx43, Drebrin, Cx43 pY265, and Cx43 pY313 antibodies.
This figure is previously published in ref. 468 (Zheng et al., 2019).
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increase in the thickness of myocyte fibrils in samples with LVH compared with normal
control samples; this finding is consistent with a clinical diagnosis of ventricular
hypertrophy. Figure 2.14 presents one control sample (transverse plane) and each of the
LVH (with and without dilatation; transverse and longitudinal planes) samples; all
remaining samples are provided in Figures 2.15, 2.16, 2.17 and 2.18. Samples were
scored on a scale from 1 to 4 with 1 representing nearly absent staining (see Materials
and Methods section for details on how scoring was calculated). In Cx43 stained samples,
a distinct decrease in staining intensity was observed in patients with LVH compared to
normal controls (Figure 2.14A,C; Median score: 4 to 3). For patients with LVH, a similar
staining intensity and distribution of Cx43 was found with and without dilatation (Median
score: 3 and 3). In contrast, we observed near absent staining for Cx43 pY313 in normal
controls (Figure 2.14B,D; Median score: 1) compared to LVH samples (Median score: 2.5).
Further, among patients with LVH, samples with ventricular dilatation stained more
intensely than samples from patients without dilatation (Median score: 3 and 2,
respectively). In the longitudinal plane (Figure 2.14E; left - LVH without dilation, right LVH
with dilation), where the intercalated disc can be observed, Cx43 pY313 signal was
present at both the disc and inside the cell. The Cx43 pY313 antibody specificity was
confirmed by peptide blocking prior to immunohistochemistry (Figure 2.14F). Next, a
double-labeled immunofluorescence experiment was performed to determine if Cx43
pY313 is a subset of the total Cx43 staining (Figure 2.19). The data show that all Cx43
pY313 staining colocalized with total Cx43 (not vice versa) and the cellular localization (at
intercalated disc and intracellularly) was consistent with the immunohistochemistry. These
data suggest that patients with LVH have an increase in phosphorylation of Cx43 residue
Y313.
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Figure 2.14. Phosphorylation of Cx43 residue Y313 is increased in cardiac left
ventricle hypertrophy (LVH) samples. Paired (A) Cx43 and (B) Cx43 pY313
immunohistochemistry staining in normal and LVH samples cut in transverse section.
Green and red arrows indicate staining for total Cx43 and Cx43 pY313, respectively.
Boxplots depicting distribution of (C) Cx43 and (D) Cx43 pY313 staining scores when
combining each sample in normal (n=2), LVH without dilatation (n=11), and LVH with
dilatation (n=11) groups. The field of view for each sample was 40x. E) Cx43 pY313
staining in LVH samples cut in the longitudinal section left - LVH without dilation, right LVH
with dilation. Red arrows indicate staining of Cx43 pY313 at the intercalated disc. Green
arrows indicate intracellular staining of Cx43 pY313. F) Cx43 pY313 antibody was preincubated with excess phospho-peptide 12 hr before being applied to the human tissue
array slide. The same immunohistochemistry staining protocol was used as in (A) and (B).
This figure is previously published in ref. 468 (Zheng et al., 2019).
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Figure 2.15. Tissue microarray samples of left ventricle hypertrophy (LVH) without
dilatation group 1. Paired total Cx43 and Cx43 pY313 immunohistochemistry staining in
LVH samples without dilatation cut in transverse or longitudinal sections. Patient samples
are numbered from BioCat: a1, a3, b1, b5, and c2 (a6 is in Figure 2.13). This figure is
previously published in ref. 468 (Zheng et al., 2019).
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Figure 2.16. Tissue microarray samples of left ventricle hypertrophy (LVH) without
dilatation group 2. Paired total Cx43 and Cx43 pY313 immunohistochemistry staining in
LVH samples without dilatation cut in transverse or longitudinal sections. Patient samples
are numbered from BioCat: c3, c4, c6, d1, and d2. This figure is previously published in
ref. 468 (Zheng et al., 2019).
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Figure 2.17. Tissue microarray samples of left ventricle hypertrophy (LVH) with
dilatation group 1. Paired total Cx43 and Cx43 pY313 immunohistochemistry staining in
LVH samples with dilatation cut in transverse or longitudinal sections. Patient samples are
numbered from BioCat: a2, a4, a5, b2, and b3 (d3 is in Figure 2.13). This figure is
previously published in ref. 468 (Zheng et al., 2019).
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Figure 2.18. Tissue microarray samples of left ventricle hypertrophy (LVH) with
dilatation group 2. Paired total Cx43 and Cx43 pY313 immunohistochemistry staining in
LVH samples with dilatation cut in transverse or longitudinal sections. Patient samples are
numbered from BioCat: b4, b6, c1, c5, and d4. This figure is previously published in ref.
468 (Zheng et al., 2019).
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Figure 2.19. Cx43 pY313 colocalized with total Cx43 in cardiac left ventricle
hypertrophy (LVH) samples. Representative immunofluorescence images of double
stained total Cx43 and Cx43 pY313 antibodies on a human tissue array slide (total Cx43,
green; Cx43 pY313, red; DAPI, blue; and merge, yellow). The blue arrow highlights costaining of Cx43 pY313 and total Cx43 at the intercalated disc in the transverse section.
White arrows indicate intracellular co-staining in both longitudinal and transverse sections.
This figure is previously published in ref. 468 (Zheng et al., 2019).
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9. Discussion
Numerous studies have documented that Src-induced phosphorylation of Cx43 leads
to down regulation of GJIC and gap junction disassembly (278, 305-307, 484, 489-491).
Studies support a “ball-and-chain” mechanism for channel closure triggered by Src, similar
to that proposed for pH gating of Cx43 channels (195, 307, 492) which results in
decreased electrical coupling by reducing the opening of channels and altering selectivity
(489). Src activation can also lead to channel closure, indirectly, through serine
phosphorylation by activation of MAPK and PKC (8, 224, 239, 307, 493). A working model
for Src phosphorylation of Cx43 includes the: 1) association initiates between Cx43
residues A276-S282 and the Src SH3 domain (85, 306, 494). SH3 binding causes Cx43CT
residues T275-P284 to adopt a left-handed type II helix (85); 2) Src kinase domain
phosphorylates Cx43 residue Y265 (239, 306); 3) Src SH2 domain binds pY265, which
stabilizes the Src-Cx43 interaction, promotes phosphorylation at Y247 (306, 494, 495),
and based upon the work presented herein, promotes phosphorylation at Y313 as well.
Lin et al. 2001 (306) performed a similar study that focused on v-Src phosphorylation;
however, only Cx43 residues Y247 and Y265 were mutated. In comparison between the
data, both conclude that phosphorylation of Y247 and Y265 are involved in disrupting
GJIC, tyrosine phosphorylation remains in the Cx43 Y247/265F mutant, and
phosphorylation of Y247 depends on Y265 phosphorylation. In addition, neither study (nor
others, (305, 484, 495)) found evidence for a role of MAPK in mediating the disruption of
GJIC by v-Src. On the other hand, one study did observe the opposite effect in that
activation of Src led to rapid down regulation of GJIC with the Cx43 Y247/265F mutant via
MAPK (307). Potential reasons for these differences include the cell systems used and
experimental design which may have identified distinct roles for acute vs. chronic effects
of Src mediated inhibition of GJIC (224). In addition, a factor not appreciated at the time
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was that Src-mediated phosphorylation of a third Cx43 tyrosine residue is important for
regulation. Our data also differ from Lin et al. 2001 (306) in that gap junction plaques from
their Cx43 Y247F, Y265F, and Y247/265F mutants were not largely affected by v-Src. We
observed ~50-60% decrease in the number of plaques. Another difference is that Lin et
al. 2001 (306) found that Y247F or Y265F alone could render Cx43 resistant to the
disruption of GJIC, in our experiments these mutants were significantly affected (Y247F,
75% decrease; Y265F, 50% decrease). Src-resistance was only achieved in this study
with the Cx43 Y247/265/313F mutant. A reasonable explanation for these differences is
that Lin et al. 2001 (306) used knockout Cx43 fibroblasts cells that were infected with the
v-Src retrovirus as opposed to HeLa cells that were transiently transfected with v-Src.
Our study presented here and those of other research groups support an additional
mechanism of Src to regulate GJIC, the altering of Cx43 protein partners to enhance
degradation (Figure 2.20). A commonality among the proteins that link Cx43 to the
cytoskeleton is that Src can inhibit their interaction. For example, Cx43CT residue Y247
phosphorylated by Src inhibits the binding of tubulin (308). At the gap junction plaque, this
may be a mechanism in the disassembly process; at the trans-Golgi network, this may reroute trafficking to the plasma membrane (e.g., lateral membrane vs. intercalated disc) or
inhibit trafficking to the plasma membrane, leading to increased intracellular proteasomal
and/or lysosomal degradation (496). In the case of Cx43CT residue Y265, we previously
observed that phosphorylation at this site decreased the binding affinity for the F-actin
binding protein Drebrin (316). Here, we demonstrated that phosphorylation of Y265 and
Y313 by Src is necessary to completely inhibit Cx43 binding to Drebrin. For Drebrin,
depletion in cells results in impaired cell-cell coupling, internalization of gap junctions, and
targeting of Cx43 for degradation (309). Phosphorylation of Y265 and Y313 also inhibits
the Cx43 interaction with β-catenin (497). Like Drebrin, β-catenin helps Cx43 to indirectly
interact with F-actin (through α-catenin) and stabilize gap junctions to favor intercellular
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Figure 2.20. Schematic summary of the model of Cx43 regulation by Src. Left: Model
of Cx43 tyrosine residues phosphorylated by Src kinase and the regulatory effects of Src
on the interaction of Cx43 carboxy-terminal domain with the cytoskeleton. Gap junctions
(GJs) remain at the intercalated disc (ID). Right: Cx43CT residues Y247, 265, and 313
phosphorylated by Src inhibits the binding of tubulin, Drebrin and F-action. Active c-Src
could compete with Cx43 to directly bind ZO-1. This would lead to GJs disassembly and
internalization to intracellular compartments from the ID (as red arrow indicated). Middle:
Cx43 pY313 colocalizes with total Cx43 in samples of cardiac left ventricular hypertrophy
(LVH). Representative immunofluorescence images of total Cx43 (green) and Cx43
pY313 (red) antibodies in a patient heart tissue. Nuclei are stained with DAPI (blue), and
colocalization of total and Y313 phosphorylated Cx43 are shown (yellow). Cx43
phosphorylated on Y313 is internalized away from the ID to intracellular compartments
under pathological conditions.
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communication (498). Conversely, we speculate they both cannot interact at the same
time. Therefore, the available data would suggest that β-catenin binds first and then at
some point in the maturation of the gap junction plaque the Cx43CT switches to interact
with Drebrin. Finally, while phosphorylation of the Cx43CT by Src does not inhibit ZO-1
binding, we found that active c-Src could compete with Cx43 to directly bind ZO-1 (85).
This would transition Cx43 from the non-junctional plasma membrane into the gap junction
plaque, and then through the degradation pathway(s) (367).
In this study, we have also validated a new tool for the gap junction field, a Cx43 pY313
antibody,

which

is

amenable

for

Western

blots,

immunofluorescence,

and

immunohistochemistry. For the LA-25 cells at 35°C (active v-Src), a majority of Cx43 (total
antibody) was intracellular with a diffuse pattern when at the plasma membrane.
Interestingly, while all Cx43 pY313 signal colocalized with total Cx43, this mainly occurred
at the plasma membrane and all Cx43 pY313 Western blot signal was in the P2 isoform.
Similarly, all Cx43 pY313 signal also colocalized with total Cx43 from LVH samples,
however, while colocalization was seen at the intercalated disk, the majority occurred
inside the cell. In this case, Western blot data observed multiple electrophoretic isoforms
(like the HeLa cell data), including at ~20 kDa. This band may be the internally translated
isoform that stabilizes actin filaments to aid Cx43 trafficking to the gap junction plaque
(482, 483). Of interest for future studies would be in determining if the level and
phosphorylation state of the ~20 kDa isoform is altered in LVH.
In summary, our data support that Cx43 residue Y313 is a novel site targeted for
phosphorylation by Src (Figure 2.20). These conclusions were based upon several
observations: 1) mass spectroscopy data, 2) Cx43 Y247/265F did not completely eliminate
tyrosine phosphorylation by v-Src nor did GJIC resemble WT, 3) v-Src enhanced Y313
phosphorylation as observed by the phospho-specific antibody, and 4) in diseased human
left ventricle, a condition where Src is activated, Y313 phosphorylation is increased.
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CHAPTER THREE

Inhibition of Both Pyk2 and Src
is Necessary to Restore Cx43
Gap Junction Intercellular
Communication
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10. Introduction
Connexin43 (Cx43), the most abundant cardiac gap junction protein (80), mediates
ventricular propagation of cardiac action potentials and maintenance of a regular beating
rhythm. The importance of Cx43 gap junctions in the heart is well established: closure,
dysregulation or mislocation disrupts propagation, and lethal arrhythmias can ensue (24,
80, 499, 500). Following a myocardial infarction (MI; early stage-remodeling), in the
surviving ventricular myocytes from the epicardial border zone (EBZ; adjacent to the
necrosing area (501)), the cardiac muscle sarcoplasm experiences a number of
abnormalities that includes an increase in Ca2+, decrease in pH, reduced PKA activity, and
a drop in ATP (238, 383, 502, 503). Additionally, there is reduced Cx43 gap junction
intercellular communication (GJIC) due to changes in Cx43 expression, phosphorylation
state, and increased deposition from the intercalated disc (ID) to the lateral membrane
(85, 504). An important consequence of cellular uncoupling is an increased dispersion of
action potential duration and refractory period, which is pronounced in the EBZ (505).
While lateralization of Cx43 is an almost ubiquitous response to cardiac pathology (505507), mechanisms of remodeling are unknown.
Left ventricle hypertrophy (LVH) following a MI (late-stage remodeling) is an adaptive
response to increased biomechanical stress (other causes include hypertension and
diabetes (508)). Initially, heart mass increases to normalize wall stress and retain normal
cardiovascular function, accompanied by a transient increase in Cx43 expression and
phosphorylation (407, 509). However, the increased cardiac mass and sustained overload
eventually lead to contractile dysfunction and heart failure through poorly understood
mechanisms (510). As LVH becomes severe, propagation velocity decreases. This
correlates with reduced Cx43 expression and ID localization, altered phosphorylation of
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Cx43, increased Cx45 expression, and extensive Cx45 co-localization with the remaining
Cx43 at the ID (seen in both ischemia and dilated cardiomyopathy (94, 511-513)).
A number of studies have attempted to reverse Cx43 remodeling in the infarct EBZ and
LVH. Unfortunately, they have not been sufficient to restore normal conduction and
prevent arrhythmias. For example, Macia et al. (514) found that in the EBZ after MI the
peptide rotigaptide partially reversed the loss of Cx43 expression but did not affect the
increase in S368 phosphorylation (pS368 decreases gap junction conductance (514,
515)), nor reverse Cx43 lateralization. The partial reversal of Cx43 remodeling was not
sufficient to restore normal conduction or prevent arrhythmias. Greener et al. (516) used
gene transfer to show that increased Cx43 expression in the infarct EBZ could improve
conduction velocity and lessen arrhythmia susceptibility. Interestingly, while an overall
increase of Cx43 was observed at the ID, the ratio of ID/lateral membrane Cx43 was the
same between control and animals receiving adenovirus Cx43. The data strongly suggest
that any targeted mechanism that can increase the Cx43 ID/lateral membrane ratio under
endogenously expressing conditions would be therapeutically beneficial. Finally, Rutledge
et al. (488) addressed if Src inhibitors would reverse Cx43 remodeling and improve heart
function after MI. Of note, studies by our lab and others have linked Src to dysregulation
of Cx43 in the heart (74, 85, 487). In the EBZ, Src inhibitors PP1 and AZD0530 (in clinical
trials to treat cancer (517, 518)) restored Src activity to sham levels, raised Cx43
expression by ~69%, and had a higher level of the Cx43 P2 phosphorylation isoform
(correlates with gap junction localization/promoting GJIC (238)). Although no change in
Cx43 lateralization was observed, this still led to ~50% improvement in conduction velocity
and lowered arrhythmia inducibility. While affecting the Cx43 phosphorylation state can
explain the beneficial effects after Src inhibition, their data indicate that a second
undiscovered process prevented full restoration of proper Cx43 function (protein level,
phosphorylation state, ID localization). Here, we present evidences that phosphorylation
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of Cx43 by Protein tyrosine kinase 2 beta (Pyk2) is the “second process” that must be
inhibited, in addition to Src, to further (if not completely) reverse Cx43 remodeling and
improve cardiac function.
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11. Materials and Methods
11.1 Antibodies
Detection reagents, manufacturers, applications, and concentration ranges for all
primary and secondary antibodies utilized in this study are summarized in Table 4.
Table 4. Antibodies and Reagents.
Primary Antibody

Manufacturers

Applications

Concentrations

Cx43

Sigma

WB/IF

1:5,000/1:500

Cx43 IF

Fred Hutchinson

IF

1:500

Cx43

ThermoFisher

IF

1:200

Cx43 pY265

Abcam

WB

1:3,000

Cx43 pY247

Fred Hutchinson

WB

1:1,000

Cx43 pY247 (Custom Ab)

LifeTein

WB

1:2,000

Cx43 pY313 (Custom Ab)

LifeTein

WB

1:500

Pyk2

Cell Signaling

WB

1:1,000

Pyk2 pY402

Abcam

WB

1:1,000

Pyk2 pY579/580

ThermoFisher

WB/IF

1:1,000/1:200

Src

Cell Signaling

WB

1:3,000

Src pY416

Cell Signaling

WB

1:3,000

ANP

Novus

WB

1:1,000

Paxillin

Cell Signaling

WB

1:1,000

Paxillin pY118

Cell Signaling

WB

1:1,000

p-JNK

Cell Signaling

WB

1:1,000

PKC

Abcam

WB

1:10,000

Cx45

Millipore

WB/IF

1:1,000/1:200

GAPDH

Cell Signaling

WB

1:5,000

β-actin

Sigma

WB

1:10,000

Sarcomeric α-actin

Abcam

IF

1:200

Secondary Antibody

Manufacturers

Applications

Concentrations

Goat α-mouse (Alexa-647)

Cell Signaling

IF

1:500

Goat α-rabbit (Alexa-488)

Cell Signaling

IF

1:500

Goat α-mouse-HRP

Cell Signaling

WB

1:5,000

Goat α-rabbit-HRP

Cell Signaling

WB

1:5,000

Fluorescent Dye/Protein

Manufacturer

Applications

Concentration

Lucifer Yellow CH

LifeTech

Fluorescence

1 mg/mL

Neurobiotin

Vector Labs

Fluorescence

5 mg/mL

Streptavidin (Alexa-647)

LifeTech

Fluorescence

1 mg/mL

DAPI

Sigma

Fluorescence

1 μg/ml
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11.2 Molecular biology
Cx43 WT and mutant construct (hCx43 Y247/265F) were generated as described
previously (468). v-Src was a gift from Joan Brugge (Addgene plasmid #14578) and
human c-Src plasmid was a gift from Robert Lefkowitz (Addgene plasmid # 42202) (519).
Pyk2 WT and CT domain (Cell Adhesion Kinase-β-Related Non-kinase, CRNK) were PCR
amplified from a pCMV-HA plasmid containing the hPyk2 sequence using primers suitable
for Gibson assembly into the pD2529 vector (Atum). Primers: Pyk2 ForwardAGCTGTCTAGAGCCGCCACCATGTCTGGGGTGTCCGAG;

Pyk2

Reverse-

CGCTTTTAGAGACCTCAACCTCACTCTGCAGGTGGGTG;

CRNK

Forward-

AGCTGTCTAGAGCCGCCACCGCCGCCACCATGAGTGACGTTTATCAGATGGAG;
CRNK Reverse- CGCTTTTAGAGACCTCAACCTCACTCTGCAGGTGGGTG. Purified
PCR product and vector were assembled using NEBuilder HIFI DNA Assembly Master
Mix (NEB) per manufacturer protocol. Pyk2 kinase dead (KD; K457A), constitutively active
c-Src (Y530F), kinase dead c-Src (K298M), ΔSH3 (c-Src SH3 domain deletion; aa 88143), SH3-deficient (W121K) or SH2-deficient (R178L) or SH3 and SH2-deficient (W121K
and R178L) c-SrcY530F constructs were made by QuikChange Lightning Site-Directed
Mutagenesis Kit (Agilent) and confirmed by DNA sequencing (ACGT, Inc.).

11.3 Cell line culture
Parental HeLa, MCF-7, and HEK 293T (gift from Dr. Myron Toews, University of
Nebraska Medical Center) cells were cultured in Dulbecco’s modified Eagle medium
(Corning) at 37°C in a humidified 5% CO2 atmosphere. Medium was supplemented with
10% fetal bovine serum (FBS, Seradigm), 2 mM L-glutamine (HyClone), 1% pen-strep
(Corning), and 0.2% Normocin (Invivogen). Stable HeLa cell lines were generated as
described previously (468). Briefly, approximately 60-70% confluent HeLa cells were
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transfected with pD2529 SalI linearized hCx43 WT and Y247/265F mutant using
Lipofectamine 2000 in OptiMem. Transfected cells were cultured 72 hr prior to addition of
puromycin (2 µg/mL; Tocris) selection media. Both Cx43 WT and Y247/265F mutant cell
lines were clonally selected using Whatman paper cloning disks. Western blots and
immunofluorescence were used to screen clones. HeLa or HEK 293T cells at ~80%
confluence were transfected using the X-tremeGENE HP (Roche) reagent at 2:1
(reagent:plasmid), diluted in OptiMem under antibiotic free conditions. HeLa and HEK
293T cells were analyzed 24 hr after transfection. HeLaCx43 cells were treated with the Src
inhibitors Saracatinib (0, 0.25, 0.5, 1, 2.5, 5 μM) or WH-4-023 (0, 0.5, 1, 2.5, 5, 7.5 μM) at
a series of concentration for 24 hr. Cell lysate was extracted for Western blot.

11.4 Pyk2 siRNA transfection
Pyk2 siRNA#1 (ThermoFisher, Catalog # 4392420, ID: s223513) and Pyk2 siRNA#2
(ThermoFisher, Catalog # 4392420, ID: s5006) was used to knock down Pyk2 expression
in HeLaCx43 cells. Negative Control #2 siRNA (ThermoFisher) with sequences that do not
target any known gene product was used as control. Reverse transfection of siRNA was
performed by using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s
protocols. After being transfected with Pyk2 or Negative Control siRNA for 24 hr, HeLa
Cx43

cells were transfected with active c-Src for 24 hr. Cells were lysed and protein levels

were detected by Western blot.

11.5 Primary cardiomyocyte isolation and culture
Neonatal rat ventricular myocytes (NRVMs) were isolated from day 1-3 rat hearts by
using the Pierce Primary Cardiomyocyte Isolation Kit. Freshly dissected hearts were
placed into separate 1.5 mL sterile microcentrifuge tubes with cold HBSS. Each heart was
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minced into 1-3 mm3 pieces and minced tissues were washed twice with ice cold HBSS
to remove blood. Heart tissues were incubated with reconstituted cardiomyocyte isolation
enzyme 1 (with papain) and enzyme 2 (with thermolysin) in a 37°C incubator for 30 min.
After being washed twice with ice cold HBSS, tissues were broken up by pipetting up and
down 30 times until the tissue was primarily a single-cell suspension. Combined individual
cell suspensions were observed for determination of cell concentration and cell viability by
using a hemocytometer. Isolated NRVMs were plated at a seeding density of 2.5 × 105
cells/cm2 in complete DMEM (DMEM provide by kit supplemented with 10% FBS and 1%
pen-strep) at 37°C in a 5% CO2 incubator for 24 hr. The medium was then replaced with
complete DMEM containing Cardiomyocyte Growth Supplement (1000X). After cultured
in complete DMEM containing Cardiomyocyte Growth Supplement for 3 days, NVCMs
were pre-treated with Saracatinib, PF4618433, or both for 4 hr and then treated with PMA
for 60 min.

Videos of NVCMs beating were recorded. The contraction of NVCMs

expressed as beats per minute and the total number of NVCMs contributing to the beats
were calculated. Cell lysate was extracted and separated by electrophoresis followed by
immunoblot.

11.6 Immunofluorescence
Cells grown on coverslips were fixed with 4% paraformaldehyde for 20 min at room
temperature (RT). Coverslips were washed 2x 5 min in 1x Tris-buffered saline (TBS) and
then blocked for 60 min at RT with blocking buffer (1x TBS, 5% Goat Serum, 0.2% Triton
X-100). Cells were immunostained with appropriate primary antibodies diluted in blocking
buffer overnight at 4°C. Coverslips were washed 3x 10 min with 1x TBS, incubated with
secondary antibody for 1 hr at RT, stained with DAPI (100 ng/mL; MP Biomedicals) for 10
min, and then washed 3x 10 min with 1x TBS. Coverslips were mounted on a drop of
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SlowFade anti-fade (Life Tech), sealed with clear nail polish, and imaged. Slides of sham
or heart failure rat heart ventricles were deparaffinized in xylene and rehydrated in graded
ethanol. After washing with TBS-T (1x TBS, 0.025% Triton), slides were permeabilized in
50% methanol followed by heat induced epitope retrieval by microwaving for 25 min in
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0). Slides were
washed again with TBS-T and blocked (1x TBS with 2.5% horse serum and 0.2% Triton)
for 1 hr at RT and incubated at 4°C overnight with the following primary antibodies: αCx43 and α-p-Pyk2 (pY579/580). The next day, sections were washed 3x 10 min with 1x
TBS-T, incubated with secondary antibody for 1 hr at RT, stained with DAPI for 10 min,
and then washed 3x 10 min with 1x TBS-T. Coverslips were mounted on a drop of
SlowFade anti-fade (Life Tech), and imaged.

11.7 Confocal imaging
All cell immunofluorescence images were acquired on a Zeiss LSM 800 Confocal
system using appropriate numerical aperture objectives and appropriate filter sets.

11.8 Western blot
Cultured cells were rinsed 2x with cold 1x TBS and then lysed in lysis buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 0.2% SDS, Complete protease inhibitor and PhosSTOP)
on ice for 30 min. Protein concentration was quantified by BCA assay (Pierce). A total of
30 μg protein lysate was resolved by SDS-PAGE and transferred to PVDF (EMD Millipore)
membrane. Blots were blocked in 5% BSA in TBS-T (plus 5 mM Na3VO4) for 1 hr at RT
and incubated with indicated primary antibody in blocking buffer overnight at 4°C. Blots
were washed 3x 10 min with TBS-T, and then incubated for 1 hr at RT with secondary
antibody. Blots were then washed again 3x 10 min with TBS-T and detected using the
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Signal West Femto kit (Thermo) per manufacturer protocol and exposed to
autoradiography film. Quantifications were done using NIH ImageJ software using a
minimum of three independent replicates.

11.9 Kinase Screen (Eurofins KinaseProfiler)
Rat Cx43CT236-382 was expressed and purified as described previously (64). Purified
protein was diluted in 1x PBS pH 7.4 to a final concentration of 200 µM in a final volume
of 1 mL, flash frozen on dry ice and shipped on dry ice to Eurofins Scientific for a custom
Kinase Profiler Assay testing the Cx43CT as substrate for the indicated kinases. Control
peptides or Cx43CT were incubated with the indicated tyrosine kinase and ATP [γ-33P]
for 40 min at RT. The reaction was stopped and then spotted onto either P30 filtermat or
Filtermat A prior to drying and scintillation counting. Quantification of raw scintillation
counts were achieved by averaging the value of two experimental well following
subtraction of the acid buffer blank for each kinase. This value was normalized to the acid
blank subtracted average of two wells of the positive control peptide for each kinase
tested.

11.10 Mass spectrometry
Rat Cx43CT236-382 was expressed and purified as described previously (475). Purified
Cx43CT WT was incubated with 1.5 µg of active Pyk2 (recombinant human residues 360690, SignalChem) and 500 µM ATP in reaction buffer (5 mM MOPS pH 7.2, 2.5 mM βglycerol-phosphate, 4 mM MgCl2, 2.5 mM MnCl2, 1.0 mM EGTA, 0.4 mM EDTA, 0.05 mM
DTT, and 40 µg/mL BSA) for 16 hr at 30°C. The reaction was stopped on ice. 10 nmol of
protein was run on a SDS-PAGE gel and stained with Coomassie blue. Once the Cx43CT
bands were cut out, it was washed extensively with MilliQ water followed by 50%
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acetonitrile in MilliQ water. After being frozen on dry ice, the sample was shipped on dry
ice to the Harvard Beth Israel Deaconess Medical Center Mass Spectrometry Core Facility
for post-translational mapping. For negative control the kinase was substituted with
reaction buffer.

11.11 In vitro kinase assay
Rat Cx43CT236-382 was expressed and purified as described previously (468, 475).
Purified Cx43CT WT and Y→F mutants (Table 5) were incubated with 1.5 µg of active
Pyk2 (recombinant human residues 360-690, SignalChem) and 500 µM ATP in reaction
buffer (5 mM MOPS pH 7.2, 2.5 mM β-glycerol-phosphate, 4 mM MgCl2, 2.5 mM MnCl2,
1.0 mM EGTA, 0.4 mM EDTA, 0.05 mM DTT, and 40 µg/mL BSA) for 16 hr at 30°C. After
reactions were stopped by the addition of 6X SDS loading buffer, products were ran on
SDS-PAGE gel followed with Coomassie staining, and western blot with a general pTyr
antibody. For negative control the kinase was substituted with reaction buffer.
Construct

Mutation

Remaining Tyrosine

Cx43CT WT

None

Y247/265/267/286/301/313

Cx43CT Y247/265

Y267/286/301/313F

Y247/265

Cx43CT Y267

Y247/265/286/301/313F

Y267

Cx43CT Y286

Y247/265/267/301/313F

Y286

Cx43CT Y301

Y247/265/267/286/313F

Y301

Cx43CT Y313

Y247/265/267/286/301F

Y313

Table 5. Constructs of Cx43 WT and mutants used for in vitro kinase assay.
11.12 Glutathione S-transferase (GST) pull-down assay
The GST pull down assay was modified from (175) and has been described previously
(468). Briefly, purified GST-fusion Cx43CT and GST control proteins were bound to
glutathione-Sepharose beads in buffer containing 25 mM Tris-HCl [pH=7.4], 150 mM
NaCl, 1 mM DTT, 0.5% Triton X-100 and Complete protease inhibitor (Roche). MCF-7
cells were lysed in cell lysis buffer containing 25 mM Tris-HCl (pH 7.4), 150 mM NaCl,
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0.5% Triton X-100, 0.5% sodium deoxycholate, 2 mM EDTA, PhosSTOP (Roche), and
Complete protease inhibitor. After concentration measured by BCA assay, 4 mg protein
of MCF-7 cell lysate was incubated with GST-fusion Cx43CT or the GST control for 6 hr
at 4°C on a rotating wheel. Beads were then washed 5x with cell lysis buffer and bound
proteins were eluted with SDS-PAGE sample buffer, and analyzed by Western blot.

11.13 Dye-transfer assay
Cells were scrape-loaded as described previously (210). Briefly, HeLaCx43 cells were
treated with Saracatinib, PF4618433, or both inhibitors, respectively 3 hr prior to PMA
(100 ng/mL) treatment. One hr after PMA treatment, cell imaging dishes with a 100%
confluent monolayer of HeLaCx43 cells were removed from the incubator. All buffer and
medium used for Dye-transfer assay were pre-warmed at 37°C. After washed twice with
1x PBS, cells were overlaid with 1x PBS containing Lucifer yellow. Cells were scrapeloaded with a fine edged micro-scalpel by three longitudinal scratches and then incubated
at RT for 5 min. Cells were rinsed quickly twice with 1x PBS and incubated in cell culture
medium at 37°C for 5 min. After incubation, cells were washed twice with 1x PBS
containing 1 mM CaCl2 and 1 mM MgCl2 to stop dye spread and fixed with 4%
Paraformaldehyde for 20 min. After stained with DAPI for 10 min, cells were mounted by
adding several drops of SlowFade anti-fade (Invitrogen). The cells were imaged using
confocal microscope.

11.14 Triton X-100 (TX-100) solubility assay
TX-100 extraction and WB: The TX-100 solubility assay was modified from a method
described previously (76, 520). In brief, HeLa cells grown in plates were incubated in 1 mL
lysis buffer for 20 min on ice before being harvested and gently pelleted. Cell pellet was
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resuspended in 1 mL lysis buffer then lysed by sonication. Protein concentrations of cell
lysate was determined by BCA assay. 450 μL of cell lysate was mixed with 50 μL of 10%
SDS and reserved as total lysate. Another 450 μL of cell lysate was mixed with 50 μL of
10% TX-100 dissolved in PBS and incubated for 30 min at 4°C under agitation. The TX100 lysate was then divided into two fractions after ultracentrifugation at 100,000 x g for 1
hr at 4°C. The supernatant was carefully aspirated and collected as the soluble, nonjunctional fraction. The remaining pellet as the insoluble, junctional fraction was solubilized
in 500 μL solubilization buffer (prepared in 1x PBS containing 8 M urea, 2.5% SDS, 0.1 M
dithiothreitol (DTT), 1X Roche complete and EDTA, 2 mM PMSF and 2 μM Pepstatin A).
The same amount of proteins from samples of total lysate (T), TX-100 soluble (S) and TX100 insoluble (I) portions were resolved by SDS-PAGE and analyzed by Western blot.
Soluble and insoluble fractions were quantified as a function of total lysate. Quantification
was performed using the ImageJ from three independent studies.
In situ TX-100 extraction: The in situ TX-100 extraction was previously described (475).
In brief, HeLa cells seeded on Fibronectin-coated glass coverslips were grown to ~90%
confluence. Cells on coverslips were then added with extraction buffer (1x PBS containing
1x Roche complete and EDTA, 2 mM PMSF, 2 μM Pepstatin, and 1% TX-100) and
incubated for 30 min at 4°C. After extraction, the cells were fixed, blocked and immunestained with a Cx43 antibody. Three independent extraction studies were performed to
ensure reproducibility. Quantification of immunostaining images was done by normalizing
the mean fluorescence intensity of the Cx43 signal by the DAPI signal using ImageJ.

11.15 MTT assay
NRVMs were seeded on each well of a 24-well plate and the cells were cultured in
complete DMEM containing Cardiomyocyte Growth Supplement at 37°C in a humidified

107

incubator containing 5% CO2 for 3 days. Saracatinib (0, 0.1, 0.5, 2.5, 10, 25 μM) and
PF4618433 (0, 0.01, 0.04, 0.2, 1, 5 μM) were individually prepared in the culture media
and added to each well of cells followed by 48 hr incubation. The control group contained
no kinase inhibitors. Each concentration and control group had 4 replicates. After that, the
drug

cytotoxicity

was

determined

using

MTT

([3-(4,5-Dimethylthiazol-2-yl)-2,5-

Diphenyltetrazolium Bromide, purchased from Sigma) assay. Generally, the media
containing the drug was aspirated and fresh culture media containing 0.5 mg/mL MTT was
added and the cells were incubated for another 3 hr. The media was then emptied and
0.5 mL DMSO (Fisher Chemical) was added to each well. The whole culture plate was
rotated for 30 min for completely dissolving the dye. Then 0.1 mL of DMSO from each well
was transferred to one well of a 96-well plate and the absorbance was determined at 540
nm wavelength with the microplate reader. The absorbance value from each group was
normalized to the average absorbance value in the control group.

11.16 Animal studies
All rats (Sprague Dawley; 200-250g) used in this study were purchased from The
Sasco Breeding Laboratories. All surgical procedures and animal care protocols were
approved by the University of Nebraska Medical Center Institutional Animal Care and Use
Committee (IACUC).

11.17 Left anterior descending artery (LAD) ligation and tissue collection
Rats were assigned into two groups randomly: the sham control and the heart failure
group. Rat heart failure model was generated by LAD ligation as previously described
(521). Heart failure and the left ventricular dysfunction degree was determined by the
hemodynamic and morphological change extent. A Mikro-Tip catheter (Millar Instruments)
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was used to measure the left ventricular end-diastolic pressure (LVEDP) at the end of
experiments. The infarct size ratio was determined by dividing the infarct area to the total
left ventricle area with the SigmaScan Pro software (Aspire Software International) (522).
Rats with both LVEDP ≥15 mmHg and infarct size ratio ≥30% were considered as heart
failure. The left ventricles of surgical hearts were collected for Western blot or
immunofluorescence staining. For WB, the total protein of the left ventricle tissues from
both group were extracted by sonication. BCA assay was used for protein normalization.
For IHC staining, the ventricle tissues were fixed by 4% PFA for 24 hr and send to the
tissue core facility for paraffin blocks processing and embedding.

11.18 Human heart ventricle tissue lysate
Human normal heart left ventricle lysate (SLH-081) was purchased form GBiosciences. Human heart left ventricle whole tissue lysate from patient with arrhythmia
(NB820-59314) and from patient with hypertension (NB820-59315) were purchased form
NOVUS.

11.19 Statistical Analysis
All data were analyzed by using GraphPad Prism 8.0 and presented as the mean +
s.e.m. Statistical analysis were either one-way ANOVA with a Neuman-Keuls post-hoc
analysis or Student’s t-test where appropriate. P-values <0.05 were considered
statistically significant.
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12. Results
12.1 Pyk2 directly interacts and phosphorylates the Cx43 carboxyl terminal (CT)
domain
Src-induced phosphorylation of Cx43 residues Y247, Y265, and Y313 leads to down
regulation of GJIC and gap junction disassembly (278, 305-307, 468, 484, 489-491).
Another target of Src is the Ca2+-dependent, nonreceptor tyrosine kinase of the FAK
family, Pyk2 (334). Pyk2 activation initiates after auto-phosphorylation at Y402, which
facilitates enhanced kinase activity after Src binding (via SH2 domain) and
phosphorylation at Y579 and Y580 (318, 332). A commonality exists between these
kinases in that increased expression and activity is observed in animal models of heart
failure and in the left ventricle of failing human hearts (323, 338, 339, 491, 523-525).
Inhibition of Src or Pyk2 (individually) reduces arrhythmias, slows ventricular remodeling,
improves ventricle function, and prevents sudden cardiac death (323, 487, 488). In relation
to Src inhibition, the level of Cx43 protein at the plaque and intercellular communication
was improved (487, 488). Based upon these commonalities and that both Src (SH4
domain-myristoylation) and Pyk2 (FERM domain-PIP2) are plasma membrane associated,
we addressed the potential for Pyk2 phosphorylation of Cx43.
An in vitro tyrosine phosphorylation screen performed by Eurofins Scientific
(KinaseProfiler) discovered that Pyk2 phosphorylates purified Cx43CT236-382 (Figure 3.1A).
FAK, the other FAK family member, had significantly less ability to phosphorylate the
Cx43CT domain (Tyk2, positive control (237); SYK and ZAP70, examples with little-to-no
Cx43CT236-382 phosphorylation). To confirm the interaction between Cx43 and Pyk2,
purified GST-tagged Cx43CT236-382 was immobilized on glutathione-Sepharose beads and
lysate from MCF-7 cells that express Pyk2 were used in a pull-down assay (Figure 3.1B).
Pyk2 can be pulled-down by GST-Cx43CT but not GST in MCF-7 cells. To identify the
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Figure 3.1. Pyk2 phosphorylates Cx43CT tyrosine residues. (A) An in vitro tyrosine
kinase screen was performed using the catalytic domain of FAK, Pyk2, SYK, ZAP70 and
Tyk2 to phosphorylate the purified Cx43CT (V236-I382) domain. The amount of Cx43CT
phosphorylation was compared with a positive control peptide for each kinase (100%
signal). (B) Purified GST or GST-Cx43CT bound on glutathione-agarose beads were
incubated ± MCF-7 cell lysate and the pull-downed product was analyzed by Western blot
using an anti-Pyk2 antibody. (C) Sequence of the Cx43CT domain. Underlined are the
phosphorylated tyrosine residues identified via mass spectrometry from the in vitro kinase
assay using the Cx43CT incubated with the Pyk2 kinase domain.
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Table 6. Phospho-Tyr containing peptides identified from mass spectrometry of the Cx43CT in vitro phosphorylated
by Pyk2. *Peptides with Mascot Delta Ion Score >7 were used to obtain the average Mascot Delta Ion Score.

Cx43CT tyrosine residue(s) phosphorylated by Pyk2, purified Cx43CT236-382 was
incubated in vitro with active Pyk2 (SignalChem). After trypsin digestion, Tandem MS/MS
identified phosphorylation at Y247, Y265, Y267, and Y313 (Figure 3.1C and Table 5). The
identical Cx43CT residues were identified to be phosphorylated by MS/MS when the
experiment was performed with active c-Src (468). To confirm that tyrosine
phosphorylation can occur at the residues detected by Tandem MS/MS, the same in vitro
kinase assay was performed using different Cx43CT236-382 (Y→F) constructs.
Phosphorylation was detected by SDS-PAGE and blotted with an anti-pTyr antibody
(Figure 3.2). In the Cx43 WT, Y247/Y265 (all other Y→F), and Y313 (all other Y→F) lanes
+ active Pyk2, a slower mobility band was observed after Coomassie staining, compared
to all the other Cx43CT mutations (Figure 3.2, top). The altered mobility is likely due to
disrupted protein-SDS interaction by the negative charges on the phosphate group (472).
The Cx43 WT, Y247/Y265, and Y313 lanes were the only lanes where a Western blot
band was observed with the anti-pTyr antibody (Figure 3.2, bottom). The data indicate that
Pyk2 phosphorylation of Cx43 occurs on Y247, Y265, and Y313 in vitro. Of note, the
pattern of Cx43 phosphorylation by Pyk2 is very similar to Src (468).

12.2 Pyk2 phosphorylates Cx43 residues Y247, Y265, and Y313 in HeLa and HEK
293T cells
To determine if Pyk2 phosphorylation of Cx43 occurs in cells, we initially tested in Cxdeficient HeLa cells (stably transfected with Cx43, HeLaCx43) if Cx43 and active Pyk2
(endogenously expressed) colocalize (Figure 3.3 and 3.4). We also used a
phosphorylation eliminating Cx43 Y247/265F mutant (HeLaCx43Y247/265F) with the goal of
enhancing the interaction by trapping Pyk2 on a non-phosphorylatable Cx43. Pyk2 was
activated (increased pY402 and pY579/Y580) after transient transfection of v-Src (Figure
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Figure 3.2. Confirmation of the Cx43CT tyrosine residues phosphorylated by Pyk2
by in vitro kinase assay. The same in vitro kinase assay in Figure 3.1 (C) was performed
using Cx43CT236-382 wild type (WT) or different tyrosine substituted CT constructs (all
replaced to a phenylalanine except the labeled tyrosine) as substrate and phosphorylation
was detected by Western blot using a general anti-pTyr antibody (top: SDS-PAGE;
bottom: Western blot).
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Figure 3.3. Pyk2 is activated by v-Src overexpression in HeLa cells. Western blot of
lysate from HeLa cells stably expressing Cx43 WT or Cx43 Y247/265F ± v-Src (24 h).
Antibodies used are labeled on the left of each panel.

115

Figure 3.4. Active Pyk2 interacts with Cx43 in HeLa cells. (A) Cellular localization of
Cx43 WT or (B) Cx43 Y247/265F ± v-Src (24 h) in HeLa cells detected by
immunofluorescence (green, p-Pyk2Y579/580; blue, DAPI-stained DNA; red, total Cx43;
yellow, p-Pyk2/Cx43 colocalization). (C) Z-stack imaging of HeLa Cx43 Y247/265F cells
after v-Src transfection. Grey arrows point to Cx43 colocalization with active Pyk2.
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3.3). The images of HeLaCx43 without v-Src (control) show a small level of active Pyk2 that
increases in the presence of v-Src (Figure 3.4A). Active Pyk2 colocalize with Cx43
(antibody recognizes total Cx43) at the plasma membrane and within intracellular
compartments. Of the remaining plasma membrane localized Cx43, the presence of active
Pyk2 and v-Src causes a significant decrease in number of plaques and plaque length
(Figure 3.5A; statistics from images using an antibody (IF) that recognizes only junctional
Cx43). When the same experiment was performed with HeLaCx43Y247/265F, the Cx43 and
Pyk2 colocalization is predominately at the plasma membrane, suggesting Pyk2
phosphorylation occurs at the plasma membrane before the internalization of Cx43 (Figure
3.4B and Figure 3.5B). A Z-stack image of the Cx43Y247/265F indicates that Pyk2
colocalization occurs in the center of the gap junction plaque (Figure 3.4C). This is
consistent with previous studies that revealed newly synthesized channels accrue along
the plaque edges and removal of channels from plaque centers (171, 526).
The ability to directly characterize the impact of Pyk2 phosphorylation on Cx43 is
challenged by the knowledge that Pyk2 requires c-Src for “enhanced” activation and that
they both phosphorylate the same Cx43CT tyrosine residues (468). Also, inhibition of Src
by chemical Src inhibitors Saracatinib and WH-4-023 at a series of concentration resulted
in a decrease of Pyk2 activity, indicating that Pyk2 phosphorylation depends on Src
activation in normal condition (no other stimuli) (Figure 3.6). Therefore, to initially address
this issue, Cx43 tyrosine phosphorylation levels were evaluated in the HeLaCx43 cells after
decreasing the activation of Pyk2 (i.e., loss of function study) and probing with the only
available Cx43 tyrosine phospho-specific antibodies pY247, pY265, and pY313 (Figure
3.7, 3.8, 3.9, 3.10, 3.11). The initial loss of function experiment used siRNA to knockdown
the expression of Pyk2 in the presence and absence of constitutively active c-Src (cSrcY530F; Figure 3.7 and 3.8). The Pyk2 siRNA knockdown efficiency test was performed
using two different Pyk2 siRNA, #1 and #2. The Western blot result, as shown in Figure
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Figure 3.5. Active Pyk2 and v-Src cause internalization of Cx43. Cellular localization
of (IF antibody, recognizes plaque localized Cx43) ± v-Src (24 h) in (A) HeLa Cx43 WT or
(B) HeLa Cx43 Y247/265F cells detected by immunofluorescence (green, p-Pyk2Y579/580;
blue, DAPI-stained DNA; red, total Cx43; yellow, p-Pyk2/Cx43 colocalization).
Colocalization of Cx43 and p-Pyk2 at the GJ plaque was analyzed based on 20 images
from three independent experiments. Immunofluorescence intensities of DAPI and Cx43
plaque were measured by ImageJ software. Cx43 plaque immunofluorescence intensitiy
was normalized by DAPI. (t-test, ***P<0.001).
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Figure 3.6. Phosphorylation of Cx43 residue Y313 by Src contributes to gap junction
disassembly. Lysate from HeLaCx43 cells treated with Saracatinib (A) or WH-4-023 (B) at
different concentrations (24hr) were Western blotted. Antibodies used are labeled on the
left of each panel. Protein levels were quantified by analyzing scanned blots using ImageJ
software, with normalization of protein expression to the control lane (value set arbitrarily
as 1). Phosphorylated protein levels were normalized to total protein. Data are
representative of three independent experiments.
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Figure 3.7. Pyk2 siRNA knockdown efficiency testing. Lysate from HeLaCx43 cells
transfected with different Pyk2 siRNA (48hr) and c-SrcY530F (active c-Src, 24 h) were
Western blotted. Antibodies used are labeled on the left of each panel. si-1: Pyk2 siRNA#1
30 pmol, si-2: Pyk2 siRNA#2 30 pmol, si-1&2: Pyk2 siRNA#1 15 pmol and Pyk2 siRNA#1
15 pmol.
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Figure 3.8. Knocking down of Pyk2 by siRNA decreases c-Src mediated Cx43
phosphorylation at residues Y247, Y265, and Y313. Lysate from HeLaCx43 cells
transfected with Pyk2 siRNA (48hr) and c-SrcY530F (active c-Src, 24 h) were Western
blotted. Antibodies used are labeled on the left of each panel. Protein levels were
quantified by analyzing scanned blots using ImageJ software, with normalization of protein
expression to the control lane (value set arbitrarily as 1). Phosphorylated protein levels
were normalized to total protein. Data are representative of three independent
experiments (one-way ANOVA, *P<0.05, **P<0.01, ***P<0.001).
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3.7, indicates that Pyk2 siRNA#1 is more efficient than Pyk2 siRNA#2. In the presence of
c-SrcY530F (control), the level of total Pyk2 and active Pyk2 (pY402 and pY579/pY580),
was lower with Pyk2 siRNA#1 than Pyk2 siRNA#2. Therefore, Pyk2 siRNA#1 was used
for the rest of the study (Figure 3.8). In the absence of c-SrcY530F (control), the presence
or absence of Pyk2 has no effect on the phosphorylation of Cx43 residues Y247, Y265,
and Y313. In the presence of c-SrcY530F, there is an increased level of active Pyk2 (pY402
and pY579/pY580) as well as Cx43 pY247, pY265, and pY313 (Figure 3.8). siRNA
knockdown of Pyk2 significantly decreased the phosphorylation of Cx43 residues Y247,
Y265, and Y313. Importantly, knockdown of Pyk2 did not affect the level of total or active
c-Src. Of note, the level of phosphorylation of Cx43 residues Y247, Y265, and Y313 is
dependent on the level of Pyk2 activation (Figure 3.7). Pyk2 siRNA#2 had a lower
knockdown efficiency, so the level of total Pyk2 and active Pyk2 (pY402 and
pY579/pY580) was higher than Pyk2 siRNA#1 transfected group, leading to higher
phosphorylation level of Cx43 on residues Y247, Y265, and Y313. Pyk2 siRNA#1 and
Pyk2 siRNA#2 (half concentration of each) mixture had intermediate knockdown.
The next loss of function experiment used expression of the Cell Adhesion Kinase-βRelated Non-kinase (CRNK, i.e. Pyk2 CT domain), an endogenously expressed inhibitor
that regulates the function of Pyk2 by blocking auto-phosphorylation at Y402 (323, 340),
to inhibit activation of Pyk2. Pyk2 CT was introduced in the presence and absence of the
indirect Src-activators phorbol 12-myristate 13-acetate (PMA) or epidermal growth factor
(EGF) (both lead to decreased Cx43 GJIC (527, 528); Figure 3.9 and 3.10). In the absence
of PMA or EGF, the presence of the Pyk2 CT domain had little-to-no effect on the level of
active Pyk2 (pY402 and pY579/pY580) as well as phosphorylation of Cx43 residues Y247,
Y265, and Y313. The addition of PMA or EGF increased the level of active Src, active
Pyk2, and phosphorylation of Cx43 residues Y247 and Y265. Conversely, expression of
the Pyk2 CT domain in the presence of PMA or EGF reduced the level of active Pyk2 and
123

Figure 3.9. Overexpression of Pyk2 CT in HeLaCx43 cells decreases PMA mediated
Cx43 phosphorylation at residues Y247, Y265, and Y313. Lysate from HeLaCx43 cells
treated with Pyk2 CT and PMA (100 nM, 1 hr) were Western blotted. Antibodies used are
labeled on the left of each panel. Protein levels were quantified by analyzing scanned blots
using ImageJ software, with normalization of protein expression to the control lane (value
set arbitrarily as 1). Phosphorylated protein levels were normalized to total protein. Data
are representative of three independent experiments (one-way ANOVA, *P<0.05,
**P<0.01, ***P<0.001).

124

Figure 3.10. Overexpression of Pyk2 CT in HeLaCx43 cells decreases EGF mediated
Cx43 phosphorylation at residues Y247, Y265, and Y313. Lysate from HeLaCx43 cells
treated with Pyk2 CT and EGF (100 ng/mL 1 hr) were Western blotted. Antibodies used
are labeled on the left of each panel. Protein levels were quantified by analyzing scanned
blots using ImageJ software, with normalization of protein expression to the control lane
(value set arbitrarily as 1). Phosphorylated protein levels were normalized to total protein.
Data are representative of three independent experiments (one-way ANOVA, *P<0.05,
**P<0.01, ***P<0.001).
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phosphorylation of Cx43 residues Y247 and Y265 without affecting the level of total or
active c-Src. Of note, although not significant, the (de)phosphorylation of Y313 had the
same trend as Y247 and Y265 in the presence of PMA or EGF experiments ± the Pyk2
CT domain.
The final loss of function experiment used a small molecule Pyk2 inhibitor (PF4618433)
in the presence of PMA (Figure 3.11). Increasing the concentration of PF4618433 to 37.5
μM counteracted the effect of PMA by returning active Pyk2 (pY402 and pY579/pY580) to
the pre-PMA treated level. The inhibitor had the additional effect of causing activated cSrc to also return to the pre-PMA treated level; this occurred at a lower concentration of
PF4618433 (12.5 μM). Noteworthy is that while additional concentrations of PF4618433
(25 and 37.5 μM) had no further effect on the level of activated c-Src, unlike Pyk2, the
level of phosphorylation of Cx43 residues Y247, Y265, and Y313 also continued to
decrease with additional PF4618433. Altogether, three different techniques to inhibit
active Pyk2 were consistent in suggesting that Pyk2 plays a direct role in the
phosphorylation of Cx43 residues Y247, Y265, and Y313.
To complement the loss of function study we used HEK 293T cells to investigate the
contribution of Pyk2 via a gain of function study. HEK 293T cells were utilized because
they endogenously express Cx43, contain a low level of endogenous Pyk2 and c-Src, and
they are highly efficient for double transfections. HEK 293T cells were transiently
transfected with c-SrcY530F and Pyk2 WT or a kinase dead (KD) mutant and evaluated for
phosphorylation of Cx43 residues Y247, Y265, and Y313 (Figure 3.12; two exposure
levels are provided to better visualize the bands). Consistent with our previous study, the
transfection of c-SrcY530F alone caused an increase in the phosphorylation of Cx43
residues Y247, Y265, and Y313 (468). However, a significant increase is observed in
phosphorylation of Cx43 residues Y247, Y265, and Y313 when Pyk2 is co-expressed with
c-SrcY530F (Figure 3.13A). Importantly, the presence of Pyk2 did not affect the level of
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Figure 3.11. Pyk2 inhibitor (PF4618433) decreases PMA mediated Cx43
phosphorylation at residues Y247, Y265, and Y313. Lysate from HeLaCx43 cells treated
with PF4618433 at different concentrations (3hr) and then treated with PMA (100 nM, 1
hr) were Western blotted. Antibodies used are labeled on the left of each panel. Protein
levels were quantified by analyzing scanned blots using ImageJ software, with
normalization of protein expression to the control lane (value set arbitrarily as 1).
Phosphorylated protein levels were normalized to total protein. Data are representative of
three independent experiments (one-way ANOVA, *P<0.05, **P<0.01, ***P<0.001).
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Figure 3.12. Overexpression of Pyk2 increases Cx43 phosphorylation at Y247, Y265,
and Y313. HEK 293T cells were co-transfected with c-SrcY530F (active c-Src; 24 hr) and
Pyk2 wild type (WT) or a Pyk2 kinase dead (KD) mutant (K457A) and lysate was Western
blotted. Antibodies used are labeled on the left of each panel.
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Figure 3.13. Statistical analysis of increased Cx43 phosphorylation at Y247, Y265,
and Y313 by overexpression of Pyk2. Protein levels in Figure 3.13 were quantified by
analyzing scanned blots using ImageJ software, with normalization of protein expression
to the control lane (value set arbitrarily as 1). A) Quantification of Western blot bands
where c-SrcY530F was co-transfected. B) Quantification of long exposure Western blot
bands without c-SrcY530F transfection. Phosphorylated protein levels were normalized to
total protein. Data are representative of three independent experiments (one-way ANOVA,
*P<0.05, **P<0.01).
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active c-SrcY530F. This increase in Cx43 phosphorylation is not seen with expression of
Pyk2 KD version (Figure 3.13B). Interestingly, examination of the long exposure control
and expression of Pyk2 WT without expression of c-SrcY530F, an increase is still observed
in phosphorylation of Cx43 residues Y247, Y265, and Y313. In total, the loss and gain of
function data are consistent in demonstrating that Pyk2 contributes to the level of Cx43
Y247, Y265, and Y313 phosphorylation.

12.3 Pyk2 has a greater impact on Cx43 phosphorylation than Src
A working model for Src phosphorylation of Cx43 includes: 1) association initiates
between Cx43 residues A276-S282 and the Src SH3 domain (85, 306, 494). SH3 binding
causes Cx43CT residues T275-P284 to adopt a left-handed type II helix (85); 2) Src kinase
domain phosphorylates Cx43 residue Y265 (239, 306); 3) Src SH2 domain binds pY265,
which stabilizes the Src-Cx43 interaction, promotes phosphorylation at Y247 and Y313
(306, 468, 494, 495). Src phosphorylation of Pyk2 includes the association of the Src SH2
domain with Pyk2 pY402 and Src kinase domain phosphorylates Pyk2 residues
Y579/Y580 to enhance activity (334). Based upon this information, another method was
employed to dissect the impact of Pyk2 and Src phosphorylation on Cx43, using a SH3or SH2-deficient active c-Src (c-SrcY530F) (Figure3.14). The idea is that a SH3-defient cSrcY530F (point mutation disrupts binding, W121K) could still activate Pyk2, but not bind
Cx43CT residues A276-S282 to initiate phosphorylation of Y265 and a SH2-defient Src
(point mutation disrupts binding, R178L) would not activate Pyk2, but could still bind
Cx43CT residues A276-S282 and phosphorylate Y265. WT, SH3-deficient, and SH2deficient c-SrcY530F constructs were transiently transfected into HeLaCx43 cells (Figure
3.15). WT c-SrcY530F increased the level of active Pyk2 and phosphorylation of Cx43
residues Y247, Y265, and Y313. The SH3-deficient c-SrcY530F was able to activate Pyk2

130

Figure 3.14. Schematic representation of the c-Src WT and all the mutation
constructs used. All deletion and point mutations are indicated.
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Figure 3.15. Src mutations demonstrate the contribution of Pyk2 to Cx43
phosphorylation at Y247, Y265, and Y313. (A) HeLaCx43 cells were transfected with
empty vector, c-SrcY530F (active c-Src), mSH3W121K (disables SH3 domain from interacting
with protein partners), or mSH2R178L (disables SH2 domain from interacting with protein
partners) for 24 h and lysate was Western blotted. Antibodies used are labeled on the left
of each panel. (B) Protein levels were quantified by analyzing scanned blots using ImageJ
software, with normalization of protein expression to the control lane (value set arbitrarily
as 1). Phosphorylated protein levels were normalized to total protein. Data are
representative of three independent experiments (one-way ANOVA,**P<0.01,
***P<0.001).
132

and while there was not a statistically significant decrease in phosphorylation of Cx43
residues Y247, Y265, and Y313 when compared to WT, the trend was lower. Conversely,
SH2-deficient c-SrcY530F was unable to activate Pyk2. Phosphorylation of Cx43 was mostly
absent with only minor phosphorylation on Cx43 residues Y265 (Figure 3.15). The data
suggest that the overall phosphorylation level of Cx43 residues Y247, Y265, and Y313 is
higher in the presence of active Pyk2 than c-Src. This result is consistent with the
PF4618433 data (25 and 37.5 μM; active Src at basal level) which showed that the
decrease in phosphorylation of Cx43 residues Y247, Y265, and Y313 correlated most
closely with the decrease in active Pyk2. A complementary experiment was performed in
HEK 293T cells. HEK 293T cells were transiently transfected with WT, active c-Src (cSrcY530F), kinase dead c- Src (c-SrcK298M) and SH3-deficient, SH3-deletion (SH3 domain
aa 88-143 completely deleted), SH2-deficient, or SH3&2 deficient c-SrcY530F constructs
with and without co-transfection of Pyk2 (Figure 3.14 and 3.16). As expected, the kinase
dead c-Src could not activate Pyk2, leading to almost no phosphorylation of Cx43.
Consistent with the previous data in HeLaCx43 cells, the SH3-deficient c-SrcY530F was able
to activate Pyk2 and the phosphorylation level of Cx43 residues Y247, Y265, and Y313
was similar to c-SrcY530F. However, the phosphorylation level of Cx43 residues Y247,
Y265, and Y313 is much lower in the presence of Pyk2 and SH2-deficient or SH3&2
deficient c-SrcY530F, only showing bands at longer exposure time. Interestingly, ΔSH3 cSrcY530F was able to activate Pyk2 even at a higher level than c-SrcY530F and there was an
increase in phosphorylation of Cx43 residues Y247, Y265, and Y313 when compared to
c-SrcY530F. A possible explanation for this might be that ΔSH3 c-SrcY530F has a higher
binding affinity to Pyk2 compared to c-Src WT, leading to higher level of activation of Pyk2.
This results in increased phosphorylation of Cx43 residues Y247, Y265, and Y313. Similar
results obtained in both HeLaCx43 and HEK 293T cells indicate that the activation of Pyk2,
rather than Src, is the dominant factor for Cx43 phosphorylation.
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Figure 3.16. Src mutations demonstrate the contribution of Pyk2 to Cx43
phosphorylation in HEK293T cells. HEK293T cells were co-transfected with Pyk2 WT
and empty vector, c-SrcY530F (active c-Src), c-SrcK298M (kinase dead c-Src), mSH3W121K
(disables SH3 domain from interacting with protein partners), c-SrcΔSH3 (deleted SH3
domain mSH2R178L (disables SH2 domain from interacting with protein partners), or
mSH2&3 for 24 h and lysate was western blotted. Antibodies used are labeled on the left
of each panel.
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12.4 Inhibition of Pyk2 is necessary to maintain gap junction intercellular
communication
To determine if Pyk2 phosphorylation affects cell-to-cell communication, junctional
transfer of the tracer Lucifer Yellow (anionic) was measured in a scrape-loading assay
using HeLaCx43 cells treated with PMA in the presence of Pyk2 (PF4618433) and/or c-Src
(Saracatinib) inhibitors. Western blot data demonstrated that 60 min of PMA treatment
was optimal for Pyk2 activation (Figure 3.17). In addition, while PF4618433 and
Saracatinib inhibited the activation of Pyk2 and c-Src, respectively, the inhibitors also can
impact the activation of each other. Similar to previously published studies, Cx43 WT
expressing HeLa cells (no PMA) were extensively coupled with respect to Lucifer Yellow
(Figure 3.18) (485). When HeLaCx43 cells were only treated with Saracatinib and/or
PF4618433, no significant differences of intercellular communication were found between
each groups (Figure 3.18A and C). However, when treated with PMA, coupling was
reduced by ~81%, which was partially reversed by the addition of Saracatinib (~53%
reduction) or PF4618433 (~41% reduction). Only in the presence of both Saracatinib and
PF4618433 was the effect of PMA on coupling completely reversed (no reduction). We
next texted the Cx43 gap junction plaque formation by an in situ Triton X-100 extraction
assay. We reasoned that the inhibitors may mediate functional recovery by preventing
Cx43 plaques internalization. Immunofluorescence from an in situ Triton X-100 extraction
assay, used to quantify the junctional (insoluble) and non-junctional (soluble) pools,
identified that the increase in coupling (seen in Figure 3.18) with the inhibitors alone and
together correlated with the increase of Cx43 in the junctional fraction at the plasma
membrane (Figure 3.19 and 3.20). Altogether, the data indicated that inhibition of both
Pyk2 and Src was needed to counteract the effect of PMA on GJIC.
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Figure 3.17. Increase of Pyk2 activity by PMA treatment is inhibited by Saracatinib
or/and PF4618433. Lysate from PMA treated (30 and 60 min) HeLaCx43 ± Src (Saracatinib,
SA) and/or Pyk2 (PF4618433, PF) inhibitors was Western blotted. Antibodies used are
labeled on the left of each panel.
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Figure 3.18. PMA mediated Cx43 gap junction closure is reversed by inhibiting
active Pyk2 and c-Src. Level of gap junction intercellular communication in HeLaCx43 cells
pre-treated with (A) Saracatinib, PF4618433 or both (3h) and (B) Saracatinib, PF4618433
or both (3hr) followed by PMA treatment (60 min) were determined using the scrape
loading transfer assay. Provided are representative immunofluorescence images (Lucifer
yellow, green; DAPI, Blue). (C) Quantification of the area of Lucifer Yellow transfer shows
the effect of inhibiting Src and/or Pyk2 phosphorylation of Cx43. Immunofluorescence
spread (area) of Lucifer Yellow transfer was measured by ImageJ software.
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Figure 3.19. PMA mediated Cx43 gap junction plaque disassembly is reversed by
inhibiting active Pyk2 and c-Src. Representative fluorescent images and quantification
of in situ TX-100 extracted Cx43 (Cx43, green; DAPI, blue) of HeLaCx43 cells treated with
(A) Src (Saracatinib, SA) and/or Pyk2 (PF4618433, PF) inhibitors (3hr) and (B) Src
(Saracatinib, SA) and/or Pyk2 (PF4618433, PF) inhibitors (3h) followed by PMA treatment
(60 min). (C) Quantification was determined by normalizing the mean fluorescent intensity
of insoluble Cx43 to DAPI. All data are representative of three independent experiments
(one-way ANOVA, **P<0.01, ***P<0.001).
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Figure 3.20. PMA mediated impairment of Cx43 gap junction plaque formation is
reversed by inhibiting active Pyk2 and c-Src. A) Western blot image of TX-100
extracted protein; total lysate (T), soluble (S), and insoluble (I) fractions. (B) Quantification
of protein in the T, S, and I fractions. Data are representative of three independent
experiments (one-way ANOVA, **P<0.01).
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Next, we addressed if inhibition of Pyk2 and Src would contribute to maintaining Cx43mediated GJIC in a more biologically relevant cell system. Thus, neonatal rat ventricular
myocytes (NVCMs) were purified (Figure 3.21A) and found viable in the presence of the
c-Src (Saracatinib) and Pyk2 (PF4618433) inhibitors (Figure 3.21B). Western blot analysis
of NVCMs lysate treated with PMA in the presence of PF4618433 and/or Saracatinib
showed a PMA-mediated increase in Src and Pyk2 activation, and a decrease in Cx43
phosphorylation (Figure 3.21C). When NVCMs are PMA treated, only 8% of the cell
population is beating and the number of contractions is ~43% of control (Figure 3.21D).
Pre-treatment with Saracatinib or PF4618433 increased the number of beating cells to the
control level. Interestingly, Saracatinib only improved the number of contractions to ~63%
of control, while PF4618433 fully restored function to control level. The results with pretreatment with both Saracatinib and PF4618433 resembled with that of PF4618433 alone.
This contrasts the HeLaCx43 cell data where both Saracatinib and PF4618433 were needed
to return GJIC to the control level.

12.5 Pyk2 activity and co-localization with Cx43 increase in the left ventricle during
heart failure
The starting point to determine if Pyk2 could become a target for therapeutic
intervention, to restore proper GJIC in heart failure, would require the interaction with Cx43
under disease conditions. MI leads to a loss in mass of the cardiomyocytes and a
progression to pathological ventricular remodeling, which can lead to ventricular
dysfunction (hypertrophy) and heart failure. This is achieved by occluding the left anterior
descending artery (LAD) in an animal model (529). Western blot analysis of left ventricle
lysate at six weeks post LAD ligation surgery showed an increase in the hypertrophy and
heart failure marker atrial natriuretic peptide (ANP) validating the heart failure model
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Figure 3.21. PMA mediated decrease in cardiac function is reversed by inhibiting
active Pyk2 and Src. (A) Immunofluorescence image illustrating the purity of isolated and
cultured NVCMs (cardiac marker sarcomeric α-actinin, red; Cx43, green, DAPI, blue). (B)
NVCMs were treated with different concentrations of c-Src (Saracatinib) and Pyk2
(PF4618433) inhibitors (48 hr) and cell viability measured using a MTT assay. (C,D)
NVCMs were pre-treated with Saracatinib, PF4618433 or both (4 hr) and then treated with
PMA (60 min). (C) Cell lysate was extracted and western blotted after video recording of
cells from each group. Antibodies used are labeled on the left of each panel. (D)
Calculated were the contraction of NVCMs expressed as beat per minutes (right) and the
total number of NVCMs contributing to the beats (left). Data are representative of three
independent experiments (one-way ANOVA, *P<0.05, **P<0.01).
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(Figure 3.22). Immunofluorescence images also confirmed heart failure by the observation
of Cx43 at the lateral membrane and within intracellular compartment (longitudinal
sections; Figure 3.23). LAD ligated animals also had an increase in active Src, active Pyk2,
and phosphorylation of Cx43 residue Y265. While there was no statistical difference for
the level of total Pyk2 and Cx43, the trend was higher and lower, respectively. The
increase in active Pyk2 was associated with an increased interaction with Cx43, observed
as colocalization of p-Pyk2 and Cx43 (Figure 3.23). Interestingly, the Pyk2 and Cx43
colocalization was observed at the ID, lateral membrane, and intracellularly.
Finally, we acquired normal and diseased human left ventricle samples to determine if
the findings observed for the animal model would also be present in human patient
samples. Western blot data for the hypertension (HTN) and arrhythmia samples are similar
with each other, and clearly different from the normal control (Figure 3.24). There is an
increase in the level of total and active Src, total and active Pyk2, and a decrease in total
Cx43. In comparison with the heart failure animal model, both systems showed an
increase in active Src and Pyk2. However, they differ in that the human disease samples
had an increase in total Src and Pyk2 and a decrease in Cx43. This information would
support an intervention to preserve Cx43 GJIC and heart function in heart diseases
through inhibition of both Pyk2 and Src activity.

13. Discussion
Cx43CT phosphorylation is a key regulator of gap junction assembly, stability,
degradation, channel gating, and selectivity properties. Phosphorylation may alter the
structure of the transmembrane α-helices to influence pore size, or modify the binding
affinities of regulatory protein partners. Notably, when phosphorylation alters the kinetics
of channel assembly or degradation (e.g., via interaction with Nedd4 (175-177)), cell-to-
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Figure 3.22. Pyk2/Src activities and phosphorylation of Cx43 increase in a heart
failure (HF) rat model. Six weeks after sham or LAD ligation surgery, left ventricle tissue
was harvested for Western blotting. Antibodies used are labeled on the left of each panel.
(B) Protein levels were quantified by analyzing scanned blots using ImageJ software, with
normalization of protein expression to the Sham group (value set arbitrarily as 1).
Phosphorylated protein levels were normalized to total protein. All rats with HF had an
average infarct area ≥30% of the left ventricle and left ventricular end-diastolic pressure
(LVEDP) ≥20 mmHg (Sham, n=4; HF, n=7, t-test, *P<0.05, ***P<0.001).
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Figure 3.23. Pyk2 activity increases and co-localizes with Cx43 in a heat failure (HF)
rat model. Six weeks after sham or LAD ligation surgery, left ventricle tissue was
harvested for immunofluorescence imaging (enhanced active Pyk2 - p-Pyk2Y579/580, green;
Cx43, red; co-localization, yellow; DAPI, blue; intercalated disc, white arrows; lateral
membrane, stars; intracellular, blue arrow). All rats with HF had an average infarct area
≥30% of the left ventricle and left ventricular end-diastolic pressure (LVEDP) ≥20 mmHg.
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Figure 3.24. Pyk2/Src activities also increases in diseased human heart ventricle
tissue samples. Western blot analysis of normal and diseased human heart ventricle
tissue lysate purchased from G-Biosciences (normal, n=1) and Novus (hypertension,
HTN, n=1; arrhythmia, n=1). All Antibodies used are labeled on the left of each panel.
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cell communication is altered. A wealth of data exists about the kinases involved in
phosphorylation of Cx43 (221-224, 237). For example, PKA is associated with enhanced
trafficking of Cx43 to the plasma membrane (127, 245, 249, 530, 531), while movement
of Cx43 into the plaque involves casein kinase 1(238). Under disease conditions (e.g.,
heart failure), growth factors and other stimuli including coordinated Cx43 phosphorylation
by several kinases lead to its trafficking away from the gap junction (157, 224). Sequential
phosphorylation of Cx43 by Akt, MAPK, PKC, and Src results in an initial increase and
then decrease in GJIC followed by internalization (157, 224). In this study we identified
that Pyk2 is involved in the direct phosphorylation and regulation of Cx43.
Pyk2 functions to transduce signals from Ca2+, integrins, and G protein-coupled
receptor to downstream MAPK and Akt signaling pathways (318, 319). Pyk2 activation
occurs from an interaction with calmodulin, causing Pyk2 homodimerization and autophosphorylation at Y402 which facilitates Src binding (332). Subsequent Src
phosphorylation at multiple Pyk2 sites enhances kinase activity and binding of several
other adaptor proteins (318). In cardiomyocytes, intracellular Ca2+ and PKCƐ also regulate
Pyk2 activation (335, 532). Pyk2 regulates a wide range of physiological effects, including
cell proliferation, differentiation, apoptosis, and cytoskeletal regulation. In the heart, Pyk2
expression is much greater in neonatal, than in adult ventricular myocytes (335). However,
in vivo studies using animal models of heart failure (e.g., pressure overload) identified an
increase in Pyk2 expression and activity (338, 523). Furthermore, expression and activity
of Pyk2 in the LV of failing human hearts is markedly increased and related to lethal
arrhythmias (339). Importantly, the endogenously expressed inhibitor CRNK improves
survival, increases LV function, and alters expression of proteins characteristic of LVH in
models of MI and dilated cardiomyopathy (323, 340). Molecular mechanisms responsible
for the adverse effects of Pyk2 dysregulation that accompany LVH and heart failure have
remained unclear. We propose one molecular mechanism by which Pyk2 exerts its
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adverse effects in the heart is to contribute to the process of Cx43 lateralization and
degradation.
First, low intracellular pH that results from the MI causes active Src and Pyk2 to
translocate to the ID, where they bind directly to Cx43 causing phosphorylation of CT
residues Y247, Y265, Y267, and Y313 (306, 468). Phosphorylation of Cx43 at Y247
inhibits the Cx43 interaction with β-tubulin (308), and phosphorylation of Cx43 at Y265
and Y313 inhibits the Cx43 interaction with Drebrin (maintains Cx43 GJs in their functional
state at the plasma membrane, binds F-actin) (316, 468), and the Src SH3 domain
interacts with the ZO-1 PDZ-2 domain causing displacement of ZO-1 (binds F-actin) from
the Cx43CT (85). Once ZO-1 unhooks from Cx43, the plaque size begins to increase (156,
254), but as it is no longer anchored at the ID (also caused by loss of interaction with
tubulin and Drebrin), the entire plaque moves away from the region of high concentration
at the ID to the lateral membrane. Consistent with this hypothesis is the lateralized GJs
appear larger-than normal plaques (533). Once there, plaques internalize for degradation
by clathrin-mediated events (534). We speculate that Pyk2 inhibition, in addition to Src
inhibition, would further reverse Cx43 remodeling and improve cardiac function as seen
from inhibiting Src alone (488). As mentioned above, the reduced phosphorylation at
Y247, Y265, and Y313 would correlate with increased binding to Drebrin and tubulin.
Additional benefits would include decreased phosphorylation of S279/282 (MAPK sites),
S368 (PKC site), and S373 (Akt site). This is based upon Src activates ERK1/2, PKC, and
Akt (239, 493, 535), Pyk2 activates MAPK and Akt (318, 319), and PKC can activate Pyk2
(335, 532). Consistent with reversing S279/282, S368, and S373 phosphorylation is the
observation that in the infarct EBZ, Src inhibition (Tyrosine phosphorylation) led to higher
levels of the Cx43 P2 phosphorylation isoform (Ser phosphorylation at S325, S328, and
S330 by casein kinase 1 that promotes GJIC) (238, 472, 488).
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Gap junction channels composed of Cx43 mediate electrical coupling and impulse
propagation in the normal working myocardium. In the failing heart caused by a MI, Cx43
remodeling (decreased expression, loss at IDs, and increased presence at lateral
membranes) contributes to ventricular arrhythmias; activated Src has been linked to this
Cx43 dysregulation. Rutledge et al. demonstrated that Src inhibition following MI
increased Cx43 expression, improved conduction velocity, reduced arrhythmia inducibility,
and may represent a new approach to arrhythmia reduction in ischemic cardiomyopathy
(488). However, while Cx43 restoration was sufficient to explain the beneficial effects after
Src inhibition, their data indicate there is an “undiscovered second process” preventing full
restoration of Cx43 levels (488). Our data suggest we may have identified this second
process (i.e., Pyk2) and mechanism used to affect Cx43 regulation (e.g., Drebrin (468)).
Thus, future studies will use a combinatorial approach to inhibit the Pyk2/Src axis as a
therapeutic approach to heart disease.
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CHAPTER FOUR

ADDITIONAL STUDIES
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In this chapter, preliminary data from two on-going studies will be discussed. The first
part includes studies focused on determining how Paxillin regulates the phosphorylation
of Cx43 mediated by Pyk2 and Src. We identified that knockdown of Paxillin indirectly
decreases Cx43 phosphorylation at Y247, Y265, and Y313. In the second part contains a
study on the mechanism that promotes Cx45 intercalated disc localization and Cx45
expression in heart failure. Our preliminary data showed Cx45 expression increased and
co-localized with Cx43 at the intercalated disc and lateral membrane in heart failure rats.
The future directions will be discussed in Chapter 5.

14. Paxillin plays a role in the phosphorylation of Cx43 by Pyk2 and Src
14.1 Introduction
As a major component of focal adhesions, paxillin is characterized as a cytoplasmic
scaffold/adaptor protein that plays significant roles in regulating focal adhesion, such as
recruitment of various kinases, phosphatases, oncoproteins, cofactors, and structural
proteins that are involved in the intracellular signaling pathways for cell motility (536).
Paxillin is mainly distributed in the focal adhesion and affects the assembly and
disassembly of focal adhesion during cell migration. It is also localized in the cytoplasm
and nucleus, where it could affect gene transcription (537).
From N-terminal to C-terminal, Paxillin contains five tandem leucine-aspartic acid-rich
LD motifs (LD1-LD5) and four cysteine-histidine-enriched LIM (LIM1-LIM4) domains
(Figure 4.1) (538). The LIM domain is a vital targeting sequence for protein-protein
interactions (539). Notably, the LIM2 and LIM3 are responsible for Paxillin localization to
focal adhesion sites (540). The LD motifs have two major characters that relate to their
biological function. One character is that LD motifs contain leucine-rich sequences, which
serve as the major targeting sequence for many protein-protein interactions (541, 542).
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Figure 4.1. Schematic domain structure, phosphorylation sites and functional
organization of Paxillin. Five leucine-rich LD domains (LD1–LD5) and four cysteinhistidine-enriched LIM domains are indicated in blue and green. The serine and tyrosine
phosphorylation residues are heighted in red. Functional modifications, regulation through
phosphorylation, and interaction with certain domain are summarized in the text boxes.
This figure is reprinted under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/) (López-Colomé et al.,
2017) (536).
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The interaction partners of LD1, LD2, and LD4 are better characterized than those of LD3
and LD5 (542). For example, FAK contains focal adhesion targeting (FAT) domain in the
C-terminus and the FAK binding to Paxillin LD2 and LD4 motifs recruits FAK from
cytoplasm to adhesion sites (543, 544). Pyk2 also has been found bind to LD2 and LD4
motifs of Paxillin through its FAT domain, with both motifs sharing similar binding affinity
for Pyk2-FAT (545). Two different conformations of Paxillin compete equally for Pyk2-FAT
and form a dynamic Paxillin-Pyk2 complex (545). The other character is that the LD motifs
contain many tyrosine and serine phosphorylation sites that are crucial for protein
activation and signal transduction (536, 546). Among all residues, the Y31
(phosphorylated by FAK) and Y118 (phosphorylated by Src) are the two major
phosphorylation sites which are responsible for Paxillin activation. Also, FAK enables
Paxillin to interact with downstream effectors and transduce the extracellular signals into
cellular responses (547). For example, eliminating phosphorylation at Y31/Y118
decreased the disassembly of FA and reduced the migration of endothelial cells (548,
549).
Based on the studies in Chapter 3, our hypothesis is that Paxillin regulates Cx43
phosphorylation by forming a Pyk2/Paxillin/Src complex and in this complex, Paxillin
serves as a scaffolding protein of Pyk2 and Src. Our preliminary results suggest that
Paxillin is necessary for proper phosphorylation of Cx43 by Pyk2/Src. Meanwhile,
inhibition of active Pyk2 and Src decreases Paxillin activity.

14.2 Methods and results
14.2.1 Inhibition of Pyk2 activation decreases Paxillin Phosphorylation
To initially address the importance of Paxillin, phosphorylation level of Paxillin was
evaluated after decreasing the activation of Pyk2 (i.e. loss of function study). HeLaCx43
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cells were cultured to 80% confluency in selection DMEM medium containing 2 ug/ml
Puromycin. Cells were treated with (A) Pyk2 siRNA and c-SrcY530F (active c-Src, 24 h),
(B) Pyk2 CT and PMA (100 nM, 1 hr), (C) Pyk2 CT and EGF (100 ng/mL 1 hr), and (D)
Pyk2 inhibitor PF4618433 and PMA (100 nM, 1 hr). Cells were then collected and lysed
for Western blot. (Figure 3.7, 3.8, 3.9, 3.10, 3.11, and 4.2). In the presence of c-SrcY530F,
there is an increased level of active Pyk2 (pY402 and pY579/pY580) as well as active
Paxillin (pY118). Conversely, siRNA knockdown of Pyk2 decreased the phosphorylation
of Paxillin (Figure 3.8 and 4.2A). Overexpression of Pyk2 CT in the presence and absence
of the indirect Src-activators PMA and EGF reduced the level of active Paxillin without
affecting the level of total or active c-Src (Figures 3.9, 3.10, and 4.2B and C). Finally, we
tested the effect of a small molecule Pyk2 inhibitor (PF4618433) in the presence of PMA
(Figure 3.11). Increasing concentration of PF4618433 counteracted the effect of PMA by
returning active Paxillin level to the pre-PMA treated level (concentration of PF4618433:
37.5 μM). The trend of phosphorylated Paxillin was similar to phosphorylated Pyk2 and
the level of Paxillin phosphorylation was back to control (without PMA treatment) at the
concentration of 25 μM (Figure 4.2D). Altogether, three different techniques to inhibit
active Pyk2 were consistent in suggesting that Pyk2 plays a direct role in the
phosphorylation of Paxillin. Of note, the level of phosphorylation of Paxillin is dependent
on the level of Pyk2 activation.

14.2.2 Overexpression of Pyk2 or/and Src increases Paxillin Phosphorylation
HEK 293T cells were co-transfected with c-SrcY530F (active c-Src; 24 hr) and Pyk2
wild type (WT) or a Pyk2 kinase dead (KD) mutant (K457A) and lysate were Western
blotted. Data for Pyk2, Src and Cx43 are displayed in Figures 3.12 and 3.13. The level of
total Paxillin and p-Paxillin (Y118) was shown in Figure 4.3. As a “gain of function” study,
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Figure 4.2. Inhibition of active Pyk2 decreases Paxillin phosphorylation. Lysate from
HeLaCx43 cells treated with (A) Pyk2 siRNA and c-SrcY530F (active c-Src, 24 h), (B) Pyk2 CT
and PMA (100 nM, 1 hr), (C) Pyk2 CT and EGF (100 ng/mL 1 hr), and (D) Pyk2 inhibitor
PF4618433 and PMA (100 nM, 1 hr) were Western blotted. Antibodies used are labeled
on the left of each panel.
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Figure 4.3. Overexpression of Pyk2 and/or Src increases Paxillin phosphorylation.
HEK 293T cells were co-transfected with c-SrcY530F (active c-Src; 24 hr) and Pyk2 wild
type (WT) or a Pyk2 kinase dead (KD) mutant (K457A) and lysate was Western blotted.
Antibodies used are labeled on the left of each panel.
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the data suggest that the transfection of c-SrcY530F or Pyk2 WT individually caused an
increase in the phosphorylation of Paxillin, while double transfection of c-SrcY530F and Pyk2
WT led to the highest activation of Paxillin, indicating activation of Paxillin is regulated by
both Src and Pyk2. The long explore blot showed a better view of phosphorylated Paxillin
by c-SrcY530F only.

14.2.3 PMA mediated activation of Paxillin is reversed by inhibiting active Pyk2 and
c-Src
HeLaCx43 cells were cultured to 80% confluency in selection DMEM medium containing
2 ug/ml Puromycin. Cells were pre-treated with Saracatinib (Src inhibitor) and/or
PF4618433 (Pyk2 inhibitor) for 3 hr, and then treated with PMA for 60 min. Cells were
then collected and lysed for Western blot. Data for Pyk2, Src and Cx43 are displayed in
Figure 3.17. The level of total Paxilllin and p-Paxillin demonstrates that 60 min of PMA
treatment in the absence of Pyk2 and Src inhibitors results in Paxillin activation (Figure
4.4 and 3.17). Inhibition of Pyk2 or Src individually decreased the level of Paxillin
phosphorylation, while in the presence of both Saracatinib and PF4618433,
phosphorylation of Paxillin was completely inhibited. Altogether, the data indicate that
inhibition of both Pyk2 and Src is needed to inhibit Paxillin activity and the counteraction
the effect of PMA on GJIC may due to the complete dysfunction of Pyk2/Src/Paxillin
complex.

14.2.4 Knockdown of Paxillin decreases Cx43 phosphorylation at Y247, Y265, and
Y313
Previously data demonstrate that Paxillin activation depends on Pyk2 and Src; two
tyrosine kinases contribute to Cx43 phosphorylation and GJIC. To directly characterize
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Figure 4.4. Increase of Paxillin activity by PMA treatment is inhibited by Saracatinib
or/and PF4618433. Lysate from PMA treated (30 and 60 min) HeLaCx43 ± Src (Saracatinib,
SA) and/or Pyk2 (PF4618433, PF) inhibitors was Western blotted. Antibodies used are
labeled on the left of each panel.

157

the impact of Paxillin activation on Pyk2/Src mediated Cx43 phosphorylation, siRNA was
used to knockdown the expression of Pyk2 and Paxillin in the presence of different Src
constructs. Briefly, HeLaCx43 cells were culture to confluence in selection DMEM medium
contained 2 ug/ml Puromycin. Cells were pre-treated with scramble control siRNA, Pyk2
siRNA or Paxillin siRNA for 24 hr, and then transfected with empty vector, c-SrcY530F
(active c-Src), mSH3W121K (c-SrcY530F with disabled SH3 domain), or mSH2R178L (c-SrcY530F
with disabled SH2 domain) for 24 hr. Cells were then collected and lysed for Western blot.
Antibodies used are labeled on the left of each panel. In the presence of c-SrcY530F or
mSH3W121K, there is an increased level of active Pyk2 (pY402 and pY579/pY580), active
Paxillin (pY118), as well as Cx43 pY247, pY265, and pY313 (Figure 4.5) with either control
siRNA, Pyk2 siRNA or Paxillin siRNA pre-tratment. As expected, siRNA knockdown of
Pyk2 significantly decreased the phosphorylation of Cx43 residues Y247, Y265, and Y313.
Interestingly, knockdown of Paxillin also reduced the phosphorylation of Cx43 residues
Y247, Y265, and Y313 and the level of phosphorylation of Cx43 residues Y247, Y265,
and Y313 was even lower than Pyk2 siRNA treatment. SH2-deficient c-SrcY530F was
unable to activate Pyk2 and phosphorylation only occurred on Cx43 residues Y265 in the
presence of either Control siRNA, Pyk2 siRNA or Paxillin siRNA. This result is consistent
with the data in Figure 3.15.

14.3 Discussion
Our preliminary results suggest that Paxillin is necessary for phosphorylation of Cx43
by Pyk2 and Src. Inhibition of active Pyk2 and Src decreases Paxillin activity. Based on
these results and the studies in Chapter 3, we hypothesize Paxillin regulates Cx43
phosphorylation by forming a Pyk2/Paxillin/Src complex and in this complex, Paxillin
serves as a scaffolding protein of Pyk2 and Src.

158

159

Figure 4.5. Knocking down of Paxillin by siRNA demonstrate the contribution of
Paxillin to Src and Pyk2 mediated Cx43 phosphorylation at Y247, Y265, and Y313.
HeLaCx43 cells were pre-treated with control siRNA, Pyk2 siRNA or Paxillin siRNA for 24
hr, and then transfected with empty vector, c-SrcY530F (active c-Src), mSH3W121K (disables
SH3 domain from interacting with protein partners), or mSH2R178L (disables SH2 domain
from interacting with protein partners) for 24 hr. Cells were then collected and lysed for
Western blot. Antibodies used are labeled on the left of each panel.
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Paxillin has been proven to contribute to function and the re-orientation of the
microtubule-organizing centers by recruiting Pyk2 (541, 550). In addition, another study
showed that Cx43 was colocalized with Paxillin at the cell periphery (551). Therefore, we
hypothesize that Paxillin is a scaffold for recruitment of tyrosine kinases Pyk2 and Src to
the plasma membrane. At completion of this study, we expect to reveal a complex interplay
between tyrosine kinases Pyk2 and Src and Paxillin in the regulation of Cx43 function.

15. Investigation of the function of Cx45 in addition to Cx43 in heart failure.
15.1 Introduction
Adult ventricular myocytes are extensively interconnected by Cx43 gap junctions at the
intercalated disc to propagate impulse along the longitudinal axis. In the failing heart,
reduced cell-to-cell communication, resulting from disturbances in the distribution and/or
reduced Cx43 protein level, are associated with increased susceptibility to inducible
arrhythmias (434, 552). However, Cx43-inducible knockout mice had neither significant
conduction delay nor arrhythmogenesis when protein levels were reduced by 70–90%
(553-555). Therefore, the modest reductions in Cx43 observed in many models of heart
disease would not likely result, on their own, in altered conduction and/or arrhythmias.
In normal adult ventricular myocytes, the protein level of Cx45 is much lower than Cx43
(556). Although Cx45 is reported to be responsible for cell-to-cell coupling in Cx43-null
ventricular myocytes (95, 557, 558), its role in the cardiac rhythm is understudied. Cx45
is up-regulated in human failing hearts and its increased expression alters coupling and
slows conductance, enhancing susceptibility to ventricular tachyarrhythmias (559). Thus,
while the contribution of Cx45 to intercellular current flow is thought to be minimal in
healthy hearts, Cx45 may influence electrical and/or metabolic coupling as a result of the
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pathophysiological overexpression observed in the failing heart. It is likely that even
modest upregulation of Cx45 has a profound effect due to its ability to form heteromeric
channels with the remaining Cx43 and thereby disrupt cardiac function in ways that even
the low levels of Cx43 could maintain. Our preliminary data also showed increased Cx45
co-localizes with Cx43 at the intercalated disc and lateral membrane of heart failure. We
also found that Cx45 could be regulated by Pyk2 and Src with opposite consequences
(i.e. increased GJIC) compared to Cx43.

15.2 Methods and results
15.2.1 Cx45 expression increases and co-localizes with Cx43 at the intercalated disc
and lateral membrane of heart failure rat ventricle
In the previous study, Western blot analysis of left ventricle lysate of heart failure rat
model showed an increase in active Src, active Pyk2 and phosphorylated Cx43 at residue
Y265 (Figure 3.22). Here, we investigated the level of Cx45, PKC, and p-JNK in the same
heart failure rat model, compared to sham rats (Figure 4.6). Heart failure rats have a
significant increase in Cx45, p-JNK, and PKC expression. Also, increased Cx45
expression was observed to colocalize with Cx43 at the intercalated disc and lateral
membrane (longitudinal sections; Figure 4.7).

15.2.2 Pyk2 and/or Src inhibitors eliminated the increase in GJIC caused by EGF
treatment in HeLaCx45 cells
Data in Chapter 3 demonstrated PMA mediated Cx43 GJ closure is reversed by
inhibiting active Pyk2 and/or c-Src, and the data above suggested the protein level of Cx45
and the activation of Pyk2 and c-Src were increased in heart failure rat model. Also, the
preliminary data from our lab showed that Cx45 can be phosphorylated by active Pyk2
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Figure 4.6. Cx45, p-JNK and PKC increase in a heat failure (HF) rat model. (A) Six
weeks after sham or left anterior descending ligation surgery, left ventricle tissue was
harvested for Western blot. Antibodies used are labeled on the left of each panel. (B)
Protein levels were quantified by analyzing scanned blots using ImageJ software, with
normalization of protein expression to the Sham group (value set arbitrarily as 1).
Phosphorylated protein levels were normalized to total protein. All rats with HF had an
average infarct area ≥30% of the left ventricle and left ventricular end-diastolic pressure
(LVEDP) ≥20 mmHg (Sham, n=4; HF, n=7, t-test, *P<0.05, **P<0.01).
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Figure 4.7. Cx45 expression increases and co-localizes with Cx43 in a heat failure
(HF) rat model. Six weeks after sham or LAD ligation surgery, left ventricle tissue was
harvested for immunofluorescence imaging (Cx43, green; Cx45, red; co-localization,
yellow; DAPI, blue; intercalated disc, white arrows; lateral membrane, stars). All rats with
HF had an average infarct area ≥30% of the left ventricle and left ventricular end-diastolic
pressure (LVEDP) ≥20 mmHg.
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and c-Src. Therefore, we are interested in understanding the role that Cx45 plays in the
failing heart and whether the phosphorylation of Cx45 by Pyk2 and/or Src has the same
effect on GJIC compared to Cx43.
Junctional transfer of the tracer neurobiotin (cationic) was measured in a scrapeloading assay using HeLaCx45 cells (HeLa cells stably expressing Cx45) treated with EGF
in the presence of Pyk2 (PF4618433) and/or c-Src (Saracatinib) inhibitors. Lucifer Yellow
(anionic) was used as a negative control. Indeed, Cx45 is cation selective and should only
allow the passage of neurobiotin. As expected, in the absence of EGF, HeLaCx45 cells were
well coupled with respect to neurobiotin (Figure 4.8) (76). Interestingly, when treated with
EGF, coupling was increased, which was reversed by the addition of Saracatinib or
PF4618433. Also, the effect of EGF on Cx45 coupling was completely inhibited in the
presence of both Saracatinib and PF4618433, suggesting Cx45 phosphorylation by Pyk2
and Src leads to increased GJIC.

15.3 Discussion
LVH is an adaptive response to increased biomechanical stress caused by many forms
of heart disease, including ischemic disease, hypertension, and heart failure (508).
Following the acute stage, heart mass increases to normalize wall stress and retain normal
cardiovascular function, accompanied by a transient increase in Cx43 expression,
phosphorylation, and GJIC (407). However, in the late stage, increased cardiac mass and
sustained overload eventually lead to contractile dysfunction and heart failure through
poorly understood mechanisms (510). As LVH becomes severe, propagation velocity
decreases. This correlates with reduced Cx43 expression and intercalated disc
localization, altered phosphorylation of Cx43, increased Cx45 expression, and extensive
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Figure 4.8. Pyk2 and/or Src inhibitors eliminated the increase in gap junction
intercellular communication (GJIC) caused by EGF treatment of HeLaCx45 cells. Level
of GJIC in HeLaCx45 cells were determined using the scrape loading transfer assay.
HeLaCx45 cells were culture to confluence in glass bottom dishes, serum starved for 24 hr,
and then pre-treated with Saracatinib, PF4618433 or both (3 hr) followed by EGF
treatment (60 min). Cells were then scrape loaded with NB and Lucifer yellow, fixed,
stained with Streptavidin 647, and imaged. Provided are representative
immunofluorescence images (Lucifer yellow, green; Streptavidin 647, red; co-localization,
yellow; DAPI, Blue).
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Cx45 colocalization with the remaining Cx43 at the intercalated disc (seen in both
ischemia and dilated cardiomyopathy (94, 401, 511-513)).
In vitro studies with NVCM and in vivo studies using animal models of LVH suggest
that these kinases are involved in the cardiomyocyte signaling pathways that lead to
ventricular remodeling and subsequent heart failure (335, 339, 523). Thus, the
biochemical sequelae of chronic cardiac hypertrophy are likely responsible for decreasing
Cx43 and enhancing Cx45 junctional localization. Based upon these data, and our
preliminary data (above), our hypothesis is that Cx43 and Cx45 are differently regulated
by Pyk2 and Src and expression of Cx45 affects the function of Cx43.
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Conclusion and Future
Directions
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16. Summary
Gap junctions are integral membrane proteins that enable the direct cytoplasmic
exchange of small molecules and low molecular weight metabolites between adjacent
cells (469). They provide a pathway for propagating and/or amplifying the signal
transduction cascades triggered by cytokines, growth factors, and other cell signaling
molecules involved in growth regulation and development. Dysfunctional intercellular
communication via gap junctions has been implicated in causing many human diseases
(470). Though the 21 connexin isoforms share significant sequence homology, the major
divergence in primary structures occurs in the cytoplasmic domains.
The importance of Cx43 gap junctions in the cardiovascular system is well established.
They allow for the propagation of the action potential and the maintenance of a regular
beating rhythm. The closure of Cx43 channels or their absence disrupt normal
propagation, and lethal arrhythmias can ensue (80, 499, 500, 560). The function of Cx43
is influenced by several parameters, such as lipophilic compounds, voltage, pH, and
phosphorylation (212, 221, 227, 277, 561, 562). Phosphorylation is one of the most
important post-translational modification which controls Cx43 gap junction assembly, size,
turnover, as well as the regulation of electrical and metabolic coupling. The Cx43CT is
differentially phosphorylated on at least 20 residues (221-224). The negative charge of the
phosphate could affect the permeability of ions to the pore, alter the structure of the
transmembrane α-helices to influence pore size, or modify the binding affinities of protein
partners involved in regulating Cx43. Notably, if phosphorylation alters the kinetics of
channel assembly or degradation, cell-to-cell communication will be changed. Particularly,
changes in the normal level of Cx43 phosphorylation are commonly observed in both
ischemic and non-ischemic forms of human heart failure (436, 563).
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Serine phosphorylation has been well studied to regulate Cx43; however, the
understanding of tyrosine phosphorylation of Cx43 is limited to Src and Tyk2 kinases. Src
is a tyrosine kinase known to both phosphorylate Cx43 residues Y247 and Y265 and affect
GJIC. However, we identified Y313 as another phosphorylation target. Based upon the
study of Lin et al. (2001), which still observed tyrosine phosphorylation by Src when using
a Cx43 Y247/Y265F mutant, we addressed the possibility of other phosphorylated tyrosine
residue(s) by Src. In vitro Src phosphorylation of purified Cx43CT followed by mass
spectroscopy revealed that Src also phosphorylates Y313. This observation was
confirmed by repeating the in vitro phosphorylation using different combinations of
Cx43CT Y→F mutants and a general anti-pTyr antibody. We also generated a phosphospecific antibody to help characterize the importance of pY313. By using stably expressing
Cx43 WT and mutants in Cx43-deficient HeLa cells, we identified Src phosphorylation of
Cx43 Y313 contributed to Cx43 intracellular localization and decreased GJIC. A
suggested mechanism for Src phosphorylation of Cx43 has been discussed in 3.4.1.2.
Briefly, Src SH3 domain initially interacts with Cx43 residues A276-S282, facilitating Src
kinase domain to phosphorylate Y265. Then Src SH2 domain binds pY265, leading to
phosphorylation on Y247 by Src kinase domain. Here, we found Cx43 Y265F inhibited the
ability of v-Src to phosphorylate Y247 and Y313, indicating the role of Y313 in this
sequential order of Cx43 tyrosine phosphorylation by Src. Furthermore, phosphorylation
at both Y265 and Y313 was necessary to inhibit the Cx43 interaction with Drebrin. Finally,
we observed Cx43 Y313 phosphorylation is increased in diseased human left ventricle.
Next, we investigated whether other tyrosine kinases involved in the regulation of Cx43
function. In Chapter 3, an in vitro phosphorylation screen identified that Protein tyrosine
kinase 2 beta (Pyk2) phosphorylated purified Cx43CT; this led us to characterize the
impact of this phosphorylation on Cx43 function. Mass spectrometry identified Pyk2
phosphorylates Cx43CT residues Y247, Y265, Y267, and Y313. Western blot and
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immunofluorescence staining using HeLaCx43, HEK 293T, and neonatal rat ventricular
myocytes identified: 1) Pyk2 is activated by Src, 2) Pyk2 interacts with Cx43 at the plasma
membrane and intracellularly, 3) overexpression of Pyk2 increases Cx43 phosphorylation
leading to decreased GJIC and internalization (and vice versa), 4) PMA activation of Pyk2
is inhibited by the small molecule PF4618433 leading to increased Cx43 GJIC.
Additionally, when paired with a Src inhibitor, PF4618433 preserved GJIC to the controllevel. An animal model of myocardial infarction induced heart failure also showed an
increase in Pyk2 activity and interaction with Cx43; increased Pyk2 activity is likewise
observed in the diseased human left ventricle. Altogether, Src inhibitors have been used
to reverse Cx43 remodeling (expression and distribution) and improve heart function after
myocardial infarction. However, a second undiscovered process is believed to prevent full
restoration of proper Cx43 function. Our data suggest we may have identified that
phosphorylation of Cx43 by Pyk2 is the “second process” that must be inhibited, in addition
to Src, to further (if not completely) reverse Cx43 remodeling and improve cardiac function.
Additionally, some preliminary studies are discussed in Chapter 4, including the
importance of Paxillin in the regulation of Cx43 as well as the function of Cx45 in cardiac
diseases. Those studies are mainly derived from the study in Chapter 3. Our preliminary
data showed that knockdown of Paxillin decreases Cx43 phosphorylation at Y247, Y265,
and Y313, indicating Paxillin may serves as a scaffolding protein of Pyk2 and Src to
facilitate Cx43 phosphorylation by Pyk2 and Src. Another finding is that Cx45 increases
and co-localizes with Cx43 at the intercalated disc and lateral membrane of heart failure
rat ventricle, compared to Sham rats. Also, the Src and Pyk2 inhibitors caused a decrease
in Cx45 GJIC. Recent unpublished work in our laboratory has suggested that specific
kinases have different effects on Cx45 than Cx43, as well as Cx43 retained in gap junction
by Cx45 is marked for turnover. Altogether, these findings lead to further investigation for
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a better understanding of the mechanism of Cx45 gap junction localization and different
regulation of Cx43/Cx45 in cardiac diseases.
In conclusion, understanding the mechanistic basis of Cx43 phosphorylation will lead
to possible points of therapeutic intervention to restore proper GJIC that has been altered
due to heart failure. This information is crucial if the role of inte rcellular communication in
normal and diseased conditions is to be fully understood and utilized for therapeutic
strategies in cardiac pathologies. The additional research plans will be discussed in future
directions.

17. Future directions
17.1 Study the role of Paxillin in the regulation of Cx43 phosphorylation by Pyk2
and Src
As a major component of focal adhesions, the scaffolding protein Paxillin interacts with
Pyk2 and also can be phosphorylated by Src. Paxillin has been proven to contribute to
function and the re-orientation of the microtubule-organizing centers by recruiting Pyk2
(541, 550). In addition, another study showed that Cx43 was colocalized with Paxillin at
the cell periphery (551). Previous studies have identified that Src can bind to Cx43 PXXP
region through SH3 domain, while the evidence of direct Pyk2 interaction with Cx43 is
lacking. In Chapter 4, our preliminary data suggest knockdown of Paxillin decreases Cx43
phosphorylation at Y247, Y265, and Y313. Altogether, we hypothesize Paxillin is a
scaffolding

protein

in the complex

of

Pyk2/Src/Paxillin

that

facilitates

Cx43

phosphorylation. To test this hypothesis, we will investigate 1) co-localization of Paxillin
with Pyk2, Src, and Cx43, as well as 2) localization of Pyk2, Src, and Cx43 in the presence
of Paxillin siRNA, when Src and/or Pyk2 are activated. Also, co-IP will be performed to
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study the complex of Pyk2/Src/Paxillin in normal condition as well as conditions where
Pyk2/Src will be activated, such as EGF or PMA treatment.

17.2 Investigate the effect of inhibition of Cx43 phosphorylation by both Pyk2 and
Src in heart failure animal model
Our study in Chapter 3 shows that inhibition of both Pyk2 and Src is necessary to
preserve Cx43 GJIC in cyto. We hypothesize that inhibition of both Pyk2 and Src
phosphorylation is required to reverse Cx43 remodeling (expression and distribution) and
improve heart function after myocardial infarction. Further, in vivo studies are necessary
to prove this hypothesis. For example, Pyk2 and Src inhibitors will be delivery to heart
failure rats one week after LAD ligation surgery. After five weeks, heart function will be
measured by Echo (to measure EF) and a pressure transducer (to measure LVEDP), and
heart

tissue

will

be

harvested

and

processed

for

WB,

histology

analysis,

immunoprecipitation, and dye-transfer assay, etc. Additionally, there is a growing interest
recently in the targeted delivery of the therapeutic cargo into the diseased region, therefore
optimizing the method of drug (Pyk2/Src inhibitors) delivery needs to be further
investigated. Of note, localized drug delivery increases drug efficacy and reduces the
systematic toxicity and side effects as compared to systematic drug administration (564).
One way of doing this is by applying the localized drug delivery in the heart through
minimal invasive syringes or catheters (565, 566).

Also, many other localized drug

delivery methods have been developed so far, including nanoparticles, microspheres, and
hydrogels, which all are potential solutions to delivery our interested therapeutic molecules
to the heart (567, 568). However, the drug loading amount and efficacy, as well as the
biocompatibility of different delivery methods should be evaluated and compared.
Moreover, we are interested in whether inhibition of both Pyk2 and Src phosphorylation
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will benefit other cardiac diseases where Pyk2/Src phosphorylation levels were reported
to increase. We may test in different cardiac diseases animal models, such as ischemiareperfusion injury or diabetic heart disease. Additionally, we also will explore the role of
Pyk2/Src-mediated Cx43 phosphorylation in human tissue samples, including normal
controls as well as samples collected from patients who have heart diseases.

17.3 Study Cx45 in addition to Cx43 in context of heart failure
Cx45 is normally localized to the specialized conducting system. However,
colocalization of extensive Cx45 with reduced Cx43 at the intercalated disc has been
showed in heart diseases, including ischemic and dilated cardiomyopathy (94, 401, 511513). In the second part of Chapter 4, our immunostaining data showed that increased
Cx45 co-localized with Cx43 at the intercalated disc and lateral membrane in heart failure
rat model. Also, our dye transfer assay demonstrated Pyk2 and/or Src inhibitors eliminated
the increase in GJIC caused by EGF treatment in HeLaCx45 cells, indicating Pyk2 and
Src may have different effects on Cx45 than Cx43. These findings are pivotal because
Cx45 is an understudied gap junction protein and future studies will provide mechanistic
insight into how can the same kinase differently regulate Cx43 and Cx45 and how
expression of Cx45 in heart failure affects Cx43 function. The next step is to knockdown
of Cx45 (both in vitro (NVCMs) and in vivo (heart failure rats)) and then investigate the
levels of all relative proteins and heart function.
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